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CHAPTER 1
Clostridioides difficile infection and disease
Originally designated as ‘Bacillus difficile’ reflecting the difficulty of isolating and culturing 
this organism in the past, Clostridioides difficile (formerly referred to as Clostridium difficile) 
is a Gram-positive and spore-forming obligate anaerobe (1-3). The organism is capable of 
causing C. difficile infection (CDI), a disease with symptoms ranging from mild diarrhea and 
gastrointestinal discomfort to potentially lethal conditions like pseudomembranous colitis 
and toxic megacolon (2, 4). Clostridioides difficile infection is the leading cause of nosocomial 
infectious diarrhea in adults and responsible for 10-25% of all antimicrobial-associated diarrhea 
(AAD) (5-7).  Antimicrobial use is the most important risk factor for CDI development, as a 
healthy and intact intestinal microflora provides colonization resistance against C. difficile (8, 9). 
Although virtually all antimicrobials predispose for CDI, the use of clinda mycin, cephalosporins 
and fluoroquinolones appear to particularly increase this risk (10). Other risk factors for CDI 
development include prior hospitalization, age and underlying comorbidities (11). 
There are several ways to characterize C. difficile isolates beyond the species level. This can 
be challenging, as it potentially leads to multiple typing designations for identical strains (12). 
One such typing method, PCR ribotyping,  is based on the specific banding pattern obtained 
after amplifying 16S-23S intergenic spacer regions and separating them by (capillary) gel 
electrophoresis (13). Currently, PCR Ribotyping is the most widely adapted method for classifying 
C. difficile in Europe. Another classification method is multilocus sequence typing (MLST) based 
on the nucleotide sequence of appointed housekeeping genes, resulting in a sequence type 
(ST) classification (14). Though there generally is congruence between the methods, strains 
of one PCR ribotype (RT) can belong to multiple STs, and vice versa (12).
A healthy, stable microbiome will prevent colonization (colonization resistance) and outgrowth 
of pathogenic organisms such as C. difficile. Although it is not entirely clear how colonization 
resistance occurs, immunological factors as well as the composition of the microbiome 
are thought to contribute (15-17). The disruption of the gut microbiome can also alter the 
composition of bile acids present in the gastrointestinal tract, potentially contributing to C. 
difficile colonization (15, 16). As a result, CDI is considered to occur after disruption of the 
gut microbiota by antimicrobial treatment when spores are ingested through the fecal-oral 
route, or when C. difficile is already present in so-called asymptomatic carriers (18-20).  In 
the first situation, spores then enter the gastrointestinal tract and are able to germinate 
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into vegetative cells after encountering primary bile acids such as (tauro)cholic acid and 
chenodeoxycholic acid (21, 22). The toxins produced by vegetative cells are considered the 
primary cause of disease in CDI (23). Three toxins can be produced by C. difficile, which are 
Toxin A (TcdA), Toxin B (TcdB) and the binary toxin C. difficile transferase (CDT). The presence 
and variability in the toxin encoding genes can be assessed by toxinotyping, and strains can 
contain all or various combinations of these toxin genes (20, 24, 25). Additionally, strains not 
carrying any toxin genes (non-toxigenic C. difficile, NTCD) have been described (24).   TcdA and 
TcdB-encoding genes are located on the pathogenicity locus (PaLoc) along with three genes 
encoding proteins that may be involved in their secretion and regulation, TcdR, TcdC and TcdE 
(26, 27). Once TcdA or TdcB is produced and secreted, these toxins can bind and enter gut 
epithelium through clathrin-mediated endocytosis (28). Once in the cytosol, certain domains 
of the  toxin interact with- and modify RHO family GTPases and cell division control protein 42 
(CDC42), inducing actin cytoskeleton rearrangement, ultimately resulting in cell death (29-31). 
Apoptosis and subsequent disruption of the gut epithelium and its tight-junctions leads to 
influx of immune cells and cytokine- and chemokine production, resulting in an inflammatory 
response (32-34). Certain C. difficile strains such as those belonging to RT027- and 078 are also 
able to produce the binary toxin CDT (35, 36). The binary toxin consists of two components, 
CDTa and CDTb, located on the binary toxin locus CDTLoc, and is able to depolarize the actin 
cytoskeleton and increase bacterial adherence by producing microtubule-based membrane 
protrusions (36, 37). This toxin  is also able to suppress a host eosinophilic response (38). 
Although presence of genes encoding the binary toxin have been reported  as associated 
with increased mortality attributable to CDI, its exact role in C. difficile pathogenesis remains 
debated and unclear, and few TcdA-TcdB-CDT+ strains have been isolated from symptomatic 
patients (39, 40). Clindamycin-challenged hamsters infected with a TcdA-TcdB-CDT+ C. difficile 
strain demonstrated inflammation, but did not develop CDI (41). Instead it seems the binary 
toxin increases virulence when TcdA is also present (42).
Outbreaks and economic burden
The incidence and severity of CDI has increased over the last two decades, particularly related 
to fluoroquinolone use and the emergence of epidemic PCR ribotypes such as RT027 and 
RT078 (10, 43-45). In North America the CDI incidence increased to 8.6 cases per 1000 hospital 
discharges in 2008 with a 7.1% mortality rate (46). PCR ribotype 027- and RT078 strains have 
caused world-wide outbreaks, as illustrated by RT027 in Canada in 2003-2004 and in the 
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Netherlands in 2005-2006 (47, 48). Two outbreaks of RT027 in the United Kingdom in 2003-
2006 ended devastatingly, increasing the annual mortality attributable to CDI by 72% in 2006 
(49). Emergence of RT027 and RT078 has been linked to their resistance to fluoroquinolones 
and its use in the clinic, and their ability to metabolize dietary trehalose, which was used as 
a food additive prior to their emergence (44, 50, 51).  However, CDI is not solely caused by 
RT027- and 078 strains as Europe and the United States frequently report infections caused 
by RT001, RT002 and RT014/020 isolates (43, 52). Apart from the ability of C. difficile to cause 
epidemics, patients suffering from (recurrent) CDI have reported a significant reduction in their 
quality of life compared to the population norm (53, 54). Additionally, a significant economic 
burden is associated with CDI case management where costs associated with a first- or recurrent 
CDI in the UK approximated £6294- and £7539 respectively. Annual costs attributable to CDI 
in the European Union approaches 3 billion euros (45).  
Recent epidemiological data on CDI in the Netherlands, obtained from the Netherlands 
reference laboratory in Leiden University Medical Center (LUMC), indicated that the mean 
incidence rate from May 2018 to May 2019 was 3.17 CDI cases per 10.000 patients days and 
was comparable to previous years (55). Mortality of CDI in this time period was 1.1% and 
the percentage of patients with severe disease decreased compared to results obtained in 
2009-2010 (55). Although CDI has primarily been  considered to be a nosocomial infection, a 
substantial amount of hospitalized CDI patients were demonstrated to have an onset in the 
community (56).
C. difficile and its role in One Health
One Health is a transdisciplinary approach assuming animal health and the environment are 
closely related to human health (57). The observations regarding reduced quality of life in CDI 
patients and the enormous resulting economic costs underline the requirement for appropriate 
preventive measures. However, the metabolically inactive endospores produced by C. difficile 
are highly resistant to stressors such as oxygen, many antimicrobials and disinfectants and 
other environmental conditions which would be lethal for vegetative cells (58). This complicates 
eradication of spores in healthcare settings and it is important instilled cleaning protocols 
are properly executed (59). Additionally, asymptomatic C. difficile carriers could potentially 
contribute to the spread of spores in hospital settings (60). These resistant endospores allow C. 
difficile to be ubiquitous despite that proliferation requires a strict anaerobic environment, and 
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indeed, they are isolated from soil and rivers, the household environment and food products 
such as meat and vegetables, most likely from manure of infected animals and contaminated 
compost (57). The occurrence of C. difficile spores in many different environments could explain 
why this organism is often found in farm animals and household pets, and as a commensal 
bacterium in neonates (Figure 1) (1, 61). This relatively large reservoir may facilitate community 
acquired CDI, which is becoming a more frequent source of infection (62, 63). Worryingly, 
common risk factors for hospital-acquired CDI do not apply to the community-acquired variant, 
as many patients who develop community-acquired CDI are younger,  demonstrate less 
comorbidities, have not been exposed to antimicrobials and were not recently admitted to 
healthcare facilities (62, 64). Although no solid evidence exists that CDI is acquired through food-
borne or environmental transmission, there is some proof for transfer of C. difficile between 
farmers and their farm animals (57, 65). It is unclear if this transfer is zoonotic, from human 
to animals or if the infection resulted from a shared source. However, these observations do 
imply the need for a One Health approach in reducing the incidence of both hospital-acquired 
and community acquired CDI and to better understand the directionality of these infections. 
The resistance of C. difficile to antimicrobials 
Antibiotics disrupt the microbiota, allowing outgrowth of C. difficile which explains why antibiotic 
use is a risk factor for CDI development (20). Additionally, the intrinsic drug resistant nature of 
C. difficile vegetative cells and its spores could contribute to antimicrobial use as a risk factor 
for CDI, as this implies the gut microbiota is disrupted but C. difficile already present in the gut 
is not killed, allowing outgrowth. Antimicrobial resistance (AMR) is a devastating and urgent, 
global problem predicted to lead to 10 million deaths worldwide in 2050 (66). Clostridioides 
difficile is often resistant to antimicrobials not used to treat CDI but commonly used in the 
clinic to resolve other bacterial infections, such as tetracyclines, aminoglycosides, lincomycin, 
erythromycin, cephalosporins and fluoroquinolones (51, 67, 68). Multidrug resistance (MDR) 
is commonly encountered in C. difficile strains and almost 60% of 139 clinical isolates were 
found to be resistant to three or more of these types of antimicrobials in the US (69).
General mechanisms of antimicrobial resistance include inactivation of the drug by altering the 
targets of the antimicrobial or preventing target access by reducing membrane permeability or 
increasing drug efflux. Approximately 10% of the C. difficile genome is made up mobile genetic 
elements (MGEs), particularly transposons, which could have been acquired by conjugation, 
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transformation or transduction (51). Resistance determinants are frequently carried on MGEs 
and the genome of C. difficile harbors many resistance genes on these elements. For instance, 
the erythromycin ribosomal methylase class B (ermB) gene present in many C. difficile strains 
confers resistance to macrolide-lincosamide-streptogramin B (MLSb) antimicrobials such as 
erythromycin, clindamycin and lincomycin, and is thought to be transferred by transposons 
Tn5398 (or related), Tn6194 and Tn6215 (70). The gene ermB encodes a 23S RNA methylase 
which methylates an adenine residue in the 23S ribosomal RNA (rRNA), reducing its affinity 
to MLSb antimicrobials which would otherwise inhibit protein synthesis. The Tn916, Tn916-
like and Tn6164 transposons participate in conferring tetracycline resistance in C. difficile by 
harboring various tet genes such as tet(M) and tet(W) (71). Additionally, a Tn916-like transposon 
is associated with the transfer of the chloramphenicol-florfenicol resistance (cfr) gene, an RNA 
methyltransferase capable of conferring resistance to many different antimicrobials such as 
phenicols, lincosamides and oxazolidinones (72). A putative plasmid carrying the cfrC gene 
was identified in silico in C. difficile, but no experiments have been performed to demonstrate 
this was indeed a plasmid and conferred resistance to MLSb antimicrobials (73). Apart from 
acquiring antimicrobial resistance through (non-conjugative) transposons, resistance can also be 
acquired by non-transferable chromosomal determinants. This form of resistance can be induced 
under antimicrobial pressure by selecting for strains carrying specific chromosomal mutations. 
This is commonly seen for rifamycin-type of antimicrobials considered for CDI treatment, 
such as rifampicin and rifamixin, for which mutations in the RNA polymerase β subunit rpoB 
were found to cause resistance (71). Exposure to rifamycins before  CDI development was a 
risk factor for infection with rifampicin resistant C. difficile strains (74). Fluoroquinolones are 
antimicrobials that inhibit type II topoisomerases such as gyrase and topoisomerase IV, which 
are required for DNA replication. While C. difficile does not contain topoisomerase IV, it does 
possess DNA gyrase subunit A (gyrA) and subunit B (gyrB) genes which can be inhibited by 
fluoroquinolones (75). Mutations in the quinolone-resistance determining region (QRDR) of 
GyrA and/or GyrB are associated with resistance to fluoroquinolones and mutations Thr82Ile 
in the GyrA subunit is frequently encountered in emerged RT027 strains (76, 77).
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Figure 1. The transmission cycle of C. difficile indicating the presence of potential reservoirs. 
Reproduced from (57) with permission of the publisher Elsevier.
Although drug efflux by multidrug transporters is most commonly encountered in Gram-
negative organisms, a clinical C. difficile isolate was reported to contain cdeA, a multidrug 
efflux transporter of the multidrug and toxic compound extrusion (MATE) family (78). This 
transporter had ethidium bromide efflux activity in E. coli and Clostridium perfringens, and 
conferred fluoroquinolone resistance in E. coli upon overexpression. However, the authors 
did not conclusively demonstrate this transporter mediated fluoroquinolone resistance in C. 
difficile. Additionally, laboratory strain 630∆erm was found to contain the ATP-binding cassette 
(ABC) transporter CD2068. Inactivation of this transporter led to an increase in ciprofloxacin 
susceptibility, suggesting this transporter could participate in drug resistance in C. difficile (79).
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As C. difficile is resistant to many different antimicrobials, the number of drugs used to treat CDI 
are limited. Currently vancomycin and fidaxomicin are recommended as the first line treatment 
for CDI according to new guidelines from the Infectious Diseases Society of America (IDSA) 
(80). Fidaxomicin will be discussed to replace vancomycin as first agent of choice, but its use 
is limited due to high cost. Formerly metronidazole was the recommended treatment over 
vancomycin for mild-to moderate CDI as this would prevent outgrowth of organisms such as 
vancomycin resistant enterococci (VRE), and is widely available due to its low cost (81, 82). The 
updated US and European guidelines preferred vancomycin over metronidazole treatment, 
as an overview of randomized-controlled trials demonstrated superiority of effectiveness 
of  vancomycin over metronidazole (80).  Despite this guideline update the prescription of 
metronidazole for CDI treatment decreased by only 3% in the 18 months that followed this 
change. The use of vancomycin and fidaxomicin did increase significantly during this time (83, 
84). The monoclonal antibody bezlotoxumab, directed against TcdB, has gained approval of 
the U.S. Food & Drug Administration (FDA) in 2016 to be used in CDI treatment (85).
Resistance to vancomycin and metronidazole is relatively rare in C. difficile. Encountered 
resistance rates are also dependent on the method of testing- and breakpoint used, as the 
EUCAST epidemiological cutoff values in determining resistance are lower than the breakpoints 
defined by the Clinical and Laboratory Standards Institute (CLSI) (86-88). According to a 
meta-analysis performed by Saha et al. a significant increase in vancomycin resistance from 
0.4% to 2.3% occurred after 2012 after exclusion of outlier studies (89). In contrast, the 
resistance rate of metronidazole in C. difficile decreased after 2012 from 2.5% to 1.7%. 
Individual metronidazole resistance rates varied from 0% to 18.3%. Metronidazole resistance 
is most frequently encountered in non-toxigenic RT010 isolates and the minimal inhibitory 
concentration (MIC) of metronidazole is higher in RT001 and RT027 strains (88, 90). Vancomycin 
and metronidazole resistant C. difficile isolates were most frequently encountered in North-, 
Central- and South-America and Asia (89). Interestingly, no fidaxomicin resistance was reported 
in the reviewed clinical studies, though preliminary data from the COMBACTE-CDI study show 
that resistance sporadically occurs in Europe (dr. Kerrie Davies, personal communication). No 
resistance development during treatment has been reported for fidaxomicin, but there is one 
mention of a fidaxomicin resistant isolate recovered from a cured CDI patient (91). 
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Although there is no evidence that resistance to metronidazole, vancomycin or fidaxomicin 
correlates with CDI treatment failure, broad-spectrum antibiotics such as metronidazole and 
vancomycin impact the diversity of the gut microbiota and are often unable to eradicate C. 
difficile spores (92). This potentially facilitates recurrent infections which occur frequently. 
Indeed, there is evidence that more than half of all recurrences are caused by infection with 
the original strain (93, 94). The chance for a recurrent infection after an initial episode of 
CDI can be as high as 25% within 30 days of infection clearance, and this risk increases with 
each subsequent recurrent infection (95, 96). For this reason the development of alternative 
treatments is urgent. The rationale behind fecal microbiota transplantation (FMT), a procedure 
in which donor fecal material is transferred to the recipient, is that replenishment of a certain 
gut microbiota composition would reduce the risk of developing recurrent infection as it 
facilitates suppression of C. difficile outgrowth. This procedure has proven highly effective at 
treating recurrent CDI compared to vancomycin and should be considered after a patient has 
had two- or more recurrent infections (97, 98). However, this procedure may not be without 
risk and long-term effects have not been adequately evaluated yet. Fecal material of one donor 
transferred extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli to two patients 
receiving FMT (99). Both patients developed bacteremia and one patient died. Additionally, 
procarcinogenic bacteria such as enterotoxigenic Bacteroides fragilis, Fusobacterium nucleatum, 
and Escherichia coli expressing the colibactin toxin were demonstrated to be transferable by 
FMT, harboring the risk of developing colon cancer in the future (100). As a result of these 
and other outcomes the FDA issued a safety warning regarding the use of FMT and risk of 
serious adverse events. It is now strongly advised to broaden screening of donor fecal material 
for these harmful, transferable micro-organisms. Both beneficial aspects and potentially 
disadvantageous (long term) effects of FMT (including transfer of resistance determinants 
and potentially harmful members of the microbiota) are studied by longitudinally following 
donors and recipients in the Netherlands by the Netherlands Donor Feces Bank located 
at the LUMC (101). However, this current uncertainty advocates for the continued use of 
antimicrobials in CDI treatment. A recently published review found that a vancomycin taper- 
and pulse regime was more effective at treating (recurrent) CDI than initially considered due 
to suboptimal comparisons- and methodology in earlier studies, and that FMT should only be 
considered when recurrent infection is no longer manageable with antimicrobial use (102). 
An extended-pulsed fidaxomicin therapy also resulted in higher sustained clinical cure rates 
than for standard vancomycin therapy (103). As only few antimicrobials are implemented in 
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CDI treatment it is important to understand how resistance- and adaptation to these clinically 
relevant antimicrobials in C. difficile occurs, in order to develop novel drugs and therapeutics 
to treat CDI.
Novel drugs in development against CDI
Novel drugs developed to treat CDI should preferentially be narrow-spectrum in order to 
diminish the disruption of the gut microbiota to reduce the development of recurrence. One 
such novel drug is the DNA replication inhibitor ibezapolstat (formerly known as ACX-362E). 
This compound acts as a dGTP analogue and specifically binds and inhibits the DNA Polymerase 
IIIC (PolC) of different organisms, including C. difficile as was demonstrated in vitro (104). As 
this type of DNA polymerase is absent in Gram-negative organisms the negative impact on 
the gut microbiota would be less pronounced compared to treatments using broad-spectrum 
antimicrobials. Ibezapolstat is currently in clinical development and has completed phase I 
trials, which showed ibezapolstat treatment resulted in a distinct microbiome profile when 
compared to vancomycin (105). Similarly, the novel drug ridinilazole seemed to primarily inhibit 
C. difficile and was not highly effective against other intestinal micro-organisms (106). Although 
its method of action is not entirely clear, preliminary data seem to indicate this compound 
inhibits DNA synthesis (107). It is currently tested in phase 3 clinical trials. Whereas ibezapolstat 
and ridinilazole seem to inhibit C. difficile directly, ribaxamase is a novel drug that inhibits C. 
difficile indirectly. Ribaxamase is a β-lactamase, a type of compound which inhibits β-lactam 
antibiotics. As β-lactams are considered to predispose patients for CDI by disrupting the gut 
microbiota, ribaxamase reduced this probability by inhibiting the negative effects of β-lactams 
on the gut microbiota (108). This drug has completed phase 2 clinical trials.
Although all of the drugs described above are promising candidates, there is no guarantee 
they will reach the market. Both surotomycin and cadazolid illustrate this, as these compounds 
were found to be non-superior and inferior to vancomycin, respectively, in phase 3 clinical 
trials and as a result clinical development was halted (109, 110). Therapies other than small 
molecule drugs designed to treat or prevent CDI are also in development, but will not be 
discussed in this thesis (111). 
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As mentioned above, vancomycin is the primary drug used for CDI treatment. Vancomycin 
is a hydrophilic antimicrobial that inhibits cell wall synthesis. It is able to bind to the 
terminal D-alanyl-D-alanine (D-Ala-D-Ala) moieties of the N-acetylmuramic acid (NAM) and 
N-acetylglucosamine (NAG) peptides of the cell wall backbone, which ultimately inhibits 
crosslinking of the peptidoglycan layer (112). In VRE vancomycin resistance can be mediated 
by vanA and vanB genes which substitute the D-Ala-D-Ala peptides on NAM for D-Alanine-D-
Lactate (D-Ala-D-Lac), reducing the affinity of vancomycin to these residues (112). Worryingly, 
transfer of vanA between VRE and Staphylococcus aureus is possible by horizontal gene transfer 
of the Tn1546 transposon (113). A vanB2 vancomycin resistance operon potentially originating 
from VRE was also found in a C. difficile isolate, although this operon was cryptic (silent) and did 
not confer vancomycin resistance (114). In contrast, active vancomycin gene clusters altering 
peptidoglycan composition have been described in C. difficile as well. The gene cluster vanG in 
C. difficile (vanGCd) is involved in the substitution of D-Ala-D-Ala peptides to D-Alanine-D-Serine 
(D-Ala-D-Ser) and is considered cryptic in different C. difficile strains (115). This cluster was 
expressed in strain 630∆erm, but its activity was not enough to confer vancomycin resistance 
in this strain. However, this originally cryptic cluster was shown to be activated by mutations in 
the genes encoding the VanSR two-component system in RT027 strains, increasing vancomycin 
tolerance in these isolates (116).  A different study has generated C. difficile isolates with 
reduced vancomycin susceptibility by serial passaging under selection and analyzed these with 
whole genome sequencing (WGS) (117). In the isolates with reduced vancomycin susceptibility 
mutations were found in murG and rpoC. MurG is involved in peptidoglycan synthesis by 
converting lipid I to lipid II and the mutated murG could reduce vancomycin affinity for the 
D-Ala-D-Ala portion of lipid II. The mutation in rpoC was somewhat surprising as these kind 
of mutations commonly reduce the effectivity of RNA polymerase (RNAP) inhibitors which 
are not considered the target of vancomycin. However, rpoC mutations have been known to 
inhibit antimicrobials that do not act on RNAP (118).
Metronidazole resistance
Although vancomycin is recommended as first line treatment for CDI in guidelines in the 
US, metronidazole use has not decreased severely (83, 84). Metronidazole is considered 
as a first choice treatment for infections with anaerobic bacteria and is also commonly 
used as prophylaxis for many surgical procedures  (119, 120). Metronidazole is effective in 
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microaerophilic organisms such as Helicobacter pylori and in anaerobes like B. fragilis and C. 
difficile (121, 122). It has been widely used against protozoa such as Giardia lamblia, Entamoeba 
histolytica and Trichomonas vaginalis (123). (119). Metronidazole is a nitroimidazole, which 
is a prodrug that requires reduction of its nitro-group under low oxygen tension to become 
activated and therefore cytotoxic (124). It is considered to enter cells by passive diffusion 
mediated by a concentration gradient of activated and inactivated metronidazole (125). 
Pyruvate:ferredoxin oxidoreductase (PFOR) is an enzyme involved in fermentation and catalyzes 
production of acetyl-CoA from pyruvate. The electrons generated in this reaction are transferred 
to ferredoxins (126). After metronidazole uptake by passive diffusion, the electrons generated 
in this reaction are transferred to its nitro group instead of to ferredoxin due to the latter’s low 
redox potential (126). Other effectors with sufficiently low redox potential able to reductively 
activate metronidazole are flavodoxin and hydrogenase, as was seen in Clostridium pasteurianum 
(127, 128). Reductive activation of metronidazole results in formation of nitro-radicals which 
are postulated to cause DNA damage (129, 130). While wildtype E. coli is resistant, strains 
deficient in DNA repair mechanisms were found to be more susceptible to metronidazole in 
anaerobic environments, implying metronidazole is indeed bactericidal by damaging DNA 
(131, 132). Alternatively, the ability of metronidazole to act as an electron sink may disturb the 
proton motive force and reduce ATP production which may ultimately be toxic to cells (124).
Metronidazole resistance mechanisms reported in other organisms include alterations in 
PFOR activity or the presence of 5-nitroimidazole reductase (nim) genes (124, 133-137). These 
modifications decrease the reductive activation of metronidazole or reductively inactivate 
metronidazole to a stable, non-toxic intermediate. Alternatively, adaptations in the oxidative 
stress response will allow cells to better handle the bactericidal effects caused by activated 
metronidazole (124). Understanding of metronidazole resistance in C. difficile is fairly limited. 
Experiments conducted with strains which developed reduced metronidazole susceptibility 
due to evolution under metronidazole pressure in the laboratory, have been informative on 
the underlying processes associated with metronidazole resistance. For instance, a clinical 
isolate of RT027 that was serially passaged to become stably metronidazole resistant developed 
mutations in hemN (coproporphyrinogen III oxidase) and fur (ferric uptake regulator), involved 
in electron transport- and iron utilization pathways respectively (138).  In line with these findings 
are the results of a study performed on a mismatch repair deficient mutator strain which was 
evolved under metronidazole pressure (139). In this strain mutations in the iron transporter 
557028-L-sub01-bw-Boekhoud




feoB1 increased the MIC to metronidazole and additional mutations in nifJ (pyruvate-ferredoxin 
oxidoreductase, PFOR), xdh (xanthine dehydrogenase) or the iron-sulfur cluster regulated 
iscR further decreased its susceptibility to metronidazole. Although the mutations found in 
feoB1 were required before the other detected mutations had any effect on metronidazole 
susceptibility, these results also illustrate the importance of electron transport, iron utilization 
and fermentation in metronidazole activity. In contrast, a RT027 isolate serially passaged on 
metronidazole which developed stable metronidazole resistance was analyzed by a shotgun 
proteomics approach. In the resistant isolate a role was found for DNA repair proteins and 
putative nitroreductases (140). However, as these studies were performed with laboratory 
evolved strains, they do not demonstrate how clinical C. difficile isolates are resistant to 
metronidazole. Proteomic analysis on nontoxigenic RT010 isolates with reduced susceptibility- or 
resistance to metronidazole revealed an increase in RecA after exposure to the antimicrobial, 
which is involved in DNA repair, but there appeared to be no straightforward relationship 
between metronidazole resistance and changes in Pfo/NifJ protein levels (141). In summary, 
it seems iron homeostasis, DNA repair and electron transport are plausible targets for the 
development of metronidazole resistance in C. difficile.
Fidaxomicin resistance 
The advantage of fidaxomicin to metronidazole and vancomycin is that fidaxomicin has a smaller 
spectrum of activity, which reduces disruption of the microbiota and subsequent predisposition 
for CDI development as explained previously (142). Although the mechanism of action of 
fidaxomicin is not yet entirely clear, it is thought to inhibit transcription by interaction with the 
RNA polymerase. After serial passaging, mutations in rpoB, rpoC and CD2212 have been found 
in  strains with reduced susceptibility to fidaxomicin (117, 143, 144). One clinical isolate with 
significantly reduced fidaxomicin susceptibility contained a Val1143Asp substitution in rpoB, 
and introducing this mutation in 630∆erm also reduced fidaxomicin susceptibility in this strain 
(145). Other mutations in rpoB resulting in amino acid substitutions such as Val1143Phe and 
Val1143Gly can cause reduced susceptibility to fidaxomicin, although these- and Val1143Asp 
mutations were associated with a fitness cost in C. difficile (145, 146). This fitness cost was 
not observed for rpoB mutations conferring resistance to rifamycins. This may explain why 
fidaxomicin resistance is not encountered frequently in clinical C. difficile isolates, even though 
decreased fidaxomicin susceptibility is developed easily under selective pressure (68).
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Adaptation and tolerance in C. difficile
Apart from acquiring antimicrobial resistance mechanisms it is known that increased tolerance 
or persistence can contribute to survival during antimicrobial exposure. This quiescent, 
dormant state desensitizes cells to antimicrobials without increasing the MIC established 
during antimicrobial susceptibility testing (147). The ability of bacteria to become more tolerant 
to antimicrobials results from their necessary ability to adapt to environmental conditions 
and repair (DNA) damage. Bacteria can induce alterations in replication and transcription 
in order to become more tolerant to these hostile conditions. For instance, the digestive 
tract is an environment in which bacteria encounter variable nutrient availability, different 
oxygen tensions, bile salts, pH- and temperature variations and bacterial competition (149). 
Additionally, infectious bacteria need to be able to withstand the host inflammatory response 
and antimicrobial compounds produced by both the host and resident microbiota  (150). 
Although more mechanisms and cellular responses can lead to tolerance or persistence, the 
SOS response and the general stress response are known to contribute to these tolerant states, 
and they also play a role in antimicrobial resistance (149). 
Figure 2. Genomic organization of the σB operon and its regulators in different Gram-positive organisms. 
Bent arrows indicate the location of a promoter and the sigma factor involved in its transcription. Slashes 
indicate a gap in chromosome location. Adapted from (148).
 
The SOS response is a regulatory network activated in response to DNA damage and initiates 
DNA repair (151). It is regulated by the transcriptional repressor LexA and the inducer 
RecA (152). Other than DNA repair the SOS response is involved in other processes such as 
pathogenesis, biofilm production and antimicrobial resistance (153). In C. difficile, the SOS 
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response was demonstrated to control biofilm- and toxin production and sporulation in addition 
to DNA repair (152). Activation of the SOS response was shown to stimulate persister cell 
formation in E. coli and can stimulate spread of antimicrobial resistance genes by horizontal 
gene transfer (142, 154, 155). Certain antimicrobials such as  tetracyclines, (fluoro)quinolones 
and aminoglycosides are known to induce the SOS response in other organisms (142, 155, 156). 
In C. difficile, the fluoroquinolone levofloxacin was shown to induce the SOS response (152).
In addition to the SOS response, the general stress response is important in regulating adaptation 
to hostile conditions. This response is regulated by sigma factor B (σB; encoded by the sigB 
gene) in Gram-positive organisms such as Bacillus cereus and C. difficile (157). Sigma factors are 
a subunit of the RNA polymerase holoenzyme and confer specificity to the RNA polymerase, 
initiating transcription of genes belonging to the regulon of the specific sigma factor. It was 
demonstrated to be important for survival in the presence of reactive oxygen species (ROS), 
hydrogen peroxide and during acid- and heat stress in organisms like Listeria monocytogenes 
and Staphylococcus aureus (158, 159). In C. difficile this sigma factor was shown to be involved 
in sensitivity to mitomycin C, rifampicin and the nitrous oxide donor diethyl-amine NoNoate 
(DEA/NO) (160). It also proved important for survival during low oxygen tension (161). 
Environmental stressors and/or nutrient depletion can lead to σB-mediated transcription, 
which is tightly regulated under unstressed conditions due to its significant energy burden and 
associated toxicity (162). A conserved partner-switching mechanism regulates σB activity (148). 
In inactive state the anti-sigma factor RsbW is bound to σB and consequently inhibits its activity. 
Upon encountering σB-activating (environmental) stressors, the anti-anti sigma factor RsbV 
is dephosphorylated by a phosphatase upon which it is able to bind to- and sequester RsbW, 
allowing σB to interact with the RNA polymerase. The proteins involved in dephosphorylation of 
RsbV are stressor- and species specific as the sigB-operon of different organisms encompasses 
different genes (Figure 2) (148). For instance, B. subtilis and L. monocytogenes are able to form 
a stressosome composed of proteins RsbR, RsbS, RsbT and RsbX, all located in the operon 
which also encodes σB, upstream of rsbV and rsbW (163). This stressosome is activated upon 
encountering environmental stress and activates RsbU, which in turn dephosphorylates RsbV. 
When undergoing energy stress or environmental stress, RsbP and RsbU, respectively, are 
ultimately responsible for RsbV dephosphorylation in B. subtilis and L. monocytogenes (148, 
164). RsbP is thought to be activated by the hydrolase RsbQ which could act as a cofactor for 
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RsbP (165). Alternatively, RsbU activity is controlled by the RsbT and RsbS proteins which are 
a part of the stressosome (148). Energy and environmental stress signals are combined in B. 
cereus by the multi-sensor hybrid kinase RsbK which acts on RsbY, leading to dephosphorylation 
of RsbV (166). Although the σB operon in S. aureus does contain rsbU, it does not possess 
rsbRST or rsbX and RsbU seems to play a different role in S. aureus than it does in B. subtilis 
(167, 168). It is possible S. aureus RsbU activity is regulated by an as of yet unknown protein 
encoded elsewhere on the chromosome, as is the case for RsbQ and RsbY in B. subtilis and 
B. cereus, respectively.
The genomic organization of the sigB-containing operon in C. difficile differs from other 
organisms as four genes are upstream of sigB, including RsbV-, RsbW-, and two genes of 
unknown function that do not appear to be involved in regulation of σB (160, 169). The PP2C 
phosphatase responsible for dephosphorylation of RsbV in C. difficile is named RsbZ and is 
located downstream the sigB promoter adjacent to CD2684 (169). Although the σB regulon in 
B. subtilis and L. monocytogenes consists of approximately 150- and 130 genes, respectively, 
σB was proposed to control almost a 1000 genes in C. difficile (148, 160).
Apart from having a crucial role in survival in the hostile environment encountered during 
the bacterial life cycle, σB seems to also be involved in antimicrobial resistance. In S. aureus 
σB overproduction lead to thickening of the cell wall and increased resistance to beta-lactam 
antimicrobials (170). Additionally, σB was involved in resolving growth-arrest induced by 
rifampin in B. subtilis (171). In C. difficile, knowledge about the role of σB in C. difficile and how 
it influences antimicrobial resistance is limited. Hydrogen peroxide, rifampicin and mitomycin 
C were more lethal against a sigB mutant strain compared to wildtype, but the mechanism 
behind this is unclear (160).
In order to develop new therapeutics against C. difficile it is important to understand how 
antimicrobial resistance and adaptation occur in this organism. A more complete understanding 
of these processes will demonstrate novel pathways and subsequent targets for drug 
development or alternative treatment strategies.
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Outline of this thesis
This introduction provides an oversight of C. difficile as a pathogen and why antimicrobial use 
is such an important risk factor for CDI. Metronidazole, fidaxomicin and vancomycin resistance 
are discussed, as well as other processes that contributes to the resilience of C. difficile. Chapter 
2 describes how a novel drug in clinical development, ibezapolstat (ACX-362E), inhibits the 
DNA polymerase and is able to cause a gene-dosage shift. This study demonstrated that an 
indirect effect of this gene-dosage shift is mediated by σB due to its origin-proximal location. 
Chapter 3 describes that the σB regulon is much smaller than previously proposed and that a 
substantial part is involved in detoxification of oxidative- and nitrosative stresses. Hydrogen 
peroxide and antimicrobials with a different mechanism of action, including ibezapolstat and 
metronidazole, activated σB-controlled genes in a manner dependent on this sigma factor. 
Chapter 4 describes the discovery of the plasmid pCD-METRO which mediates metronidazole 
resistance in clinical C. difficile isolates and is most likely acquired horizontally from an unknown 
donor organism. Chapter 5 illustrates that clinical C. difficile isolates utilize heme to become 
less susceptible to metronidazole and that a deletion in hsmA correlates with heme-mediated 
metronidazole resistance in a specific PCR ribotype. Chapter 6 is the general discussion and 
provides an outlook of the results described in this thesis.
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Clostridioides difficile is a potentially lethal gut pathogen that causes nosocomial and community 
acquired infections. Limited treatment options and reports of reduced susceptibility to current 
treatment emphasize the necessity for novel antimicrobials. The DNA-polymerase of Gram-
positive organisms is an attractive target for the development of antimicrobials.  ACX-362E 
(N2-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine; MorE-DCBG) is a DNA polymerase 
inhibitor in pre-clinical development as a novel therapeutic against C. difficile infection. This 
synthetic purine shows preferential activity against C. difficile PolC over those of other organisms 
in vitro and is effective in an animal model of C. difficile infection. In this study we have 
demonstrated that at concentrations below the minimal inhibitory concentration, the presumed 
slowing (or stalling) of replication forks due to ACX-362E leads to a growth defect. We have 
determined the transcriptional response of C. difficile to replication inhibition and observed 
an overrepresentation of up-regulated genes near the origin of replication in the presence of 
PolC-inhibitors, but not when cells were subjected to sub-inhibitory concentrations of other 
antibiotics. This phenomenon can be explained by a gene dosage shift, as we observed a 
concomitant increase in the ratio between origin-proximal versus terminus-proximal gene copy 
number upon exposure to PolC-inhibitors. Moreover, we show that certain genes differentially 
regulated under PolC-inhibition are controlled by the origin-proximal general stress response 
regulator sigma factor B.  Together, these data suggest that genome location both directly 
and indirectly determines the transcriptional response to replication inhibition in C. difficile.
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 27
27
Genome location dictates the transcriptional response to PolC-inhibition in Clostridioides difficile
2
Introduction
Clostridioides difficile, formerly known as Clostridium difficile (3), is a Gram-positive, anaerobic 
bacterium that can asymptomatically colonize the intestine of humans and other mammals (2, 
20, 172). However, when the normal flora is disturbed C. difficile can overgrow and cause fatal 
disease, as has been dramatically demonstrated in the Stoke Mandeville Hospital outbreaks in 
2004 and 2005 (173). The ability to form highly resistant endospores coupled to its extensive 
antibiotic resistance have contributed to its success as a nosocomial and community acquired 
pathogen (2, 20, 172). Recent years have seen an increase in the incidence and severity of C. 
difficile infections (CDI), due to the emergence of certain PCR ribotypes (20, 174). Antibiotic 
use is a well-established risk factor for CDI (175), and the emergence of the epidemic PCR 
ribotype 027 has been linked to fluoroquinolone resistance (44). At present two antibiotics, 
metronidazole and vancomycin are commonly used to treat CDI and a third, fidaxomicin, is 
indicated for the treatment of relapsing CDI (176, 177). Clearly, limited treatment options and 
reports of reduced susceptibility to current treatment (88, 140, 178) emphasize the necessity 
for the development of novel antimicrobials and a better understanding of tolerance and 
resistance towards existing therapeutics. 
It is increasingly realized that off-target effects that occur when cells are exposed to 
antimicrobials  can contribute to their efficacy, but also facilitate the emergence of tolerance 
and/or resistance (179). Antimicrobials may act as signaling molecules which modulate gene 
expression (179). Additionally, in particular those targeting DNA replication (such as polymerase 
inhibitors) can cause transcriptional effects as a result of differences in gene dosage (180).
The polymerase of Gram-positive organisms is an attractive target for the development of 
novel antimicrobials (181). First, these PolC-type polymerases are absent from Gram-negative 
organisms and humans (182, 183). HPUra, one of the first such compounds, is therefore highly 
active against a wide range of Gram-positive bacteria, but does not affect Gram-negative bacteria 
(182, 183). Template-directed elongation is blocked by the inhibitor through simultaneous 
binding to the cytosine of the DNA strand and near the active site of PolC. Second, compounds 
can be derived that have an increased specificity towards specific microorganisms. ACX-362E 
(Figure 1) is a compound in pre-clinical development as a novel therapeutic against C. difficile 
as it is shows preferential activity against C. difficile PolC over those of other organisms in vitro 
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(184, 185), and will progress to clinical trials in the near future (Acurx Pharmaceuticals, personal 
communication). PolC-inhibitors can cause a stress response and cell death after prolonged 
exposure. In Bacillus subtilis, this stress is characterized by a combination of DNA damage (SOS) 
response, and an SOS-independent pathway dependent on the DNA replication initiator DnaA 
(186, 187). In Streptococcus pneumoniae cells, devoid of an SOS-response, competence for 
genetic transformation is induced upon replication stress (188). The response of C. difficile to 
this particular class of compounds is unknown. 
Figure 1. Mechanism of action of the PolC-inhibitors ACX-362E. A) Ternary complex of inhibitor ACX-
362E, DNA, and PolC. B) H-bonding between inhibitor molecule ACX-362E and a cytosine residue of 
DNA.
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In this study, we characterized aspects of the action of PolC-inhibitors towards C. difficile. We 
investigated the effects of sub-inhibitory levels of PolC-inhibitors on growth of C. difficile in 
liquid medium and performed RNA-seq analyses to determine the transcriptional response 
to PolC-inhibitors in our laboratory strain 630Δerm. Finally, marker frequency analysis and 
transcriptional reporters were used to provide a mechanistic explanation for the observed 
up-regulation of origin-proximal genes under conditions of replication inhibition.  
 
Results 
Treatment with ACX-362E leads to a pleiotropic transcriptional response
In order to determine the transcriptional response of PolC-inhibitors, we established the 
optimal concentration of both inhibitors which affected growth of C. difficile in liquid medium. 
The laboratory strain C. difficile 630Δerm (PCR ribotype 012, MLST Clade 1)(189, 190) was 
grown in medium with varying amounts of HPUra (10-40 μg/mL) or ACX-362E (0.25-8 μg/
mL) (Supplemental Figure 1). The growth kinetics of C. difficile under the influence of varying 
concentrations of HPUra was marginally affected when using concentrations from 10-40 µg/
ml, at >80 percent of the non-treated culture. Growth kinetics of cultures containing PolC-
inhibitor ACX-362E 1-8 µg/ml were similar and resulted in -30-40 percent reduced growth 
compared to the untreated culture. For subsequent experiments we used concentrations of 
PolC-inhibitors that result in a maximum reduction in growth of 30% compared to a non-treated 
culture (Supplemental Figure 1) (HPUra: 35 μg/mL; ACX-362E: 4  µg/mL).
Above, we established that growth of C. difficile is partially inhibited at certain concentrations 
of PolC-inhibitors. Slowing down or stalling of replication forks might lead to a stressed 
state, as observed for other organisms (187, 188). As nothing is known about the effect 
of replication inhibition on the physiology of C. difficile, we determined the transcriptional 
response to replication inhibition by sub-MIC levels of PolC-inhibitors through strand-specific 
RNA sequencing (RNA-Seq).
C. difficile 630Δerm was grown for 5h in medium with HPUra (35 μg/mL) or ACX-362E (4  µg/
mL) starting from an OD600 of 0.05 after which cells were harvested for RNA isolation. Purified 
RNA was converted to cDNA and used for RNA-Seq as described in the Materials and Methods. 
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For ACX-362E, 722 genes were differentially expressed, of which 438 genes were up-regulated 
and 284 genes were down-regulated. The number of differentially expressed genes in HPUra 
treated samples was approximately 2-fold lower: 360, of which 124 genes were up-regulated 
and 236 genes were down-regulated. The full list of differentially regulated genes is available 
as Supplemental Table 1 and the top 10 of up- and down-regulated genes are shown in Table 
1 (HPUra) and Table 2 (ACX-362E). Here, we highlight three aspects of the results. 
First, we performed a Gene Set Enrichment Analysis (GSEA)(191) via the Genome2D web 
server (192) using the locus tags of the differentially regulated genes (Supplemental Table 1) 
as input. Among the genes up-regulated by ACX-362E, there is a strong overrepresentation of 
those involved in translation, ribosome structure and ribosome biogenesis. Not unexpectedly, 
also replication, recombination and repair processes are affected. This suggests that genes 
from these pathways show a coordinated response in the presence of ACX-362E. Among the 
genes down-regulated in the presence of ACX-362E, the levels of significance for specific 
processes are generally much lower, suggesting that there is a more heterogeneous response 
among genes from the same pathway. Nevertheless, metabolic pathways (especially carbon 
metabolism and coenzyme A transfer) and tellurite resistance were found to be significantly 
affected. Strikingly, a GSEA analysis on lists of genes that are differentially expressed in the 
presence of HPUra revealed similar processes to be affected.
The findings from the GSEA analysis prompted us to evaluate the overlap in the lists of 
differentially regulated genes between the ACX-362E and HPUra datasets in more detail. If 
both compounds act via a similar mechanism, we expect a conserved response. Indeed, we 
observe that >90% of the genes that are up-regulated in the presence of HPUra compared to 
the non-treated condition, are also identified as up-regulated in the presence of ACX-362E 
(Figure 2A). Though the overlap is not as strong for the down-regulated genes, we find that 
>30% of the genes affected by HPUra are also identified as affected by ACX-362E (Figure 2B). 
Notably, the directionality of the response is conserved, as no genes were found to be up-
regulated in one but down-regulated in the other condition. Based on these observations, 
we believe that the differentially expressed genes identified in this study are representative 
for a typical response to inhibition of PolC in C. difficile.
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Finally, we related the changes in transcription to genome location. C. difficile has a single 
circular chromosome and one origin of replication (oriC) from which the process of DNA 
replication occurs bi-directionally towards the terminus (terC) (Figure 3A). Though neither 
oriC nor terC has been definitively defined for C. difficile, it is assumed that oriC is located at or 
near dnaA (CD0001; CD630DERM_RS00005). The terminus region is generally located at the 
inflection point of a GC skew ([G - C]/[G + C]) plot. Such a plot places the terC region around 
2.2Mb from CD0001, near the CD1931 (CD630DERM_RS10465) open reading frame (Figure 
3A) (193). We noted that the differential expression appeared to correlate with genome 
location (Table 1, Table 2 and Supplemental Table 1): many of the up-regulated genes have 
either low or high gene identifiers (CD numbers) indicative of an origin proximal location and, 
conversely, many of the down-regulated genes appear to be located away from oriC. Though 
this correlation is not absolute, we observed a clear trend when plotting the mean fold-change 
against genome location for all genes (Figure 3B).
Overall, our data shows that inhibition of DNA replication by PolC-inhibitors causes a consistent 
and pleiotropic transcriptional response that is at least in part is directly dictated by genome 
location.
Gene dosage shift occurs at sub-inhibitory concentrations of ACX-362E PolC-inhibitor
A possible explanation for the relative up-regulation of oriC-proximal genes and down-regulation 
of terC-proximal genes is a gene dosage shift (195-197), due to the fact that PolC-inhibition 
slows down replication elongation but does not prevent re-initiation of DNA replication (188, 
198). To determine if this in fact occurs in C. difficile when replication elongation is inhibited, 
we performed a marker frequency analysis (MFA) to determine the relative abundance of an 
origin proximal gene relative to terminus proximal gene on chromosomal DNA isolated from 
treated and untreated cells.
We designed qPCR probes against the CD0001 and CD1931 regions, representing oriC and 
terC, respectively (190, 193). Using these probes, we could show that C. difficile demonstrates 
multi-fork replication in exponential growth phase and that the MFA assay detects the expected 
decrease in oriC:terC ratio when cells enter stationary growth phase (data not shown). Next, 
we analyzed the effects of PolC-inhibitors on the oriC:terC ratio. When cells were treated with 
HPUra (35 μg/mL), the MFA showed a modest increase in oriC:terC ratio of 2,6-fold compared 
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to untreated cells. However, when cells were treated with ACX-362E (4 µg/ml), the MFA showed 
a >8-fold increase in the oriC:terC ratio compared to untreated cells. In contrast, such an 
increase was not observed for cells treated with metronidazole (0.25 ug/mL; a DNA damaging 
agent), fidaxomicin (0.00125 ug/mL; an RNA polymerase inhibitor) or surotomycin (0.625 ug/
mL; a cell-wall synthesis inhibitor) (Figure 4) or chloramphenicol (2 μg/mL; a protein synthesis 
inhibitor) (Supplemental Figure 2). We conclude that inhibition of PolC-activity, but not the 
actions of any of the other tested antimicrobials, lead to a gene dosage shift in C. difficile.
Figure 2. Overlap in the transcriptional response to different PolC-inhibitors.  A) Venn diagram 
of the number of genes up-regulated in the presence of ACX-362E (red), in the presence of HPUra 
(blue) or under both conditions (overlapping region). B) Venn diagram of the number of genes down-
regulated in the presence of ACX-362E (red), in the presence of HPUra (blue) or under both conditions 
(overlapping region). The size of the circles is proportional to the number of genes that showed 
differential expression.
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Figure 3. Genome location correlates with differential expression upon PolC inhibition. A)  Schematic 
representation of the chromosome of C. difficile. Higher than average GC skew ([G - C]/[G + C]) (red) and 
lower than average GC skew (blue) were calculated with DNAPlotter (194). Vertical lines indicate the 
position of the predicted origin (oriC) and terminus (terC) of replication. Arrows indicate the direction 
of replication.  B) Sliding window analysis (bins of 51 loci, step size 1) of the median log fold change 
(FC) projected on a linear genome map. The oriC of the circular chromosome is located on either size 
of the linear graph (0/4.29Mb), whereas terC is indicated with a vertical red line. The trend in log(FC) is 
highlighted using a green line. Light blue shading indicates the median absolute deviation of the mean 
(188).
Figure 4. Polymerase inhibitors lead to an increase in oriC:terC ratio. A marker frequency analysis of 
the effects of sub-inhibitory amounts of polymerase inhibitors (red; HPUra: 35 μg/mL; ACX-362E: 4 μg/
mL) and three antibiotics with different modes of action (blue; metronidazole: 0.25 μg/mL; fidaxomicin: 
0.00125 ug/mL, surotomycin: 0.625 μg/mL) compared to non-treated cells (black). Datapoints are 
averages of technical replicates (N=3). Black lines behind the datapoints indicate the average of the 
biological replicates (N=3) and whiskers indicate the standard deviation of the mean. Data have been 
normalized compared to the non-treated control. The mean of HPUra and ACX-362E treated samples is 
statistically different from the other samples (p<0.0001).
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Origin proximal sigB contributes to the transcriptional response
Elegant work in S. pneumoniae has shown that the transcriptional response to replication 
inhibition can also be affected by origin-proximal regulators that respond to the gene dosage 
effect (188). In C. difficile the gene encoding the general stress response sigma factor σB (sigB, 
CD0011) is located close to the origin of replication (199). We wondered whether this regulator 
contributes to the transcriptional effects observed in our studies. 
First, we compared the list of differentially regulated genes from our study (Supplemental Table 
1) to those under the control of σB (160). In contrast to most anaerobic gram-positive organisms, 
C. difficile encodes a homolog of the general stress response sigma factor, σB (199, 200).  A 
transcriptome analysis comparing sigB mutant versus wild type cells was recently published 
(160). Strikingly, we find ~40% of the genes (21/58) identified as involved in stress response 
under the control of σB to be differentially expressed in our ACX-362E dataset (Supplemental 
Table 2). Similarly, we observed that 7/20 (~35%) of the genes containing a transcriptional 
start site with a σB consensus sequence are differentially expressed in our ACX-362E dataset 
(Supplemental Table 2). These data suggest that the response to DNA replication inhibition 
is at least partially dependent on σB. 
To demonstrate that exposure to ACX-362E causes a transient up-regulation of sigB, we 
constructed a reporter fusion of the secreted luciferase reporter sLucopt with the predicted 
promoter of the sigB operon (PCDC0007). We monitored luciferase activity of a strain harboring 
a plasmid containing this reporter fusion (WKS2003) after dilution of an overnight culture 
into fresh medium with or without ACX-362E (Figure 5). In non-treated cells, expression from 
the sigB promoter is relatively stable over the course of 5.5h. By contrast, luciferase activity 
strongly increases from 1.25h to 3h after inoculation into medium with ACX-362E. These data 
show that exposure to ACX-362E transiently induces transcription of the sigB operon. 
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Figure 5. The sigB operon is transiently induced upon exposure to ACX-362E. The putative promoter 
of the sigB operon (160) was fused transcriptionally to a plasmid-based luciferase reporter (201). 
Luciferase activity was measured regularly between 30 mins and 5.5h of growth in liquid medium in 
the presence (+362E) or absence (no Ab) of polymerase inhibitor ACX-362E.
Next, a sigB mutant was constructed using Allele-Coupled Exchange (202) as described in the 
Materials and Methods. The chromosomal deletion of sigB and absence of σB protein was 
verified by PCR and Western Blot, respectively (Supplemental Figure 3). To directly demonstrate 
a role for sigB in the regulation of genes with altered transcription upon PolC-inhibition, we 
fused the predicted promoter regions of selected genes to a secreted luciferase reporter 
(201) and evaluated luminescence in wild type and sigB mutant backgrounds, after 5-hour 
growth in the presence and absence of 4 µg/mL ACX-362E.  All genes tested demonstrated 
a significant increase in promoter activity in a wild type background in the presence of ACX-
362E compared to the non-treated control, validating the results from the RNA-Seq analysis 
(Figure 6).  Three distinct patterns were observed. For CD0350 (encoding a hypothetical 
protein) and CD3963 (encoding a putative peptidoglycan-binding exported protein) there was 
virtually no expression in a sigB mutant background (Figure 6A and B). We conclude that these 
genes are strictly dependent on σB for their expression under the conditions tested. CD3614 
(encoding a hypothetical protein) shows a basal level of expression, but no significant increase 
in transcription levels in the presence of ACX-362E in a sigB mutant background compared to 
the non-treated control (Figure 6C). This suggests that the transcriptional up-regulation under 
these conditions is σB dependent, and indicates that the basal level of transcription observed is 
likely independent of σB. Finally, CD3412 (uvrB, encoding a subunit of an excinuclease) shows 
reduced transcriptional up-regulation in ACX-362E treated cells compared to non-treated 
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controls (Figure 6D). Thus, the transcription of this particular gene under conditions of ACX-362E 
exposure is brought about by both a σB-dependent and a σB-independent regulatory pathway. 
Together, these results demonstrate that sigB controls the expression of at least a subset of 
genes that are up-regulated under PolC-inhibition. 
Figure 6. Genes differentially expressed due to polymerase inhibitors are regulated by σB. The putative 
promoters of the indicated genes were fused transcriptionally to a plasmid-based luciferase reporter 
(201). Luciferase activity was measured after 5 h of growth in liquid medium in the presence (+362E) 
or absence (no Ab) of polymerase inhibitor ACX-362E. N.S. = non-significant, *=p<0.05, **=p<0.005, 
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Discussion
Activity and specificity of ACX-362E 
Limited treatment options and reports of reduced susceptibility to current treatment (140, 
178, 203) emphasize the necessity for the development of novel antimicrobials. As CDI can 
be induced by use of broad spectrum antibiotics (175), new antimicrobials ideally should only 
target C. difficile, thereby maintaining integrity of the colonic microbiota. In this study, we have 
tested inhibitors HPUra and ACX-362E which specifically target the PolC enzyme, essential for 
DNA replication. The majority of PolC-inhibitors target Gram-positive bacteria with low G+C 
content, but ACX-362E has been reported to demonstrate increased specificity towards C. 
difficile PolC in vitro and showed promising results for the efficacy in vivo based on a limited set 
of C. difficile strains (184, 185). The compound will progress to clinical trials in the near future 
(Acurx Pharmaceuticals, personal communication). Mutations that abolish binding of HPUra 
or ACX-362E are likely to affect the essential enzymatic activity of the polymerase and for that 
reason unlikely to occur in vivo. A single mutation (azp-12) has been described in B. subtilis 
that confers resistance to HPUra (204). This T>G transversion results in the replacement of a 
serine with an alanine  in the highly conserved PFAM07733 domain of the polymerase (205). 
To our knowledge, it is unknown whether this mutation prevents binding of HPUra to PolC 
of B. subtilis. Few other mutations have been described that confer resistance against other 
PolC-inhibitors (206, 207). It will be of interest to see if similar mutations in C. difficile result 
in resistance to HPUra and/or ACX-362E and what the effect on binding of these compounds 
to C. difficile PolC is. 
ACX362 may have off-target effects unrelated to its replication-inhibitory activity. For C. difficile, 
it has not been established that PolC inhibition is the sole mode of action of the inhibitor. 
PolIII-inhibitors can affect PolC, DnaE or both (207), though in vivo activity appears to correlate 
with PolC-inhibition. C. difficile possesses PolC and DnaE polymerase (208). To verify the mode 
of action the activity of ACX-362E towards purified DnaE and PolC should be determined.
Though there is an indication that ACX-362E inhibits C. difficile efficiently and shows limited 
activity towards certain other anaerobes (184), these findings highlight the necessity to perform 
additional (microbiome) studies to more clearly define the antimicrobial spectrum of this 
compound. It also shows that ACX-362E may have therapeutic potential outside treatment of CDI. 
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Regulators of the transcriptional response to PolC-inhibitors
The present study is the first to describe the transcriptional response of C. difficile to inhibition 
of DNA replication. We find that ~200 genes show differential expression under conditions 
of PolC-inhibition by both HPUra and ACX-362E, when compared to non-treated cells. When 
considering only ACX-362E, approximately 13% of all genes in the genome show statistically 
significant altered transcription. We demonstrate that this large reprogramming of transcription 
is likely to be caused directly by a gene dosage shift.
In addition to direct effects, it is conceivable that at least part of the transcriptional response 
is indirect. Our list of differentially regulated genes includes several putative regulators; sigma 
factors (including sigE, sigG and sigH), transcription factors and anti-terminators. The relatively 
long time (5h) at sub-MIC levels of antimicrobials may have contributed to secondary effects, 
through one or more of these regulators. Though shorter induction times are thought to provoke 
more compound-specific responses (209), we did observe a highly consistent transcriptional 
signature with both HPUra and ACX-362E.
Major stress response pathways are poorly characterized in C. difficile. On the basis of 
experiments in other organisms (186-188, 210-212), we expect that inhibition of DNA replication 
inhibition might possibly induce an SOS response (LexA)(213), a DnaA-dependent transcriptional 
response (186), and possibly a heat shock response (HrcA/CtsR)(214) and/or a general stress 
response (σB)(200). Of these, the best characterized stress response pathway in C. difficile 
is the one governed by σB (160). We noted a significant overlap in putatively σB-dependent 
genes and those differentially expressed upon exposure to PolC-inhibitors. In addition, our 
luciferase reporter fusions directly implicate sigB in the expression and/or up-regulation of 
some of these. It should be noted that the sigB-operon itself was not differentially expressed 
in our RNA-seq analysis. A sigB-reporter fusion suggests that sigB is transiently up-regulated 
prior to the time point of sampling for the RNA-Seq analysis. Similar transient up-regulation of 
sigB followed by a persistent response of σB-dependent gene expression has been observed 
in other organisms (214-216). To our knowledge, this is the first indication that sigB- and σB 
-dependent gene expression could be subject to a gene-dosage effect.
To date, no genes have been identified that are regulated by DnaA in C. difficile and direct 
regulation of genes through the other stress response pathways has not been demonstrated. 
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Many parameters (such as the medium used, cell density, concentration of antibiotics, and 
protocol used to arrest transcription between cell harvest and lysis) can influence overall 
transcription signatures (209), and can also govern an incomplete overlap between our data 
and the stress regulons proposed by others (215-217). 
Genome location contributes to the transcriptional response to PolC-inhibition
Our analysis of differential regulation in relation to genome location revealed a striking pattern 
of relative up-regulation for oriC-proximal genes, and down-regulation for terC-proximal genes 
under conditions of PolC inhibition. Antimicrobials directed at DNA replication in bacteria 
have a profound negative effect on the processivity of replication forks, though initiation of 
DNA replication is not or only marginally affected (188, 198). As a consequence, the presence 
of multiple replication forks simultaneously increases the copy numbers of genes located in 
close proximity of the origin of replication and such a gene dosage differences can result in 
functionally relevant transcriptional differences, either directly or indirectly (180). We found an 
increase of oriC:terC ratio when performing MFA on chromosomal DNA of cells subjected to a 
sub-inhibitory concentration of ACX-362E (and HPUra, albeit less pronounced), consistent with 
findings in other organisms (188). This is the first demonstration of gene-dosage dependent 
transcriptional regulation in C. difficile. Our experiments suggest that at least part of the 
transcriptional response to PolC-inhibition can be explained by an indirect gene dosage effect, 
as also observed for S. pneumoniae (188). The positioning of stress-response regulators close 
to oriC may therefore be a conserved strategy in bacteria to respond to DNA replication insults 
that is independent of the nature of the regulator. 
Though it is likely that an increase in gene copy number leads to an increase in transcription 
of these genes, it is less clear whether this is the case for the observed down-regulation. Most 
methods of normalization for transcriptome analyses are based on the assumption that there 
is no overall change in transcription or that the number of transcripts per cells is the same 
for all conditions and this may not be the case when a global copy number shift occurs (180). 
Absolute transcript levels for down-regulated genes might therefore be similar under both 
conditions (but lower relative to oriC-proximal transcripts). 
It is interesting that certain processes are highly enriched in the list of genes up-regulated under 
conditions of PolC-inhibition (most notably ribosome function and DNA-related functions), 
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 42
42
CHAPTER 2
whereas this is less so for the down-regulated genes. This suggests that pathways susceptible 
to replication dependent gene-dosage effects demonstrate a functional clustering of genes 
near oriC, whereas clustering of genes from specific pathways in the terC-proximal region is 
less pronounced. Indeed, most ribosomal gene clusters in C. difficile are located close to the 
origin of replication (190, 199) and also many genes involved in DNA replication and repair are 
located in these regions. Consistent with this, positioning of genes involved in transcription 
and translation close to the origin appears to be under strong selection as such genomes tend 
to be more stable (218).
In conclusion, both direct and indirect effects of gene dosage shifts are likely to contribute to 
the transcriptional response of C. difficile to replication inhibition.
Materials and Methods
Bacterial strains and culture conditions
Plasmids and bacterial strains used in this study can be found in Table 3. E. coli was cultured 
aerobically at 37°C (shaking at 200 rpm) in Luria-Bertani (LB) broth supplemented with 20 µg/ml 
chloramphenicol and 50 µg/ml kanamycin when appropriate. C. difficile strains were cultured 
in Brain Heart Infusion (BHI) broth (Oxoid) supplemented with 0,5% yeast extract (Sigma-
Aldrich), Clostridium difficile Selective Supplement (CDSS, Oxoid) and 20µg/ml thiamphenicol 
when appropriate. C. difficile was grown anaerobically in a Don Whitley VA-1000 workstation 
in an atmosphere of 10% CO2, 10% H2 and 80% N2. Liquid cultures were grown under gentle 
agitation (120 rpm).
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 Name Relevant features Source/reference
Plasmids pAP24 tetR Ptet-slucopt catP; derived from pRPF185 (44)
 pIB27 PCD3412-sluc
opt catP; derived from pAP24 This study
 pIB54 pMTL-SC7315 containing the up- and downstream area of the 
630Δerm sigB CDS (950 bp each)
This study
 pIB68 PCD0350-sluc
opt catP; derived from pAP24 This study
 pIB69 PCD2963-sluc
opt catP; derived from pAP24 This study
 pIB74 PCD3614-sluc
opt catP; derived from pAP24 This study
 pMTL-SC7315 pMTL83151 with codA catP (43)
 pH28 PCD0007-sluc
opt catP; derived from pAP24 This study
Strains DH5α E. coli F– endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
purB20 φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK–mK+), λ–
Laboratory stock
 CA434 E. coli HB101 [F- mcrB mrr hsdS20(rB-mB-) recA14 leuB6 ara-14 
proA2 lacY1 galK2 xyl-5 mtl-1 rspL20(SmR)glnV44λ-] R702
(76)
 C. difficile 
630Δerm
MLS susceptible derivative of strain 630 (30, 31)
 IB37 630Δerm pIB27; thiaR This study
 IB56 630ΔermΔsigB This study
 IB95 630Δerm pIB68; thiaR This study
 IB96 630Δerm pIB69; thiaR This study
 IB98 IB56 pIB27; thiaR This study
 IB99 IB56 pIB68; thiaR This study
 IB100 IB56 pIB69; thiaR This study
 IB108 630Δerm pIB74; thiaR This study
 IB111 IB54 pIB74; thiaR This study
 WKS2003 630Δerm pPH28; thiaR This study
Table 3. Plasmids and strains used in this study.
 
Sub-MIC determination
C. difficile 630Δerm (189, 190) was grown in 20 mL Brain Heart  Infusion (Oxoid) supplemented 
with 0.5% yeast extract (Sigma-Aldrich) (BHI/YE) starting from an optical density measured at 
600nm (OD600) of 0.05 using an exponentially growing starter culture (3 biological replicates 
per concentration). To determine the effects on growth at sub-inhibitory concentrations of 
ACX-362E, cells were cultured in the presence of the following concentrations; 0.25, 0.5, 1, 
2, 4, and 8 µg/mL ACX-362E and compared to an untreated culture. To determine the effects 
on growth at sub-inhibitory concentrations of HPUra, cells were cultured in the presence of 
the following concentrations: 10, 20, 40 µg/mL HPUra and compared to an untreated culture. 
The OD600 was monitored every hour until stationary phase was reached.
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Name Sequence (5’ –> 3’ ) * Description
CD-0001- F GAGACAAGAATTGCTATACTTA Forward primer CD0001   MFA 
(oriC)
CD-0001- R CAACCACTCTAGTTAATGC Reverse primer CD0001   MFA (oriC)
CD-0001-
probe-FAM
CTCAACTAGAACGTATAGATGTGCCAA Probe CD0001 MFA (oriC)
CD-1931- F GCAGGAATTTTAGATGAAGA Forward primer CD1931   MFA 
(terC)
CD-1931- R GGCTGAAGTCTTATTAAATTTC Reverse primer CD1931   MFA (terC)
CD-1931-
probe-TXR
CCTCTTAACTGTAGCAGATTCACCAT Probe CD1931 MFA (terC)
oIB-26 GGAAGGTACCGTTGAATAAAGTATTTATTTTCCATG Forward primer for PCD3412 
containing a KpnI restriction site
oIB-27 GGTAGAGCTCAGTATCACTCCTTTTTTCGAAC Reverse primer for PCD3412 containing 
a SacI restriction site
oIB-44 CGTAGAAATACGGTGTTTTTTGTTACCCTACTTATAG
TAGCAATTTATTTAGCTAAAAC
Forward primer for region 950 bp 
upstream of sigB CDS
oIB-45 TACTTTTTTTATATTTTTTTAAATATCAACTCCTAAATATTTAGTC Reverse primer for region 950 bp 
upstream of sigB CDS
oIB-46 GGAGTTGATATTTAAAAAAATATAAAAAAAGTATTGACCTACTG Forward primer for region 950 bp 
downstream of sigB CDS
oIB-47 GGGATTTTGGTCATGAGATTATCAAAAAGG
GGACTACCAGGGTATCTAATC
Reverse primer for region 950 bp 
downstream of sigB CDS




Forward primer to verify sigB 
deletion
oIB-78 GGAGATGTTAACTAATGAATGCATGG Forward primer to verify sigB CDS 
deletion




Forward primer for PCD0350
oIB-82 ctagcataaaaataagaagcctgcatttgcTTG
TGTTTAAGGGATTTTGAAAG
Forward primer for PCD2963
oIB-92 ctagcataaaaataagaagcctgcatttgcGAAT
AAAAAAGGTGGTGTC
Forward primer for PCD3614
oIB-94 agctattaataattttttacttggtctcatTTTTACCT
CCATGTAACATTTATTG
Reverse primer for PCD0350
oIB-95 agctattaataattttttacttggtctcatAATTAAATC
CTTCCTTACATTGTAATTAC
Reverse primer for PCD2963
oIB-100 agctattaataattttttacttggtctcatATAAACACCCTCCTATTCTTTG Reverse primer for PCD3614
oPH-19 ctagcataaaaataagaagcctgcatttgcCGATTGCCAAAAT
AAATATTGAAG
Forward primer for PCD0007
oPH-20 agctattaataattttttacttggtctcatAACAATTACTCCTTT
CAATTTTAAATTTTTATC
Reverse primer for PCD0007
oWKS-1240 CACCTCCTTTTTGACTTTAAGCCTACGAATACC Forward primer on pAP24 
backbone to amplify insert
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Name Sequence (5’ –> 3’ ) * Description
oWKS-1241 CACCGACGAGCAAGGCAAGACCG Reverse primer on pAP24 backbone 
to amplify insert
oWKS-1537 TAGGGTAACAAAAAACACCG Reverse primer to amplify pMTL-
SC7315 backbone
oWKS-1538 CCTTTTTGATAATCTCATGACC Forward primer to amplify pMTL-
SC7315 backbone
oWKS-1580 ATGAGACCAAGTAAAAAATTATTAATAGC Forward primer to amplify pAP24 
backbone
oWKS-1582 GCAAATGCAGGCTTCTTATTTTTATG Reverse primer to amplify pAP24 
backbone
Table 4. Oligonucleotides and probes used in this study.
* Restriction sites are underlined. Overlap with the vector backbone is indicated in lowercase letters.
Marker Frequency analysis
C. difficile 630Δerm (189, 190) was grown in 20 mL BHI supplemented with 0.5% yeast extract 
with sub-MIC amounts of antimicrobials (HPUra: 35 μg/mL; ACX-362E: 4 μg/mL; metronidazole: 
0.25 μg/mL; fidaxomicin: 0.00125 μg/mL, surotomycin: 0.625 μg/mL), starting from an OD600 
of 0.05 using an exponentially growing starter culture. These samples were taken in the course 
of an independent, but simultaneously performed, set of experiments for which we obtained 
surotomycin and fidaxomicin from Cubist Pharmaceuticals. Metronidazole was commercially 
obtained (Sigma-Aldrich). We confirmed that these concentrations did not lead to a >30% 
reduction in growth compared to non-treated cultures (Supplemental Figure 1 and data not 
shown). In parallel, cultures were grown without inhibitors from the same starter culture. 
All conditions were performed in biological triplicates. Previous experiments have shown 
that oriC:terC differences are reliably detected >3h after dilution into fresh medium (188). 
Therefore, after 5 hours, 1mL cells was harvested (OD600 ~ 0.5), and stored at -20°C. Isolation 
of chromosomal DNA was performed the next day with the QIAamp DNA Blood Mini kit 
(Qiagen) according to the instructions of the manufacturer. Marker frequency analysis (MFA) 
was performed to assess the relative abundance of origin proximal genes relative to terminus 
proximal genes.  As a proxy for oriC, a probe was designed that targets the CD0001 region 
(CD0001-probe-FAM). By using plots of the GC skew ([G - C]/[G + C]) generated using DNAPlotter 
(194), the approximate location of the terminus region for the C. difficile chromosome was 
determined and a probe targeting this region (CD1931) was designed (CD-1931-probe-TXR). 
Probe design was performed with Beacon DesignerTM (Premier Biosoft, Palo Alto CA, USA). Real-
time PCR reactions were performed on a Biorad CFX96TM real-time PCR detection system (95°C 
15 m, 39 × (94°C 30 s + 55°C 30 s + 72°C 30 s). Sequences for primers and probes are listed in 
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Table 4. For each biological replicate, three technical replicates were performed. Amplification 
efficiency was determined using standard curves obtained from DNA late stationary phase cells 
of strain 630Δerm, for which an oriC:terC ratio of 1 was assumed. RT-PCR results from antibiotic 
treated cells were normalized to the oriC:terC ratio of DNA samples (3 biological replicates) 
from non-treated cells. Calculations were performed in Microsoft Office Excel 2010, plotted 
using Prism 7 (GraphPad) and prepared for publication in Corel Draw Suite X8. Significance was 
determined using a One-way ANOVA and a Tukey’s test for multiple comparisons (GraphPad).
Growth and RNA isolation for RNA-Seq
For RNA-Seq analysis, C. difficile 630Δerm (189, 190) was grown for 5h in BHI medium with HPUra 
(35 ug/mL) or ACX-362E (4  µg/mL) starting from an OD600 of 0.05 using an exponentially growing 
starter culture, after which cells (3mL) were harvested  for RNA isolation. These concentrations 
were some of the highest concentrations that resulted in a modest effects on growth (<30% 
reduction of growth compared to wild type cells, Supplemental Figure 1). RNA isolation was 
performed with NucleoSpin© RNA kit (Macherey-Nagel). Although the kit includes on column 
rDNAse digestion, a second treatment was performed in solution and RNA was precipitated 
and recovered by NaAc precipitation to remove residual DNA. Concentration determination 
and quality control (16S/23S ratio and RNA integrity number [RIN]) was performed with a 
fragment analyzer (Agilent bio-analyzer), according to the instructions of the manufacturer. 
Samples with a RIN>9 and 16S/23S ratio >1.4 were submitted for analysis by RNA-Seq. 
RNA-Seq
RNA-Seq was performed  at a commercial provider (GenomeScan, Leiden, The Netherlands). 
In short, the NEBNext Ultra Directional RNA Library Prep Kit for lllumina was used to process 
the samples. Sample preparation was performed according to the protocol “NEBNext Ultra 
Directional RNA Library Prep Kit for lllumina” (NEB #E7420S/L). Briefly, after selective removal 
of rRNA (Ribo-Zero rRNA Removal Kit  for gram-positive Bacteria) and fragmentation of the 
mRNA, cDNA synthesis was performed. cDNA was ligated to the sequencing adapters and the 
resulting product was PCR amplified. Clustering and DNA sequencing using the lllumina NextSeq 
500 platform was performed according to manufacturer’s protocols. A concentration of 1.5 
pM of DNA was used. Image analysis, base calling, and quality check was performed with the 
lllumina data analysis pipeline RTA vl.18.64 and Bcl2fastq v2.17. Per sample, four technical 
replicates were included in the RNA-Seq experiment. In case of insufficient reads, the sample 
was re-run on another flow cell to reach satisfactory quantities (≥ 20 M).
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Analysis of RNA-Seq data
Analysis of the data was performed using T-REx, a user-friendly webserver which has been 
optimized for the analysis of prokaryotic RNA-seq-derived expression data (219). The pipeline 
requires raw RNA expression level data as an input for RNA-Seq data analysis. For data 
normalisation and determination of the genes, the factorial design statistical method of 
the RNA-Seq analysis R-package EdgeR is implemented in the T-Rex pipeline. Some samples 
displayed incomplete rRNA depletion and rRNA mapping reads had to be removed manually 
prior to analysis. 
To analyse the genome-wide pattern in differential gene expression a sliding window analysis 
was performed essentially as described (188). In short, genome locations (start of the locus tag) 
were coupled to the locus tags in the T-Rex output. Next, the median log(FC) was calculated for 
bins of 51 loci with a step size of 1. For each bin of [X1, X2…X51] the median absolute deviation 
of the median (MAD=median(|Xi-median(X)|) was calculated as an robust indication of the 
distribution around calculated median values. Calculations were performed and three curves 
(median, median-MAD and median+MAD) were plotted in Microsoft Office Excel 2010 and 
the graph was prepared for publication using Adobe Photoshop CC and Corel Draw Suite X8. 
A GSEA analysis (191) was performed via the Genome2D webserver (219), using our reference 
genome sequence for C. difficile 630Δerm, GenBank identifier LN614756.1 (listed in Genome2D 
as “Clostridioides_difficile_630Derm”)(190). As input a single list of locus tags was used of 
either up- or down regulated genes. The output was copied to Microsoft Excel 2010. The 
single_list column was split, and a column was inserted to calculate the significance of the 
overrepresentation using the formula “(# hits in list/ClassSize)*-log(p-value; 2)” to allow for 
sorting of the output of the GSEA analysis by significance. Data for the RNA-Seq experiment 
has been deposited in the Gene Expression Omnibus (GEO) database (220), accession number 
GSE116503.
General molecular biological techniques
E. coli strain DH5α was used for maintenance of all plasmids. All plasmid transformations into 
E. coli were performed using standard procedures (221). E. coli CA434 was used as a donor 
for conjugation of plasmids into the recipient C. difficile (222). Conjugation was performed 
as previously described (222). Briefly, 1 mL of an overnight culture of donor cells was mixed 
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with 200 µl of the recipient and spotted onto anaerobic BHI agar plates and incubated for 
5-8 hours. After incubation cells were collected and tenfold serial dilutions were plated onto 
fresh BHI plates containing thiamphenicol and CDSS.
Plasmid DNA was isolated using the NucleoSpin Plasmid (Macherey-Nagel) mini prep kits per 
manufacturer’s instructions. C. difficile genomic DNA was isolated using the DNeasy Blood 
and Tissue kit (Qiagen) with pre-treatment for gram-positives according to instructions of 
the manufacturer.
Construction of luciferase-reporter fusion plasmids
All PCR reactions for plasmid construction were carried out with Q5 polymerase (New England 
Biolabs). Putative promoter regions were amplified using C. difficile 630Δerm chromosomal 
DNA (190) as a template. 
The PCD3412 luciferase reporter plasmid was created by restriction-ligation using the restriction 
enzymes KpnI and SacI. PCD3412  was amplified using primers oIB-26 and oIB-27 (Table 5). The 
resulting dsDNA fragment was digested and ligated into KpnI-SacI digested pAP24 (201), yielding 
plasmid pIB27. Plasmids pIB68 (PCD0350), pIB69 (P CD2963), pIB74 (PCD3614) and pPH28 (PCD0007) were 
constructed using a Gibson assembly (223). The plasmid backbone of pAP24 was linearized 
by PCR using primers oWKS-1580/oWKS-1582, and the predicted promoter areas of CD0350, 
CD2963 and CD3614 were amplified with primers oIB-80/oIB-94, oIB-82/oIB-95, oIB-92/oIB-
100 and oPH-19/oPH-20, respectively. Primers were designed using the NEBuilder assembly 
tool v.1.12.17 (New England Biolabs) using a 30 bp overlap. For the assembly, 100 ng of vector 
DNA was assembled to a five-fold molar excess of the PCR fragment of the desired promoter 
using a homemade Gibson Assembly Master Mix at 50oC for 30 minutes (final concentration: 
4 U/µl Taq Ligase (Westburg), 0.004 U/µl T5 exonuclease (New England Biolabs), 0.025 U/µl 
Phusion polymerase (Bioké), 5% polyethyleneglycol (PEG-8000), 10 mM MgCl2, 100 mM Tris-Cl 
pH=7.5, 10 mM dithiothreitol, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dCTP, 0.2 mM dGTP, and 1 
mM β-nicotinamide adenine dinucleotide) and transformed into E. coli DH5α.  Transformants 
were screened by colony PCR using primers oWKS-1240 and oWKS-1241. Transformants yielding 
PCR fragments of the correct size were verified by Sanger sequencing.
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Construction of C. difficile IB56 (ΔsigB)
The up- and downstream regions (both 950 bp each) of the sigB coding sequence were amplified 
with primers oIB-44/oIB-45, and oIB-46/oIB-47, respectively. Vector pMTL-SC7315 (202) was 
linearized by PCR using primers oWKS-1537/oWKS-1538. Assembly was done according to the 
method of Gibson (201, 223). The assembled plasmid was transformed into E. coli DH5α and 
verified using PCR and Sanger sequencing. Generation of the unmarked sigB deletion mutant 
was performed using Allele-Coupled Exchange essentially as described (202, 224). Briefly, 
pIB54 was introduced into C. difficile 630Δerm (190) by conjugation. Transconjugants were 
grown for two days on BHI agar plates supplemented with yeast extract, thiamphenicol and 
CDSS, struck onto fresh pre-reduced plates and incubated anaerobically at 37°C for two days. 
Single-crossover integration was confirmed using PCR, and those clones were plated onto 
non-selective BHI agar plates to allow the second-crossover event to occur. Colonies were then 
serially diluted and plated onto minimal agar supplemented with 50 µg/ml 5-fluorocytosine 
(Sigma) as described (202). DNA was isolated from thiamphenicol-susceptible colonies and 
the chromosomal deletion was verified by PCR using primers oIB-78/oIB-79 (Supplemental 
Figure 3) as well as Sanger sequencing of the PCR product using primers oIB-53/oIB-76/oIB-78.
Luciferase reporter assay
Strains containing luciferase reporter plasmids were inoculated to an OD600=0.05 from an 
exponentially growing starter culture. Fresh inoculums were grown in BHI broth  supplemented 
with yeast extract, with or without 4 µg/ml ACX-362E for 5 (for putative sigB target genes) or 
5.5 (sigB promoter) hours. The supernatants from 1mL of culture (harvested by centrifugation 
for 10 min, 4°C, 8000 rpm) were analyzed in a GloMax®-Multi Microplate Multimode Reader 
(Promega) as described before (201). Statistical significance of the data (p<0.05) was determined 
by two-way analysis of variance (ANOVA) and a pairwise Tukey-Kramer test using Prism 7 
(GraphPad) where appropriate. 
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Supplemental information
Supplemental Figure 1. Relative inhibition of growth by varying concentrations of PolC-inhibitors. A) 
Growth kinetics of a culture grown in the presence of the indicated amount of HPUra, relative to a non-
treated culture. B) Growth curve of a culture grown in the presence of the indicated amount of HPUra. 
C) Growth kinetics of a culture grown in the presence of the indicated amount of ACX-362E, relative to a 
non-treated culture. Growth in liquid media was abolished at >2x the MIC (data not shown). D) Growth 
curve of a culture grown in the presence of the indicated amount of ACX-362E. 
 
Supplemental Figure 2. Chloramphenicol does not result in a gene dosage shift. A marker frequency 
analysis of the effects of sub-inhibitory amounts of ACX-362E (red; 4 μg/mL) and chloramphenicol 
(blue; 20 μg/mL) compared to non-treated cells (black). Datapoints are averages of technical replicates 
(N=3). Black lines behind the datapoints indicate the average of the biological replicates (N=3) and 
whiskers indicate the standard deviation of the mean. Data have been normalized compared to the 
non-treated control. The mean of ACX-362E treated samples is statistically different from the other 
samples (p<0.0001). 
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Supplemental Figure 3. Confirmation of the sigB mutant strain (IB54). DNA electrophoresis of PCR 
fragments and immuno blot analysis of whole cell lysates confirm absence of the sigB coding sequence 
and σB protein, respectively. A) DNA electrophoresis. DNA was isolated from 630Δerm (WT) and IB54 
(ΔsigB) cultured for 15 hours and a PCR using primers oIB-78 and oIB-79 was performed (Table 4). 
Expected product sizes aree 3597 bp (WT) and 2823 bp (ΔsigB). DNA electrophoresis was performed 
using a 0.5xTAE 1% agarose gel. B) Immunoblot analysis of whole cell lysates of 630Δerm (WT) and IB54 
(ΔsigB) cultured for 15 hours. The expected size of the σB protein is 34 kDa as indicated by the arrow. 
A clear signal is detected in the WT sample, but none can be observed in ΔsigB. The asterisk indicates 
an non-specific cross-reacting protein in the C. difficile lysates. Cells from 1 mL of was pelleted (10 min, 
4°C, 8000 rpm) and cell pellets were lysed in 250 μl 1x SDS sample buffer. OD corrected samples were 
analyzed by SDS-PAGE (12,5%) and transferred onto a 0.45 μm PVDF membrane. The membrane was 
probed with a rabbit anti-σB antibody in 5% low-fat milk in 0.1% TBST at 4oC overnight. The probed 
membranes were analyzed with a swine-anti-rabbit-HRP antibody (Agilent) incubated 1:2000 in 5% 
low-fat milk in 0.1% TBST for 2-3 hours at room temperature. Detection was of chemiluminescent 
signal was performed using a Uvitec Alliance Q9 Advanced imager (BioSPX), after 5 min incubation with 
Clarity Western ECL substrate (Bio-Rad). “M” = marker, “-“ = no sample loaded. 
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In many Gram-positive bacteria the general stress response is regulated at the transcriptional 
level by the alternative sigma factor sigma B (σB). In C. difficile σB has been implicated in 
protection against stressors such as reactive oxygen species and antimicrobial compounds. 
Here, we used an anti-σB antibody to demonstrate time-limited overproduction of σB in C. 
difficile despite its toxicity at higher cellular concentrations. This toxicity eventually led to the 
loss of the plasmid used for anhydrotetracycline-induced σB gene expression. Inducible σB 
overproduction uncouples σB expression from its native regulatory network and allowed for 
the refinement of the previously proposed σB regulon. At least 32% the regulon was found 
to consist of genes involved in the response to reactive radicals. Direct gene activation by C. 
difficile σB  was demonstrated through in vitro run-off transcription of specific target genes 
(CD0350, CD3614, CD3605, CD2963). Finally, we demonstrated that different antimicrobials 
and hydrogen peroxide induce these genes in a manner dependent on this sigma factor, using 
a plate-based luciferase reporter assay. Together, our work suggests that lethal exposure to 
antimicrobials may result in the formation of toxic radicals that lead to σB-dependent gene 
activation. 
Importance
Sigma B is the alternative sigma factor governing stress response in many gram-positive 
bacteria. In C. difficile, a sigB mutant shows pleiotropic transcriptional effects. Here, we 
determine genes that are likely direct targets of σB by evaluating the transcriptional effects of 
σB overproduction, provide biochemical evidence of direct transcriptional activation by σB, and 
show that σB-dependent genes can be activated by antimicrobials. Together our data suggest 
that σB is a key player in dealing with toxic radicals.  
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Introduction
Disruption of the normal gastrointestinal flora as a result of antimicrobial treatment can lead 
to a Clostridioides (Clostridium) difficile infection (CDI) (225). Clostridioides difficile is a gram-
positive, spore-forming obligate anaerobe and the primary cause for nosocomial infectious 
diarrhea (20). Its highly resistant endospores are usually transmitted via the oral-fecal route 
and germinate into vegetative cells in the colon upon contact with primary bile acids and other 
inducing factors (58). In the gut vegetative C. difficile cells are facing many environmental 
stressors, including variations in oxygen tension, pH, osmolarity, nutrient availability, and 
the inflammatory responses of the immune system (150). The bacteria are also faced with 
antimicrobial compounds produced by the host, the resident microbiota, or given externally 
during medical therapy (80). The physiological response of C. difficile to these insults and the 
inflammatory responses triggered by CDI can result in the production of Reactive Oxygen 
Species (ROS), Reactive Nitrogen Species (RNS) and nitric oxide (NO) (20, 172). 
Bacteria need to adapt to changing environmental conditions, including stresses, by adapting 
their physiology in a timely manner. This is achieved by fast transcriptional reprogramming, 
followed by shortly delayed changes at the translational level (216). The alternative sigma factor 
sigma B (σB, encoded by the sigB gene)  -  which regulates the general stress responses in a 
variety of Gram-positive organisms  -  is central to the maintenance of the cellular homeostasis 
during stress adaptation (148, 226).
Sigma factor B activity in Firmicutes is regulated at the protein level by a partner-switching 
mechanism in which the anti-sigma factor RsbW binds and inhibits σB association with the 
RNA polymerase under non-stressed conditions. When a σB-activating stress is sensed the 
dephosphorylated anti-anti-sigma factor RsbV sequesters RsbW, allowing for the association 
of free σB  with the RNA polymerase core enzyme (148, 227). In C. difficile, the phosphatase 
RsbZ is responsible for RsbV dephosphorylation (169). The tight regulation of σB activity by a 
partner-switching mechanism is necessary as the energy burden associated with σB activity 
was found to be disadvantageous in several different organisms (162, 228). 
Despite the burden associated with its expression, σB is essential for survival for several 
pathogenic bacterial species in response to host-dependent stressors or antimicrobials. For 
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example, in L. monocytogenes σB is involved in counteracting the effects of the acidic pH 
encountered in the stomach and upon invasion of intestinal epithelial cells in the lysosome 
(229, 230). In Staphylococcus aureus σB overproduction leads to thickening of the cell wall 
and increased resistance to beta-lactam antimicrobials (170). The sigB homologue sigF of 
Mycobacterium tuberculosis is induced by small amounts of rifamycin (231). Analogously, B. 
subtilis σB is involved in resolving a rifampin-induced growth arrest (171). There is also evidence 
for the involvement of σB in C. difficile in the response to antimicrobial substances. Mutants of 
sigB show increased susceptibility to rifampicin and mitomycin C, and are also more sensitive to 
hydrogen peroxide, nitroprusside and di-ethylamine NONOate (160). However, the underlying 
molecular mechanisms remain unknown. Finally, indirect activation of σB-dependent genes 
as the result of a gene-dosage shift has been demonstrated for C. difficile exposed to DNA-
polymerase inhibitors such as the Phase II drug ibezapolstat/ACX-362E (232). 
In this study, we demonstrate that σB overexpression is detectable and tolerated for short 
periods of time. This allowed for the experimental identification of a set of genes that is 
most likely directly regulated by σB by performing transcriptome analyses under conditions 
of acute σB overexpression. The obtained results show that genes involved in the oxidative 
and nitrosative stress response form the core of the regulon. Additionally, we show that 
various antimicrobials and hydrogen peroxide induce the expression of σB-regulated genes in 
a σB-dependent manner, suggesting a link between the lethal exposure to antimicrobials and 
oxidative and nitrosative stresses in C. difficile.
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Figure 1. Recombinant σB was used to generate a C. difficile specific antibody for intracellular 
detection. A) Coomassie Blue-stained 12.5% SDS-PAGE gel of purified recombinant σB-6xHis. B) 
Western Blot using affinity purified σB antibody (1:500) on strains IB58 (sigB::CT Ptet-sigB) and IB61 
(sigB::CT Ptet-sluc
opt). Cells were grown in lincomycin (20 µg/mL) and in the presence or absence of 
thiamphenicol (20 µg/mL) until OD600nm≈0.3, after which the indicated samples were induced with 100 
ng/mL ATc. Samples were collected directly after the addition of ATc (or at the time ATc would have 
been added in the uninduced controls) at T=0h and after 1 hour of induction (T=1).
 
Results
C. difficile σB is measurably overproduced upon induction of the sigB gene 
Previous investigations of σB in C. difficile have used a sigB mutant and characterized its gene 
expression in the stationary growth phase in comparison with a wild type strain (160). Though 
informative, this method is likely to result in indirect effects of σB due to stationary phase 
heterogeneity, prolonged incubation and possible positive or negative feedback in the σB 
regulatory circuit. To circumvent these issues and identify genes likely to be regulated by σB 
directly, we set out to uncouple sigB expression from its native regulatory circuit by expressing 
it from an inducible promoter. 
First, in order to confirm overproduction of σB, we measured cellular σB levels using 
immunoblotting. For this purpose, we heterologously overproduced and purified σB containing 
a C-terminal His-tag (Figure 1A) and used this protein to raise a polyclonal antiserum. 
Corresponding polyclonal antibodies were affinity-purified to prevent unspecific immune 
reactions.
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Next, we set out to validate the overproduction of σB in transconjugant C. difficile cells harboring 
plasmids containing sigB under the control of the anhydrotetracyclin (ATc)- dependent 
promoter Ptet (233). For this purpose, σ
B was produced in a sigB mutant background (strain 
IB58; sigB::CT Ptet-sigB). As a control, we introduced a non-related expression construct in the 
same background (IB61; sigB::CT Ptet-sluc
opt) such that this control strain carries a plasmid with 
the same replicon, resistance marker and inducible promoter. 
We expected a signal at approximately 30 kDa in Western blot experiments for cells grown 
in the presence of inducer ATc for strain IB58, but not for the uninduced cultures of IB58 or 
the control strain IB61. Additionally, by growing in the presence or absence of thiamphenicol, 
we investigated whether overproduction of σB required selection for the Ptet-sigB expression 
plasmid. When strains were grown in BHIY medium supplemented with 20 µg/mL lincomycin 
and induced for one hour with or without 100 ng/mL ATc in the presence or absence of 20 
µg/mL thiamphenicol, we did not detected any signal at the molecular weight expected for 
σB  in the ATc-induced control samples (sigB::CT Ptet-sluc
opt) or in any of the uninduced samples 
(Figure 1B). In contrast, after one hour of induction a clear band of the expected molecular 
weight of σB (~30 kDa) was observed only in the IB58 (sigB::CT Ptet-sigB) samples (Figure 1B). 
Plasmid selection by inclusion of thiamphenicol in the growth medium did not influence 
σB overproduction in this time frame which might have occurred as a trade-off between σB 
overexpression and cellular toxicity (see also further below).
We conclude that the affinity purified rabbit-α-σB antibody is specific for σB and can be used 
for its detection in lysates of C. difficile. Furthermore, it is possible to uncouple sigB expression 
from its tight regulatory network by ATc-inducible overexpression for one hour in trans.
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Figure 2. Overexpression of σB is toxic for C. difficile and leads to plasmid loss. A) Tenfold serial 
dilutions on BHIY agar plates of 630∆erm (wildtype), AP34 (Ptet-sluc
opt) and JC096 (Ptet-sigB). Similar 
results were obtained for strains IB58 and IB61 (data not shown). B) Percentage of cells retaining the 
plasmid in AP34 (Ptet-sluc
opt) and JC096 (Ptet-sigB). C) Percentage of cells retaining the plasmid in strains 
IB61 (sigB::CT Ptet-sluc
opt) and IB58 (sigB::CT Ptet-sigB). Percentages were calculated based on the ratio 
of CFU/mL of the paired selective (with thiamphenicol)- and non-selective (without thiamphenicol) 
plates. * p<0.05 and **** p≤0.0001 as determined by an unpaired student’s t-test, n=3.
Prolonged overexpression of σB is lethal and leads to loss of plasmids harboring Ptet-sigB 
Above we showed that it is possible to overproduce σB in C. difficile and that it is tolerated 
by the bacterium for one hour. This observation is somewhat at odds with the previously 
reported toxic nature of overproduced σB (148, 169). To reconcile these two observations, 
the effect of long-term overexpression of σB and the stability of the plasmids used for σB 
overproduction under such conditions were investigated. First, overnight cultures of 630∆erm 
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opt) and JC096 (Ptet-sigB) were adjusted for their OD600nm values and 
ten-fold serially diluted. Subsequently, 2 µl spots per dilution were made on selective (20 µg/
mL thiamphenicol) and non-selective BHIY agar plates, part of which contained 200 ng/mL 
ATc to induce Ptet-dependent gene expression. All plates were then incubated anaerobically 
for 24 hours. On plates without thiamphenicol, regardless of the presence of the inducer ATc, 
comparable growth was observed for all three strains (Figure 2A). As expected, when selecting 
for the plasmid using thiamphenicol no growth was observed for the susceptible 630∆erm 
strain (which lacks the catP gene contained on the expression vector). In the absence of the 
inducer, no difference in growth was observed for the vector control strain (AP34; Ptet-sluc
opt) 
compared to the strain carrying the Ptet-sigB plasmid (JC096). However, upon induction of sigB 
expression on selective plates a 3-4 log growth defect was observed for the strain carrying 
Ptet-sigB compared to the vector control strain. We conclude that prolonged induction of sigB 
expression is toxic when cells are cultured in the presence of thiamphenicol. Our results thus 
corroborate the finding that σB overproduction is toxic to C. difficile cells in liquid culture (169). 
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Table 1. Setup of the DNA array and number of differentially expressed (DE) genes, including number 
of positively (POS) and negatively (NEG) regulated genes. Numbers inbetween brackets correspond 
to the number of differentially expressed genes after subtracting the differentially expressed genes 
identified in hybridisations 1 and 3 (that are not dependent on σB induction).
The lethality associated with σB overproduction was not seen when cells were grown without 
thiamphenicol in our experiment (Figure 2A). We considered two possible explanations for 
this observation. As thiamphenicol is used for ensuring plasmid maintenance, its absence 
might result in plasmid loss due to segregation or negative selection pressure when a toxic 
protein such as σB is overproduced. The remaining cells, that no longer express σB would 
consequently be susceptible to thiamphenicol (due to the loss of catP) but might outgrow 
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those carrying the plasmid. Alternatively, the combination of σB and thiamphenicol might be 
toxic to the bacteria. To test whether plasmid loss was the cause of the observed lethality 
of bacteria overproducing σB in the presence of thiamphenicol, cells from the plates without 
thiamphenicol (with and without ATc) were resuspended in PBS at 1.0 McFarland turbidity, 
and ten-fold serially diluted in BHI medium. Ten-µl spots of these dilutions were plated on 
plasmid-selective (thiamphenicol) and non-selective (no thiamphenicol) plates. Based on 
the ratio of CFU/mL of the selective and non-selective plates, the percentage of cells which 
lost their plasmid was calculated. If σB overproduction led to the loss of the plasmid under 
conditions that do not select for its maintenance (no thiamphenicol), we expected significantly 
reduced growth on plates containing thiamphenicol. Although some plasmid loss was observed 
under uninduced conditions, as well as for the negative control strain AP34 (Ptet-sluc
opt), all 
cells originally containing the Ptet-sigB plasmid (strain JC096) completely lost this plasmid upon 
induction of σB overproduction with ATc (Figure 2B). Similar results were obtained for sigB 
mutant strains IB58 (sigB::CT Ptet-sigB) and IB61 (sigB::CT Ptet-sluc
opt), indicating the observed 
effects were solely due to in trans σB overproduction, and did not result from an interference 
of the native sigB regulatory network (Figure 2C). Together, these results are consistent with 
a model in which the vector with the low-copy number pCD6 replicon are rapidly eradicated 
upon expression of a gene (here sigB) that causes lethal defects (234, 235).  
σB primarily activates genes relating to oxidative/nitrosative stress responses 
Above, we have shown that long-term overproduction σB is detrimental and that this leads 
to loss of the expression plasmid in the absence of thiamphenicol (Figure 2), but that σB 
overproduction nevertheless could clearly be demonstrated when induction is limited to 
1 hour (Figure 1C). Therefore we used the time-limited induction to refine the previously 
proposed regulon (160) in both the presence and absence of thiamphenicol to strike a balance 
between potential secondary effects due to toxicity associated with σB overproduction (with 
thiamphenicol), and loss of the expression plasmid from a subpopulation of cells (without 
thiamphenicol) (Table 1). We compared transcriptome data from strain IB58 (sigB::CT Ptet-sigB) 
to that of strain IB61 (sigB::CT Ptet-sluc
opt). IB61 harbors a vector for the inducible expression 
of a luciferase gene which does not lead to any toxicity and growth phenotype (201).
We expected no or a limited number of genes to be differentially expressed (log2 foldchange 
(log2FC) of ≤ -1.5 or ≥1.5, and adjusted p-value of <0.05) under non-inducing conditions. 
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Indeed, we found only five differentially expressed genes in the Ptet-sigB strain (IB58) compared 
to the Ptet-sluc
opt control (IB61) strain (hybridizations 1 and 3) (Dataset S1). These genes were 
similarly positively (CD0583, CD0584, both GGDEF domain containing proteins (236); CD2214, 
CD2215, both potential transcriptional regulators (237)) and negatively (CD1616, an EAL domain 
protein (236)) regulated in all hybridizations, including those where sigB expression was not 
induced. These results suggest that the basis for the observed differential expression of these 
genes was vector specific, but not dependent on σB induction. These genes were therefore 
not investigated further and are excluded from the numbers discussed below. 
Locus tag Gene 
name
log2FC adjusted  
p-value
Predicted function
Genes upregulated by aerobic stress and positively regulated by σB
CD630DERM_00530 mrnC 1.9 3.29E-05 Ribonuclease III domain
CD630DERM_01750 8.2 1.11E-06 Oxidoreductase, Fe-S subunit
CD630DERM_01760 8.0 1.52E-06 Oxidoreductase, NAD/FAD binding subunit
CD630DERM_01920 cls 2.6 2.35E-04 Cardiolipin synthetase 1
CD630DERM_03500 1.9 4.63E-05 Putative hydrolase, HAD superfamily
CD630DERM_03510 1.8 5.66E-05 Conserved hypothetical protein
CD630DERM_05600 nfo 4.0 3.5E-05 Endonuclease IV
CD630DERM_05610 2.0 2.39E-05 Putative aldo/keto reductase; putative ferredoxin
CD630DERM_05650 nth 3.7 5.66E-06 Endonuclease III
CD630DERM_05660 2.5 6.62E-06 Putative tRNA/rRNA methyltransferase
CD630DERM_05800 gapN 6.2 1.38E-06 Glyceraldehyde-3-phosphate dehydrogenase 
(NADP(+)) (GADPH)
CD630DERM_11250 5.5 1.15E-05 Nitroreductase-family protein
CD630DERM_11570 norV 4.0 5.16E-06 Anaerobic nitric oxide reductase flavorubredoxin 
(FlRd) (FlavoRb)
CD630DERM_13410 exoA 1.8 6.76E-05 Exodeoxyribonuclease
CD630DERM_14630 1.8 1.77E-04 Conserved hypothetical protein
CD630DERM_15240 4.8 1.88E-05 Putative rubrerythrin
CD630DERM_15260 pyrC 1.6 1.98E-04 dihydroorotase
CD630DERM_15760 1.6 2.71E-02 putative arylesterase
CD630DERM_16220 2.7 1.03E-04 Putative lipoprotein
CD630DERM_16230 6.5 4.21E-06 NADH-oxygen oxidoreductase
CD630DERM_16240 vanR 1.6 8.84E-05 two-component response regulator
CD630DERM_16900 trxA 5.3 1.31E-06 Thioredoxin reductase
CD630DERM_16910 trxB 5.3 1.62E-06 Putative thioredoxin-disulfide reductase
CD630DERM_17780 2.6 1.19E-05 Conserved hypothetical protein
CD630DERM_17790 2.4 1.46E-05 Conserved hypothetical protein
CD630DERM_18180 ispH 1.8 5.35E-05 4-hydroxy-3-methylbut-2-enyl diphosphate 
reductase
CD630DERM_18220 bcp 6.1 2.70E-05 Putative thiol peroxidase 
CD630DERM_18970 1.8 3.20E-05 Conserved hypothetical protein
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 65
65
Redefining the Clostridioides difficile σB regulon:  σB activates genes involved in detoxifying radicals that 
can result from the exposure to antimicrobials and hydrogen peroxide
3
Locus tag Gene 
name
log2FC adjusted  
p-value
Predicted function
Genes upregulated by aerobic stress and positively regulated by σB
CD630DERM_19430 3.3 3.62E-06 Conserved hypothetical protein
CD630DERM_20460 5.5 5.60E-06 Conserved hypothetical protein
CD630DERM_21170 trxB2 5.0 1.86E-05 Thioredoxin reductase
CD630DERM_21650 2.2 1.04E-04 Transcriptional regulator, HTH-type
CD630DERM_24760 4.6 5.84E-06 Conserved hypothetical protein
CD630DERM_27960 cwp10 5.1 2.47E-05 Cell surface protein
CD630DERM_27970 5.1 1.75E-05 Putative calcium-binding adhesion protein
CD630DERM_29930 3.8 3.07E-05 Conserved hypothetical protein
CD630DERM_30380 3.9 2.21E-05 Conserved hypothetical protein
CD630DERM_30390 4.1 1.07E-05 Putative ATPase
CD630DERM_30400 2.1 8.46E-05 Conserved hypothetical protein
CD630DERM_30420 2.6 2.47E-05 Putative membrane protein
CD630DERM_33070 3.8 1.51E-06 Putative phosphoesterase
CD630DERM_33100 3.1 6.31E-06
Putative D-isomer specific 2-hydroxyacid 
dehydrogenase
CD630DERM_33110 2.9 1.19E-05 Conserved hypothetical protein
CD630DERM_34080 2.3 3.38E-05 Putative DNA mismatch repair ATPase MutS
CD630DERM_34090 scoC/hprK 2.4 1.74E-05 PTS system, HPr kinase/phosphorylase
CD630DERM_34100 uvrC 2.7 1.19E-05 Excinuclease subunit C
CD630DERM_34730 atpC2 1.6 2.90E-04 ATP synthase C chain
CD630DERM_34760 atpZ 1.6 2.42E-04 putative ATP synthase protein
CD630DERM_36100 4.6 2.38E-05 Conserved hypothetical protein
CD630DERM_36140 2.5 1.07E-05 Conserved hypothetical protein, DUF1130 family
 Other genes involved in oxidative/nitrosative stress positively regulated by σB
CD630DERM_01740 cooS 8.3 1.20E-06 Carbon monoxide dehydrogenase
CD630DERM_12790 iscS2 2.8 2.00E-03 Cysteine desulferase
CD630DERM_12800 3.0 1.56E-03 Putative NifU-like protein
CD630DERM_14740 5.0 1.28E-05 Putative rubrerythrin (Rr)
CD630DERM_15940 cysK 3.4 4.44E-03 O-acetyl-serine thiol-lyase A (O-acetyl-
sulfhydrylase)(OAS-TL)
CD630DERM_18230 6.8 5.93E-06 Conserved hypothetical protein, UPF0246 family
CD630DERM_21660 msrAB 4.7 1.24E-05 Peptide methionine sulfoxide reductase MsrA/
MsrB
Table 2. Selected genes differentially expressed upon overexpression of σB. Genes positively 
regulated by σB and aerobic stress and other genes involved in oxidative/nitrosative stress (160, 216) 
are highlighted here. CD numbers corresponding to the published annotation of strain CD630 (199) can 
be derived by removing “630DERM_” and removing the last digit (in case of a 0) or replacing it with an 
A (in the case of a 1).
Upon induction of sigB expression 145 genes were differentially expressed when strains 
were cultured without thiamphenicol (hybridization 4), and 178 genes were differentially 
expressed when thiamphenicol was present during cultivation (hybridization 2) (Figure 3, 
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 66
66
CHAPTER 3
Table 1 and Dataset S1). The majority showed an increase in expression upon induction of 
sigB expression (132 in the samples without thiamphenicol, and 163 in the samples with 
thiamphenicol), consistent with its function as a sigma factor (238), while a minority revealed 
a decreased expression (13 in the samples without thiamphenicol, and 16 in the samples with 
thiamphenicol). Of note, we observed only a minor difference in the number of differentially 
expressed genes between the cells grown in the absence and presence of thiamphenicol 
(33 genes). Together, these results demonstrate a high level of consistency in the σB regulon, 
despite potential plasmid-loss  (when grown in the absence of thiamphenicol) or toxic effects 
(when grown in the presence thiamphenicol). Our results also show that σB primarily activates 
gene expression. 
Figure 3. Volcano plot of the transcriptome analysis of the σB regulon. Graphical representation 
of differential gene regulation upon overproduction of σB. Dashed lines indicated the significance 
threshold: |log2FC|>1.5 and adjusted p-value <0.05. Genes significantly up-regulated by σB are 
indicated in red, and genes downregulated are indicated in blue. The top-10 of up-regulated genes 
and 5 selected down-regulated genes are annotated in the figure. An interactive version of the graph is 
available for exploration via the URL provided in the Text S1.
 
We focused our further analyses on the data obtained from hybridization 2 (with ATc and 
thiamphenicol), as this condition provided the broadest dataset (178 differentially expressed 
genes) for the re-definition of the σB regulon under our experimental conditions (Dataset S1). 
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Of the 163 genes up-regulated by σB the vast majority appeared to be associated with an 
response to oxidative stress, since they encode various oxidoreductases, peroxidases, and 
thioredoxin reductases (Table 2). Notably, approximately 51% of the 98 genes previously found 
to be up-regulated under aerobic stress (216) were also positively regulated by σB (Table 2). 
Five additional genes associated with aerobic/nitrosative stress (CD0174/cooS, CD1279/iscS2, 
CD1280, CD1594/cysK, CD1823 and CD2166/msrAB) were also found to be induced by σB, in 
agreement with previous findings (160).
Our findings are recapitulated in a volcano plot (239), which clearly shows that genes with lower 
expression upon sigB induction (in blue) cluster close to the significance threshold whereas 
those with increased expression (in red) show a larger fold change (Figure 3). We calculated 
the Manhattan distance for each data point (Dataset S2), and discuss the proteins encoded 
by the top-10 of the differentially expressed genes below.
CD0051A is a small hypothetical protein of unknown function. It does not contain any 
recognizable domains and a secondary structure prediction using Phyre2 does not give any clues 
as to its potential function (240). CD0580 (GapN) is annotated as an glyceraldehyde-3-phosphate 
dehydrogenase (GADPH), a key glycolytic enzyme, and contains an aldehyde dehydrogenase 
domain. Interestingly, its activity has been shown to be redox-controlled in other bacteria 
and has been implicated in the response to reactive oxygen and nitrogen species (241-243). 
CD1623 is a putative oxidoreductase with similarity to FAD flavoproteins  and rubredoxins. 
CD1690 (TrxA) and CD1691 (TrxB) are likely encoded in the same operon (244), and form a 
thioredoxin/thioredoxin-disulfide reductase couple. CD0174 (CooS; IPR010047), CD0175 and 
CD0176 are likely also encoded in a single operon (244), and function as carbon monoxide 
dehydrogenase, and two putative oxidoreductases. As mentioned above, CD0174 has been 
implicated in aerobic/nitrosative stress and it is likely that CD1623, CD1690 and CD1691 also 
function in this pathway. Finally, CD2115A encodes another small hypothetical protein and as 
for CD0051A, no function could be assigned on the basis of secondary structure prediction.
As the σB regulon that we define here is substantially smaller than that previously reported, 
the major conclusion is that at least 32% of the σB regulon is involved in positively regulating 
oxidative/nitrosative stress responses. In the previous investigation  of the σB regulon they 
were approximately 3.2% (~32/1000) (160). Overall, we conclude that the core functions of 
the σB regulon lie in the regulation of the detoxification response to oxygen- and nitro-radicals.
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In vitro run-off transcriptions demonstrate direction activation of PCD0350, PCD2963, PCD3412 and 
PCD3605 by σ
B
Gene expression can directly or indirectly be influenced by σB, and to date no attempts have 
been made to discriminate these possibilities biochemically (160, 169). Despite the short time 
of induction and the uncoupling of σB from its normal regulatory network, our analyses could 
possibly also have picked up indirect effects. To determine if the transcription of selected genes 
is directly activated by σB, in vitro transcription run-off reactions were performed using purified 
σB6xHis and RNA polymerase core enzyme (RNAP
core) on the upstream regions of a selection of 
genes. The genes CD0350 (encoding a putative hydrolase involved in oxidative stress; Table 
2), CD2963 (encoding an L,D-transpeptidase), CD3412 (encoding UvrB, involved in nucleotide 
excision repair), CD3605 (encoding a ferredoxin) and CD3614 (encoding a hypothetical protein 
involved in oxidative stress; Table 2) were selected on the basis of differential expression in our 
transcriptome analyses (Dataset S1) and those of others (160), availability of reporter constructs 
that could be used to generate a template for the in vitro transcription reactions (232) and/
or the presence of a putative σB consensus upstream in the upstream region (169). The gene 
CD0872 (maltose O-acetyltransferase) was not differentially expressed in our transcriptome 
data and was thus included as a negative control. The promoter of the toxin A gene (tcdA) 
in combination with purified TcdR was used as a positive control for the assay, as previously 
described (245). As expected, no in vitro transcript was observed for a linear DNA fragment 
containing PCD0872 incubated with purified σ
B
6xHis
 and RNAPcore under our experimental conditions, 
whereas a specific product was obtained for the positive control PtcdA, in the presence of TcdR 
and RNAPcore (Figure 4). An RNAPcore- and σB6xHis-specific signal was observed for fragments 
containing the putative promoter regions of the genes CD0350, CD2963, CD3412 and CD3605, 
demonstrating that expression of these genes was directed by σB. For the fragments containing 
the putative promoter of CD3614 we did not get a consistent product in the in vitro transcription 
experiments, though some smearing is visible in the lane with RNAPcore and σB6xHis. As CD3614 
demonstrates clear differential expression in the DNA array experiments and it upstream 
region harbors the σB consensus sequence WGWTT-N13-17-(G/T)GGTWA (160), we consider it 
likely that this gene is directly regulated by σB and our failure to obtain a discrete signal is due 
to our experimental conditions or the lack of an auxiliary factor in our in vitro assays. 
Overall, we provide the first biochemical evidence for direct σB-dependent activation of several 
genes identified via transcriptome analyses as part of the σB regulon in C. difficile. 
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Figure 4. In vitro run-off transcription of selected promoter regions. Samples were run on an 8% urea 
gel. The two bands corresponding to 82 bp and 64 bp are end-labelled oligonucleotides. Reactions 
without sigma factor (σB or TcdR, respectively) or RNAPcore were analyzed as controls. Asterisks 
indicate the presence of distinct transcripts. RNAPcore= E. coli RNA polymerase core enzyme (NEB). A) 
Controls for the in vitro run-off transcriptions. Purified TcdR, a sigma factor demonstrated to activate 
tcdA transcription in vitro (245), was used with PtcdA (pCD22) as a positive control for the assay. PCD0872 
(derived from pIB21) shows no altered transcription in the DNA array analysis and was taken along as 
negative control. B) In vitro run-off transcriptions for selected genes induced by σB overproduction.
Antimicrobials and hydrogen peroxide activate σB -directed gene transcription 
The redefined σB regulon pointed towards a substantial role for σB in coordinating the oxidative- 
and nitrosative stress response, which could result from antimicrobial treatment. In order 
to test for the activation of σB-dependent promoters by antimicrobials, we set up a plate-
based luciferase reporter assay.  In this assay cells harboring σB-dependent luciferase reporter 
constructs were plated on BHIY agar to give confluent growth and exposed to antimicrobials 
either through an epsilometer test (E-test) or through a filter disc. Subsequently, luciferase 
activity was imaged (for details, see Materials and Methods). A strain harboring Ptet-sluc
opt (AP34) 
served as negative control, as this promoter is not expected to respond in a σB-dependent 
manner (Figure 5A). First, the σB-dependent response to metronidazole was investigated. 
Metronidazole, formerly used as a first line treatment for CDI, is believed to cause DNA damage 
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through the formation of nitro-radicals although its exact mode of action remains unclear (172, 
246). To survey a full spectrum of metronidazole concentrations, we evaluated luminescence 
after 24h of incubation of an metronidazole E-test. If metronidazole treatment results in σB-
dependent activation of gene transcription, we expect to see a luciferase signal in the wild 
type, but not in a sigB knockout background. In agreement with this, activation of PCD0350 was 
observed at the edge of the halo resulting from the metronidazole E-test in the wild type 
background, but not in the sigB knockout strain (Figure 5B). No signal was observed for the 
negative control Ptet-sluc
opt (Figure 5A).  The observed activation σB-dependent activation 
of gene expression at the edge of the halo, but not further into the plate suggests that the 
metronidazole induced, σB-dependent activation of PCD0350 occurred close to the Minimal 
Inhibitory Concentration (MIC). Expression of the luciferase from PCD2963 was found to be strictly 
dependent on σB as no luciferase activity was observed in the sigB knockout strain. However, 
there was limited to no increase in reporter gene expression in the presence of metronidazole. 
Metronidazole strongly activated transcription from PCD3412 at MIC levels of metronidazole, 
but this appeared to be independent of σB in this assay since in the sigB mutant a similar 
induction was observed. Finally, in a manner comparable to PCDD0350, the activation of PCD3614 
was strongly induced by metronidazole at values close to MIC in a σB-dependent manner, 
but residual activity was observed in the sigB knockout strain independent of metronidazole 
levels . We noted that metronidazole-induced promoter activation appeared to occur on the 
inside of the E-test halo, which might be attributed to the secretion of the luciferase reporter. 
The observed diverse regulatory responses at different tested promoters during the treatment 
of C. difficile with metronidazole (with respect to basal level, σB dependence and induction) 
pointed towards a more complex regulatory network with the participation of σB, but also 
influenced by other factors. Antimicrobial-driven (and σB-dependent) activation of σB target 
genes could be specific to metronidazole or represent a more general response to cellular 
(toxic) stresses. Therefore, we evaluated the effects of different antimicrobial compounds and 
the radical producer H2O2 as a positive control (160), using the PCD0350 reporter construct, as this 
promoter demonstrated the clearest σB dependent activation in the presence of metronidazole 
(Figure 5B). We tested the cell wall biosynthesis inhibitor vancomycin, the protein synthesis 
inhibitor lincomycin and the DNA polymerase inhibitor ibezapolstat (formerly known as ACX-
362E) (247). We observed clear activation of PCD0350 in the presence of all added stressors, but 
not for a negative control containing water (Figure 5C). 
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Figure 5. Plate-based luciferase assay shows σB-dependant promotor activity from antimicrobial 
and hydrogen peroxide exposure. A) Setup of the assay. E-test halos (left panel) were sprayed with 
luciferase substrate and imaged (right panel). The dotted line indicates the location of the halo based 
on the left panel. Strain AP34 (Ptet-sluc
opt) shows no signal due to the absence of inducer. B) Luciferase 
reporters of different σB regulated promoters were tested for luciferase signal after a metronidazole 
E-test. Halos are indicated by the dashed lines as in panel A. C) Luciferase activity of the PCD0350 luciferase 
reporter was imaged in the presence of discs containing 10 µL of various compounds: sterile H2O 
(mQ), Lincomycin (3000 µg/ml; Lin), metronidazole (200 µg/ml; Met), vancomycin (200 µg/ml; Van), 
Ibezapolstat (400 µg/ml; Ib) and hydrogen peroxide (1M; H2O2). Halos and the location of the different 
stressors are indicated by red circles (disc) and black dashed circles (halo). Signals outside the halo in 
these images are representative for the signals across the plate. Experiments were performed at least 
in triplicate with qualitatively similar results.
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We conclude that, at least for the σB dependent promoter of CD0350, activation does not only 
occur upon exposure to lethal levels of metronidazole, but also with unrelated antimicrobials 
and toxic stressors such as hydrogen peroxide. 
 
Discussion
In this work we have demonstrated by Western blotting using an affinity purified anti-σB 
antibody that σB can be overproduced for a limited period of time,  sufficient for transcriptome 
analyses. The induced production of σB in a sigB mutant background yielded highly consistent 
results, despite potential toxicity and plasmid-loss (Figure 2), and the results were used to 
redefine the surprisingly large σB regulon previously proposed (160). As our approach more 
accurately measures changes in transcription directly related to σB production, the refined 
regulon described here is much smaller (Dataset S1). Its size is fully in line with that of the σB 
regulon of other gram-positive bacteria such as L. monocytogenes (~130 genes), B. subtilis (~150 
genes) and S. aureus (~200 genes) (148). The redefined regulon underscores the importance 
of σB in responding to oxidative/nitrosative stresses as genes implicated in such processes are 
significantly enriched in the smaller regulon.  
The majority of the genes in our regulon were found to be induced, rather than repressed,  by 
σB. This is in line with sigma factors acting as specificity determinants for transcription initiation 
(238). Similar observations have been made for the σB regulon of L. monocytogenes (248, 249). 
For the first time, direct evidence of C. difficile σB-dependent gene activation is provided by 
the results of the in vitro run-off transcriptions (Figure 4), which demonstrate that RNAPcore 
and σB are sufficient to generate transcripts from PCD0350, PCD2963, PCD3412 and PCD3605.
 Notably, 
these experiments pave the way for a further in vitro characterization of this sigma factor in C. 
difficile including validation of the σB binding sequence and the interplay with other regulators.
Although the promoters of CD3412 (uvrB) and CD3614 were reported to have a σB consensus 
sequence and are differentially expressed upon σB overexpression (160, 247), our results 
clearly demonstrate that they can also be expressed in a σB-independent manner (Figure 5B). 
This is most notable for PCD3412, which is still activated by metronidazole in the absence of σ
B, 
in line with results obtained with ibezapolstat in a different study (232). Both metronidazole 
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and ibezapolstat treatment can cause DNA damage, and DNA-damage dependent induction 
of CD3412 therefore likely depends on a σB-independent pathway.
The observed σB-dependent gene repression is expected to be indirect (σB induces the 
transcription of a repressor gene), or the result of competition (σB competes with other 
sigma factors for RNAP) as sigma factors by their very nature induce gene expression (238). We 
consider the second scenario more likely for the following reasons. First, little overproduction of 
σB was detected after 30 minutes of induction. This leaves only a limited time for indirect effects 
to occur in our setup. Second, the majority of genes down-regulated upon overexpression of 
σB fall into a single functional group (flagellar motility). These genes are known to be regulated 
by the dedicated sigma factor, σD (250), supporting the model of sigma factor competition. 
Strikingly, in L. monocytogenes σB activity (indirectly) also results in down-regulation of flagellar 
gene expression, but this is mediated by the repressor MogR (251). Protein BLAST analyses 
revealed that C. difficile does not possess a MogR homologue. Nevertheless, the conserved 
inverse correlation between the σB-dependent general stress response and bacterial motility 
could represent a cost-saving strategy for bacterial cells (252). The indirect mechanism 
underlying the observed σB-dependent down-regulation in C. difficile remains to be determined.
There appears to be an intriguing link between σB and the response to toxic compounds, as 
a sigB mutant was more susceptible to rifampicin and mitomycin C (160) and exposure to 
antimicrobials (metronidazole, vancomycin, lincomycin and ibezapolstat) or hydrogen peroxide 
leads to σB-dependent promoter activation (Figure 5C). The mechanism behind the latter 
is unclear. It has been suggested that antimicrobials at toxic concentrations can influence 
metabolism and respiration (253, 254), potentially resulting in the formation of bactericidal 
concentrations of radical species (124, 255, 256). A strong connection between σB and oxidative 
(and/or nitrosative) stress in C. difficile (Table 2) and other bacteria (160, 171, 216), as well 
as a recently described radical scavenging strategy that increases tolerance to antimicrobials 
(257) are consistent with such a model. However, additional research is necessary to determine 
exactly how these processes occur and are influenced by antimicrobials in anaerobic organisms 
under anoxic conditions.
In conclusion, we have demonstrated that σB is directly involved in metabolic and oxidative 
stress responses and that lethal stresses may influence these processes, resulting in activation 
of σB targeted genes.
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Construction of σB expression- and luciferase-reporter vectors
All oligonucleotides used in this study can be found in Table 3. Plasmids and strains are listed 
in Table 4. All PCR products used for sequencing or plasmid synthesis were generated with 
Q5 high-fidelity polymerase (NEB). The PT7-sigB6xHis expression vector pIB14 was created by 
restriction-ligation using restriction enzymes NdeI and XhoI. Using primers oIB-1 and oIB-2 
on C. difficile 630∆erm chromosomal DNA, the sigB CDS was amplified by PCR. The resulting 
DNA fragment was digested and ligated into NdeI-XhoI digested pET21b(-) vector, generating 
expression vector pIB14. Plasmids pIB27, pIB68, pIB69 and pIB74 have been described previously 
(232). The CD0872 promoter area was amplified using primers oIB-14 and oIB-15 and the 
PCD0872 luciferase-reporter plasmid was created by restriction-ligation using restriction enzymes 
KpnI and SacI in digested pAP24 backbone, generating plasmid pIB21. The PCD3605 luciferase-
reporter plasmid was generated by Gibson assembly as described (232) using primers oIB-90 
and oIB-99, yielding plasmid pIB73. A plasmid containing Ptet-sigB was generated by cloning 
the 630∆erm sigB CDS amplified with oWKS-1498 and oWKS-1499 in pMiniT (NEB E1202) per 
manufacturer’s instructions. Using restriction enzymes SacI and BamHI this PCR fragment was 
cloned into pRPF185, yielding pWKS1760. All plasmids were verified by Sanger sequencing.
Bacterial strains and growth conditions
Strains of E. coli were grown aerobically at 37oC in Luria-Bertani broth (Affymetrix) supplemented 
with ampicillin (50 ug/mL), kanamycin (50 ug/mL) and/or chloramphenicol (20 ug/mL) when 
required. Plasmids were maintained in E. coli strains DH5α or MDS42 (Scarab Genomics) under 
appropriate antimicrobial selection and cells were transformed using standard procedures 
(221). For plasmid conjugation into recipient wild type C. difficile 630∆erm and the isogenic 
sigB mutant, E. coli strain CA434 was used as a donor strain as previously described (222). C. 
difficile strains were cultured anaerobically at 37oC in either a Don Whitley VA-1000 or A55 
workstation.
 Cells were cultured in Brain Heart Infusion (BHI, Oxoid) broth supplemented with 0.5% 
(w/v) yeast-extract (BHIY) and 20 µg/ml thiamphenicol when appropriate. Unless additional 
antimicrobials/stressors were added (metronidazole E-test and sterile pads supplemented 
with different stressors), medium was supplemented with C. difficile Selective Supplements 
(CDSS, Oxoid).
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The sigB ClosTron mutant described in this manuscript was generated as described (258), using 
pMTL007C-E2_sigB171s::intron_ermB, synthesized by DNA2.0 (now ATUM). Design of the 
retargeted intron was performed with the Perutka algorithm, via the ClosTron website (http://
clostron.com/). The mutant was verified using primers Cdi-sigB-F, Cdi-sigB-R, EBSuniversal, 
ErmRAM-F and ErmRAM-R.
Overproduction, purification and affinity purification of σB6xHis
 for synthesis of a polyclonal 
anti-σB antibody
Overproduction and purification of σB6x-His
Overexpression of σB6x-His was performed by using Escherichia coli (E. coli) Rosetta (DE3) pLysS 
cells (Novagen) harboring the E. coli expression plasmid pIB14. These cells were cultured in 
Luria-Bertani (LB) broth and induced with 0.5 mM IPTG for one hour starting at an optical 
density ≈ 0.6. Cells were collected by centrifugation at 4oC and the resulting cell pellets were 
resuspended in lysis buffer (pH = 8.0, 50 mM NaH2PO4, 300 mM NaCl, 5mM β-mercaptoethanol, 
0.1% NP-40 and Complete protease inhibitor cocktail (CPIC, Roche Applied Science). Through 
the addition of 1 mg/mL lysozyme and sonication (6 times 20 seconds) cells were lysed. The 
lysate was drawn through a blunt 1.2 mm needle and was clarified by centrifugation at 13000 
x g at 4oC for 25 minutes. Recombinant σB6xHis was purified from the supernatant on TALON 
Superflow resin (GE healthcare) per manufacturer’s instructions. Proteins were dialyzed and 
stored in buffer (pH=8.0) containing 50 mM NaH2PO4, 300 mM NaCl and 12% glycerol. Protein 
concentrations were determined using a Bradford assay (Biorad). Two mL of σB6x-His protein 
solution containing 2 mg/mL protein was sent to BioGenes GmbH (Berlin) for generation of 
a polyclonal rabbit-anti-σB antibody.
Affinity purification of the polyclonal anti-σB antibody
Affinity purification of the antibody was performed to increase specificity of σB detection. 
Approximately 350 µg of purified σB6xHis protein was loaded onto an SDS-PAGE gel. After 
electrophoresis and transfer of proteins to a PVDF membrane using standard blotting 
procedures, purified σB6xHis protein was visualized by Ponceau S staining and the membrane 
containing the protein was cut as small as possible whilst retaining the region with the protein. 
The membrane was destained and washed with TBST buffer (500 mM NaCl, 20 mM Tris-base, 
0.05% v/v Tween-20, pH = 7.4) twice for 5 minutes at room temperature. The membrane 
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was then pre-eluted by soaking in acidic glycine solution (100 mM, pH = 2.5) for 5 minutes 
prior to washing with TBST twice for five minutes at room temperature. Subsequently the 
membrane was blocked in 5% non-fat milk powder solution (Campina Elk, dissolved in TBST 
buffer) for one hour at room temperature after again washing twice with TBST for 5 minutes. 
Serum containing anti-σB antibody was incubated on the membrane overnight at 4oC. After 
three 5-minute washes with TBST, the membrane was washed twice for 5 minutes in PBS. 
Affinity purified antibody was eluted from the membrane by adding acidic glycine solution 
and incubating for 10 minutes at room temperature. The pH of the eluate was adjusted to 7.0 
through the addition of 1 M Tris-HCl (pH = 8.0). This step was repeated twice more and the 
eluates were pooled and centrifuged (1 min maximum speed) to remove precipitated protein 
and membrane particles. Bovine serum albumin (BSA) and sodium azide were added to the 
affinity purified anti-σB antibody to end concentrations of 1 mg/mL and 5 mM respectively, 
and the affinity purified antibody was stored at -80oC. 
Characterization of the σB regulon
σB overproduction in C. difficile 
Exponentially growing starter cultures of C. difficile strain  IB58 and IB61 were diluted to an 
OD600=0.05 in BHIY medium supplemented with 20 µg/mL lincomycin and thiamphenicol (20 
µg/mL) where appropriate. Cells were grown until OD600 ≈ 0.3 after which a 1-mL sample was 
taken for control by Western blotting and gene expression was induced with 100 ng/mL ATc 
for one hour. Subsequently, 1 mL of sample was taken for control by Western Blotting and 
50 mL was collected by centrifugation and stored at -20oC until RNA extraction. Non-induced 
samples were treated and collected identically, except that no ATc was added at OD600 ≈ 0.3. 
All samples were corrected for OD600 prior to analysis by Western Blot.
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Name Relevant features Source
Plasmids pAP24 Ptet-sluc
opt; catP (201)
pCD22 PtcdA; catP (259)
pIB14 PT7-sigB6xHis; amp This study
pIB21 PCD0872-sluc













sigB-retargeted intron (ermB) This study
pWKS1750 Ptet-sigB ; catP This study
Strains 630∆erm MLS-susceptible derivative of Clostridioides 
difficile strain 630
(190) or (260)
AP34 630∆erm pAP24; thiaR (201)
DH5α Escherichia coli F-endA1 glnV44 thi-1 recA1 relA1 






IB14 Rosetta (DE3) pLysS pIB14; ampR, chlorR This study
IB18 630Δerm  sigB::CT; ermR/lincoR This study
IB37 630∆erm pIB27; thiaR (232)
IB56 630∆erm ∆sigB (232)
IB58 IB18 pWKS1750; thiaR, ermR/lincoR This study
IB61 IB18 pAP24; thiaR, ermR/lincoR This study
IB95 630∆erm pIB68; thiaR (232)
IB96 630∆erm pIB69; thiaR (232)
IB98 IB56 pIB27; thiaR (232)
IB99 IB56 pIB68; thiaR (232)
IB100 IB56 pIB69; thiaR (232)
IB108 630∆erm pIB74; thiaR (232)
IB111 IB56 pIB74; thiaR (232)
JC096 630∆erm pWKS1750; thiaR This study
Table 4. Plasmids and strains used in this study.
RNA extraction
Bacterial RNA was extracted and analyzed as previously described (261). Briefly, cell pellets 
were lysed for 30 mins at room temperature in enzymatic lysis buffer consisting of 15 mg/mL 
lysozyme and TE buffer. Further disruption of cells was performed by vigorous mechanical lysis 
for 3 minutes in RLT buffer to which one spatula of glass beads was added. After samples were 
centrifuged (3 minutes at 10.000 rpm at 4oC) and 100% ethanol was added to the supernatant, 
RNA was purified using the Qiagen RNeasy Kit protocol according to manufacturer’s instructions. 
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DNA contamination was removed by using RNAse-free DNAse I (Qiagen) twice prior to elution 
of the RNA samples in H 2O. RNA quality and integrity numbers (RINs) were assessed with a 
Bioanalyzer 2100 (Agilent) and RNA 6000 Nano Reagents (Agilent). Only samples with an RIN 
of ≥7 were used for further analysis.
DNA microarray and data analysis
A customized whole-genome DNA microarray of 630∆erm was used (8x15K format, Agilent) 
(261). Quadruplicate samples were analyzed for the DNA microarray. Using the ULS fluorescent 
labelling kit for Agilent arrays (Kreatech), 1 µg of total RNA was used for labelling with either 
Cy3 (Ptet-sigB) or Cy5 (Ptet-sluc
opt). After pooling and fragmentation, 300 ng of labelled RNA 
per sample was hybridized according to the two-color microarray protocol from Agilent. DNA 
microarrays were scanned with an Agilent C scanner and analyzed as described (261). A gene 
was considered differentially expressed if the log2 foldchange (log2 FC) was ≤ -1.5 or ≥1.5 and 
the p-value was <0.05. Results were visualized in VolcanoseR (239), and are available as an 
interactive graph via the URL contained in Text S1. The data used in the visualization has been 
deposited at Zenodo for this purpose (doi: 10.5281/zenodo.3945936). Full transcriptome data 
has been deposited in the GEO database, and can be accessed through the identifier GSE152515. 
In vitro transcription 
DNA oligonucleotides oWKS-1506 and oWKS-15136 (64- and 82 bp, respectively) were end-
labelled with ɣ-32P-ATP using T4 Polynucleotide Kinase (PNK, Invitrogen) and used as a size 
indicator for the in vitro transcription reactions. For the end labelling reaction, 1 µl ɣ-32P-ATP 
was incubated together with 200 pmol oligonucleotide and 1 µl (10 U) PNK in Forward Reaction 
buffer (70 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 100 mM KCl, 1 mM 2-mercaptoethanol) at 
37oC for 30 minutes. For the in vitro run-off transcriptions sigma factors and RNA polymerase 
core enzyme were preincubated with PCR amplified promoter areas (for PCD0350, PCD0872, PCD2963, 
PCD3412, PCD3605 and PCD3614) or XbaI linearized pCD22 (PtcdA) for 30 minutes at 37
oC prior to start 
of the reaction. PCR products of the promoter areas as used for the in vitro transcription 
reactions were loaded on and excised from agarose gels and purified using a NucleoSpinTM Gel 
and PCR Clean-up kit (Macherey-Nagel). In vitro transcription reactions mixtures contained 1 
µl (1 U) E. coli RNAPcore (NEB M0550S), 16 pmol sigma factor, 0.5 pmol DNA, 10 mM NTP mix 
and 0.3 µl α-32P-ATP in reaction buffer (40mM Tris-HCl, 150 mM KCl, 10 mM MgCl2, 1 mM 
DTT, 0.01% triton X-100, pH=7.5) and were incubated for 15 minutes at 37oC. Transcripts and 
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labelled oligonucleotides to be used as a size indication were purified using P-30 Bio-Gel spin 
columns (Biorad). All reactions were stopped in gel loading buffer II (Invitrogen) containing 95% 
Formamide, 18 mM EDTA and 0.025% each of SDS, xylene cyanol, and bromophenol blue at 
95oC for 5 minutes and loaded on 8% monomeric UreaGel (SequaGel, National Diagnostics). 
Gels were dried and exposed to PhosphorImager screens overnight (approximately 17 hours) 
and imaged with a Typhoon 9410 scanner (GE Healthcare).
Spot assay for viability upon σB overproduction in C. difficile and vector stability assay
C. difficile overnight pre-cultures were corrected for OD600 and subsequently tenfold serially 
diluted in BHI medium. Two-µl spots of each dilution were plated on selective (20 µg/mL 
thiamphenicol) and unselective square (90x15 mm, VWR international) BHI plates with or 
without 200 ng/mL anhydrotetracycline (ATc). Growth was evaluated after 24 hours and 
subsequently swabs were taken from all strains grown on unselective BHI agar plates with- and 
without 200 ng/mL ATc for the vector stability assay. These swabs used for the vector stability 
assay were resuspended in PBS to a turbidity of 1.0 McFarland, adjusted for their OD600-values 
and tenfold serially diluted in non-selective BHI medium. Of these serially diluted suspensions, 
10-µl spots of each dilution were then plated on selective (20 µg/mL thiamphenicol + CDSS) and 
non-selective (BHI +CDSS) plates and CFU/mL was counted after 24 - 48 hours of growth. The 
percentage of cells retaining the plasmid was calculated as [CFU/mL]selective/[CFU/mL]non-selective x 
100%. If no growth was detected on selective plates containing thiamphenicol the percentage 
of plasmid maintained was set as 0%. To calculate statistical significance between % plasmid 
maintained in strains induced or not induced by ATc, an unpaired student’s t-test was used.
Plate based luciferase assay with metronidazole E-test and disk diffusion 
Strains harboring luciferase-reporter plasmids were grown on prereduced, selective BHI plates 
for 24 hours. Subsequently bacterial suspensions corresponding to 1.0 McFarland turbidity 
were applied on BHI agar supplemented with 0.5% yeast-extract after which a metronidazole 
E-test or plain disks were applied. Disks were spotted with 10 µl each of sterile H2O, 1 M 
H2O2, 3000 µg/mL lincomycin, 200 µg/mL metronidazole, 400 µg/mL ibezapolstat and 200 
µg/mL vancomycin. After 24 hours of growth luciferase activity was visualized by spraying 
1:100 reconstituted NanoGlo Luciferase substrate (Promega N1110) on the agar plate using 
a disposable spray flask. One spray corresponded to approx. 250 µl reconstituted NanoGlo 
Luciferase substrate. Luminescence was recorded using a Uvitec Alliance Q9 Advanced imager 
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(BioSPX) after 10 sec exposure time per plate. Luciferase were conjugated into a sigB knockout 
made by Allelic Coupled Exchange (202) whereas a ClosTron mutant background was used 
for the DNA arrays. However, no differences between these backgrounds have ever been 
observed in our assays.
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Metronidazole was until recently used as a first line treatment for potentially life-threatening 
Clostridioides difficile (CD) infection. Although cases of metronidazole resistance have been 
documented, no clear mechanism for metronidazole resistance or a role for plasmids in 
antimicrobial resistance has been described for CD. Here, we report genome sequences of seven 
susceptible and sixteen resistant CD isolates from human and animal sources, including isolates 
from a patient with recurrent CD infection by a PCR ribotype (RT) 020 strain, which developed 
resistance to metronidazole over the course of treatment (Minimal Inhibitory Concentration 
[MIC] = 8 mg/L). Metronidazole resistance correlates with the presence of a 7-kb plasmid, 
pCD-METRO. pCD-METRO is present in toxigenic and non-toxigenic resistant (n=23), but not 
susceptible (n=563) isolates from multiple countries. Introduction of a pCD-METRO-derived 
vector into a susceptible strain increases the MIC 25-fold. Our finding of plasmid-mediated 
resistance can impact diagnostics and treatment of CD infections.
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Introduction
Clostridioides difficile (Clostridium difficile) is a Gram-positive obligate anaerobe capable of 
causing Clostridioides difficile Infection  (CDI) upon disruption of the normal intestinal microbiota 
(225). Although it is one of the major causes of nosocomial infectious diarrhea, community-
acquired CDI is becoming more frequent (62, 262). CDI infection poses a significant economic 
burden with an estimated cost at €3 billion per year in the European Union and impairs the 
quality of life in infected individuals (45, 53). The incidence of CDI has increased over the last 
two decades with outbreaks caused by epidemic types such as PCR ribotype (RT) 027 (NAP1/
BI)(44). CDI is not restricted to this type, however, as infections caused by RT001, RT002, 
RT014/020 and RT078 are frequently reported in both Europe and the United States (20, 52). 
Metronidazole is used for the treatment of mild-to-moderate infections and vancomycin for 
severe infections, though vancomycin is increasingly indicated as a general first-line treatment 
(80, 263-269). Fidaxomicin has recently also been approved for CDI treatment, but its use 
is limited by high costs (80). Fecal Microbiota Transplantation (FMT) is effective at treating 
recurrent CDI (rCDI) that is refractory to antimicrobial therapy (15). Reduced susceptibility 
and resistance to clinically used antimicrobials, including metronidazole, has been reported 
and this, combined with the intrinsic multiple drug-resistant nature of C. difficile, stresses the 
importance for the development of better diagnostics and new effective treatment modalities 
(20). 
Routine antimicrobial susceptibility testing is generally not performed for C. difficile and 
consequently, reports of resistance to metronidazole are rare (51, 270, 271). Longitudinal 
surveillance in Europe found that 0.2% of clinical isolates investigated were resistant to 
metronidazole (271), but reported rates from other studies vary from 0-18.3% (90, 272-274). 
These differences may reflect geographic distributions in resistant strains, or differences in 
testing methodology and breakpoints used (178, 275). Moreover, metronidazole resistance 
can be unstable, inducible and heterogeneous (124). Finally, metronidazole resistance appears 
to be more frequent in non-toxigenic strains such as those belonging to RT010, which have a 
7-9 fold increase in Minimal Inhibitory Concentration (MIC) values compared to RT001, RT027 
and RT078 (90, 275). 
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 86
86
CHAPTER 4
Metronidazole is a 5-nitroimidazole prodrug that upon intracellular reductive activation induces 
cellular damage through nitro-radicals (124). It is not only used in the treatment of CDI, but 
also an important drug for treating parasitic infections and as prophylactic antimicrobial in for 
instance abdominal surgery (120, 124). Mechanisms associated with metronidazole resistance 
described in other organisms include the presence of 5-nitroimidazole reductases (nim genes), 
altered pyruvate-ferredoxin oxidoreductase (PFOR) activity and adaptations to (oxidative) 
stress (124). The knowledge on resistance mechanisms in C. difficile is very limited, but may 
involve modulation of core metabolic and stress pathways as well (140, 141).  Of note, levels 
of metronidazole achieved in the colon are generally low and this could be relevant for the 
selection of resistant strains (276). 
Here, we present a case of a patient with rCDI due to an initially metronidazole susceptible 
(MTZS) RT020 strain which developed resistance to metronidazole over time. We analyze 
the genome sequences of these toxigenic MTZS and metronidazole resistant (MTZR) strains, 
together with 5 MTZS and 11 MTZR non-toxigenic RT010 strains. We identify pCD-METRO, a 
7-kb plasmid conferring metronidazole resistance. This plasmid is internationally disseminated 
and also occurs in epidemic types. We thus report a clinically relevant phenotype associated 
with plasmid-carriage in C. difficile. 
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Results
In-patient development of a metronidazole resistant strain
A 54 year old kidney-pancreas transplant patient with a medical history of Type I diabetes 
mellitus, vascular disease and a double lower leg amputation was on hemodialysis when 
developing diarrhea. The patient was subsequently diagnosed with CDI and a toxigenic 
metronidazole sensitive (MIC=0.25 mg/L) RT020 strain was isolated from the fecal material 
of the patient. Treatment with metronidazole was started, leading to initial resolution of 
the symptoms (Figure 1). Two more episodes of CDI occurred during which the patient was 
treated primarily with vancomycin (but also metronidazole) prior to an FMT provided by the 
Netherlands Donor Feces Bank. At the start of the second episode a MTZS RT020 strain was 








C. difficile strain PCR ribotype, metronidazole susceptible
C. difficile strain PCR ribotype, metronidazole resistant
Clinical information other than antibiotics. 
Figure 1. Timeline of the course of the antibiotic treatment and rCDI in the patient. Dates and 
timepoints on which treatment was initiated or stopped and C. difficile isolates were recovered are 
indicated above the timeline. (r)CDI was diagnosed when both a toxin enzyme-immune assay and 
nucleic acid amplification test were positive for C. difficile in combination with a physician’s assessment 
of symptoms consistent with CDI. Yellow highlighting indicates the time where pCD-METRO positive 
MTZR C. difficile was isolated. Source data are provided as a Source Data file.
Three months after the first FMT, the patient once again developed bloody diarrhea and two 
more episodes of rCDI were diagnosed which were treated with a vancomycin and a fidaxomicin 
regime. At two instances, RT020 strains were again isolated from the fecal material of the 
patient. Strikingly, these two clinical isolates were now phenotypically resistant to metronidazole 
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(MIC=8 mg/L as determined by agar dilution). Ultimately the patient was cured by a second FMT. 
We hypothesized that the rCDI episodes were due to clonal RT020 strains that persisted despite 
antimicrobial therapy and an FMT. Clonal MTZS and MTZR strains would allow us to determine 
the underlying genetic changes that resulted in metronidazole resistance. To determine the 
relatedness between these RT020 isolates whole genome sequencing (WGS) was performed 
(Table 1). We also included 2 more MTZR RT020 strains and a non-related RT078 strain isolated 
from the same patient and 4 MTZS and 8 MTZR RT010 strains from our laboratory collection 
(Supplemental Dataset 1) to perform single nucleotide polymorphism (SNP) analyses. Strains 
were considered resistant to metronidazole with MIC values >2 mg/L according to the EUCAST 
epidemiological cut-off value (87). All strains resistant to metronidazole (n=12) showed cross-
resistance to the nitroimidazole drug tinidazole. 
Assembly of the MTZR RT020 strain IB136 (Supplemental Dataset 2) resulted in a genome 
of 4166362 bp with 57 contigs, and an average G+C-content of 28.5% (N50= 263391 bp, 
mapping rate 98.97%). A BLAST comparison between this genome and the NCBI nt database 
showed that the genome is closest to the genome of strain LEM1 (277). As expected, 5/6 
strains isolated from the patient (all RT020) showed 100% identity over the majority of all 
contigs, suggesting they are highly similar. All RT020 strains were found to be of multi-locus 
sequence type (ST) 2, consistent with data from others (278). The sixth strain (IB137), was a 
clear outlier and was identified as being closest to the RT078 reference strain M120 (279). 
This is consistent with another ribotype (RT078) and sequence type (ST11) assignment. All 
RT010 strains belonged to ST15.
Resistance does not correlate with a SNP
Previous studies analyzing the mechanism behind metronidazole resistance in C. difficile only 
studied a single isolate each (138, 141). We performed a core genome SNP analysis on selected 
strains (n=18; Table 1), comparing MTZS (n=6) and MTZR (n=12) strains within and between 
the different PCR ribotypes (RT010, RT020 and RT078).  
The evolutionary rate of C. difficile has been estimated at 0-2 SNPs per genome per year but 
might vary based on intrinsic (strain type) and extrinsic (selective pressure) factors (280). 
Our analysis identified a single SNP in the MTZR RT020 (IB136), compared to the MTZS  RT020 
strains derived from the same patient, conclusively demonstrating that these strains are clonal. 
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Considering the time of isolation of the susceptible and resistant isolates, this implies the MTZS 
RT020 strain most likely acquired metronidazole resistance. In contrast, between the MTZS and 
MTZR RT010 isolates (which come from diverse human and animal sources) 457 SNPs were 
detected. Moreover, RT010 and RT020 were separated by >25000 SNPs. 
The SNP identified in the RT020 strains discriminating the MTZS from the MTZR isolates is 
located in a conserved putative cobalt transporter (CbiN, IPR003705). However, the SNP is not 
observed in the MTZR RT010 strains. Thus, metronidazole resistance is either multifactorial or 
not contained within the core genome. We did not investigate the contribution of this SNP to 
metronidazole resistance further.
MTZR C. difficile strains contain a 7-kb plasmid 
Next, we investigated extrachromosomal elements (ECEs), which can include plasmids. Although 
plasmids containing antimicrobial resistance determinants have been described in Gram-
positive bacteria, they appear to be more common in Gram-negatives (281).  Plasmids in C. 
difficile are known to exist, but no phenotypic consequences of plasmid carriage have been 
described to date (282). The investigation of the pan-genome of all sequenced strains, including 
a prediction of ECEs predicted by an in-house pipeline similar to PLACNET (283, 284), showed 
a single contig that was present in all MTZR strains (4.6% - 19.27% of reads mapped, with a 
minimum of 479497), but absent from MTZS strains, of both RT010 and RT020 (0% of reads 
mapped with a maximum 327 reads). Circularization based on terminal repeats yielded a 
putative plasmid of 7056bp with a G+C-content of 41.6% (Figure 2A). Correct assembly was 
confirmed by PCR (Figure 2B) and Sanger sequencing.
To confirm the circular nature of the contig, total DNA isolated from the MTZR RT010 strain 
IB138 before and after PlasmidSafe DNase (PSD, Epicentre) (282) treatment was analyzed by 
PCR using primers specific for chromosomal DNA (gluD) and the putative plasmid (Figure 2C). 
A positive signal for gluD was only observed in samples that had not been treated with PSD, 
demonstrating that PSD treatment degrades chromosomal DNA to below the detection limit 
of the PCR. By contrast, a signal specific for the putative plasmid was visible both before and 
after PSD treatment. Consequently, we conclude that our whole genome sequence identified 
a legitimate 7-kb plasmid.
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A total of 8 open reading frames (ORFs) were annotated on the plasmid (Figure 2A). ORF1-
5 encode a hypothetical protein (ORF1), a MobC-like relaxase/Arc-type ribbon-helix-helix 
(ORF2; PF05713), a MobA/VirD2 family endonuclease relaxase protein (ORF3; PF03432), 
a hypothetical protein with a MutS2 signature (ORF4), and a predicted replication protein 
(ORF5), respectively. ORF6 is a small ORF that is likely a pseudogene, and the remaining 
ORFs encode a metallohydrolase/oxidoreductase protein (ORF7; IPR001279) and a Tn5-like 
transposase gene (ORF8; PF13701). Intriguingly, ORF6 showed homology on the protein 
level to the 5-nitroimidazole reductase (nim) gene nimB (33% identity, 54% positives over 61 
amino acids) described in Bacteroides fragilis (CAA50578.1) and found in both metronidazole 
resistant- and susceptible isolates of anaerobic Gram-positive cocci (136, 285). The ORF lacks 
the region encoding the N-terminal part of the Nim protein, and the Phyre2-predicted protein 
structure shows it lacks the  catalytic site residues. Of note, the plasmid sequences from all 
strains are highly similar. Compared to the plasmid of strain IB136, only strains IB143, IB144 
and IB145 contained a single SNP resulting in a Y286S mutation within the Tn5-like transposase 
ORF (Supplemental Figure 1).
Figure 2. pCD-METRO is a 7-kb plasmid. A) Structure of plasmid pCD-METRO and its ORFs. The two 
innermost circles represent GC content (outer circle) and GC skew (innermost circle) (both step size 5nt 
and window size 500nt; , above average in yellow, below average in purple). The unique HaeIII site used 
to construct pCD-METROshuttle (see methods) is indicated. B) Gene specific PCR products amplifying 
regions of ORFs 6 (lane 1+2), ORF5 (lane 3), ORF7 (lane 4) and ORF3 (lane 5), and a chromosomal 
locus (gluD) (C) The product of plasmid specific amplification (targeting ORF6) or chromosomal specific 
amplification (gluD) before and after PlasmidSafe DNase treatment. Source data are provided as a 
Source Data file.
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Together, these results show that all of the MTZR strains, but none of the MTZS strains, sequenced 
in this study contain a plasmid,  hereafter referred to as pCD-METRO (for plasmid from C. 
difficile associated with metronidazole resistance). 
pCD-METRO is found in strains from different countries 
Two clinical isolates with stable metronidazole resistance have been described and we evaluated 
the presence of pCD-METRO in the assembled genome sequences from these strains using 
BLAST (138, 141). We failed to identify pCD-METRO in the draft genome of a toxigenic NAP1 
isolate that acquired stable metronidazole resistance through serial passaging under selection 
(138). We did identify pCD-METRO (fragmented over multiple contigs) in the draft genome 
a non-toxigenic Spanish RT010 strain with stable metronidazole resistance (strain 7032989), 
whereas neither the reduced-susceptible strain nor the susceptible strain from the same study 
contained the plasmid (141). We confirmed these results using PCR, as described for strain 
IB138 (Figure 3; lanes SP), demonstrating pCD-METRO is indeed present in strain 7032989. 
These data show that the presence of pCD-METRO may explain at least part of the cases 
of metronidazole resistance described in literature. We did not detect pCD-METRO in the 
sequence read archive in entries labelled as C. difficile, or otherwise.
Our observations above raise the question how prevalent pCD-METRO is in MTZR C. difficile 
isolates and if there is a bias towards specific types or geographic origins. As metronidazole 
resistance in C. difficile is rare, we expanded our collection of clinical isolates through our 
network (including the ECDC) (n=76) and with selected strains from the Tolevamer (n=42) 
and MODIFY (n=46) clinical trials (111, 174, 286). To correct for interlaboratory differences in 
typing and antimicrobial susceptibility testing, all strains were retyped by ribotyping and tested 
for metronidazole resistance using agar dilution according to Clinical & Laboratory Standards 
Institute (CLSI) guidelines in our laboratory with inclusion of appropriate control strains (13, 
86). Although these strains, with the exception of the Tolevamer strains, were characterized 
as having altered metronidazole susceptibility by the senders (n=122), agar dilution performed 
in our own laboratory classified nearly all of these strains as metronidazole susceptible (MIC 
<2 mg/L). We expected pCD-METRO to be present in MTZR strains, but not in MTZS strains. 
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Figure 3. pCD-METRO is internationally disseminated.  PCR analysis of strains 7032989 (RT010, Spain) 
(SP), LUMCMM190960 (RT027, Poland) (PL), LUMCMM19 0880 (RT010, Czech Republic) (CZ) and 
P016134 (RT010, Germany) (DE). The product of plasmid specific amplification (targeting ORF8) or 
chromosomal specific amplification (gluD) before and after PlasmidSafe DNase treatment are shown. 
Source data are provided as a Source Data file.
We identified three additional metronidazole resistant strains: a RT027 isolate from Poland 
(LUMCMM19 0960; MIC>8 mg/L), a RT010 isolate from the Czech Republic (LUMCMM19 
0880; MIC>8 mg/L) and a RT010 isolate from Germany (P016134; MIC>8 mg/L) (Table 1). A 
PCR on PSD-treated chromosomal DNA isolated from these strains yielded a positive signal 
using primers targeting the plasmid, but not the chromosome (Figure 3, lanes PL/CZ/DE), 
demonstrating all three strains contain pCD-METRO. WGS showed that pCD-METRO in strain 
LUMCMM19 0960 was identical to that of strain IB136, whereas LUMCMM19 0880 contained 
a single SNP resulting in a D131N substitution in ORF1. We also screened our laboratory 
collection of RT010 strains from human and animal sources and identified 7 more MTZR strains 
(as determined by both agar dilution and epsilometer tests [E-test]), 6 of which were positive 
for pCD-METRO (86%; Supplemental Dataset 1). A single RT010 strain (LUMCMM19 0830) 
tested MTZR resistant in agar dilution according to CLSI guidelines (MIC=4 mg/L) (86), but this 
strain was negative for pCD-METRO in both PCR and WGS. Using E-tests, we found this strain 
to be susceptible to metronidazole (MIC=0.19 mg/L) when grown on standard laboratory 
Brain-Heart Infusion (BHI) agar but resistant (MIC=16 mg/L) on Brucella Blood Agar (BBA), 
suggesting a contribution of medium components (possibly haem) to the resistance phenotype 
(Figure 4). On both media RT010 control strains IB138 and IB140 are resistant and susceptible, 
respectively (Figure 4), with 2-4-fold differences in MIC between the medium conditions.  Thus, 
all pCD-METRO containing strains in this study show medium-independent metronidazole 
resistance with a MIC≥ 8 mg/L in agar dilution (22/22). By contrast, all susceptible isolates 
(n=563) lacked pCD-METRO. 
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Taken together, our results show that pCD-METRO is internationally disseminated and can 
explain metronidazole resistance in both non-toxigenic- and toxigenic isolates of C. difficile, 
including those belonging to epidemic ribotypes such as RT027. 
Figure 4. Medium-dependent metronidazole resistance. Strains were grown as described under 
Antimicrobial Susceptibility Testing in the Methods section and spread onto either Brucella Blood Agar 
(BBA) plates, or onto BHIY/CDSS agar plates (BHI). E-tests were placed, and plates were incubated for 
48h before imaging. 2 mg/L is the EUCAST epidemiological cut-off for metronidazole that was used 
to define resistance in this study (87). E-test values for the indicated strains are shown next to their 
respective panels. The images represent 3 independent repeats with a single replicate per condition. 
Source data are provided as a Source Data file.
 
pCD-METRO is likely acquired via horizontal gene transfer
Our whole genome sequence analysis suggested the acquisition of pCD-METRO by a toxigenic 
RT020 strain during treatment of rCDI. We made use of longitudinal fecal samples that were 
stored during treatment to investigate the presence of pCD-METRO in total fecal DNA at various 
timepoints. Total DNA derived from the fecal sample harboring the MTZS RT020 was positive 
for the presence of pCD-METRO (Figure 5). This indicates that pCD-METRO was present in 
the gut reservoir of the patient. Post-FMT, pCD-METRO was no longer detected in total fecal 
DNA, suggesting that the fecal transplant reduced levels of pCD-METRO containing C. difficile 
and/or the donor organism to below the limit of detection of the assay. Fecal samples were 
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stored in the absence of cryoprotectant and as a result we were unable to reculture the 
possible donor organism.
Though we cannot exclude the possibility that the MTZR RT020 strain was already present at 
the moment the MTZS RT020 strain was isolated, our results indicate that pCD-METRO was 
most likely acquired through horizontal gene transfer between the MTZS C. difficile strain and 
an as-of-yet uncharacterized donor organism in the gut of the patient.
Figure 5. pCD-METRO is detectable in fecal total DNA. pCD-METRO is detectable in fecal total DNA 
from the same sample from which a MTZS RT020 C. difficile was isolated. Shown are the results from 
a PCR targeting ORF6, but similar results were obtained for other plasmid-specific primer sets. Source 
data are provided as a Source Data file. 
 
PCR-based identification of metronidazole resistant strains
We implemented a PCR targeting pCD-METRO in our routine surveillance and ad hoc typing, as 
part of the Dutch National Reference Laboratory (NRL) for C. difficile. In the period February-
August 2019, we characterized 721 strains by ribotyping, and identified a single pCD-METRO 
positive strain (LUMCMM19 0348) by PCR. These preliminary data suggest a prevalence of 
<0.14% in an endemic setting in the Netherlands. The identified strain belonged to RT020 and 
was confirmed to be MTZR in an E-test on BBA (Supplemental Figure 2). As described for the 
patient case above, we were able to identify an earlier RT020 isolate from the same patient 
(LUMCMM18 0002) that was pCD-METRO negative and MTZS (Supplemental Figure 2). WGS 
revealed that the susceptible and resistant strains were identical (0 SNPs difference), but differed 
as expected in carriage of pCD-METRO. pCD-METRO in the MTZR isolate contained two SNPs 
compared to the plasmid of strain IB136; a G>A conversion located intergenically between 
ORF6 and ORF7, and a mutation resulting in a V13A mutation in ORF8 (Supplemental Figure 1). 
Our data suggests that selection by metronidazole is crucial in the acquisition of, or selection 
for, pCD-METRO containing C. difficile.    
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pCD-METRO confers metronidazole resistance in C. difficile
Above, we have clearly established a correlation between the presence of pCD-METRO and 
metronidazole resistance. Next, we sought to unambiguously demonstrate that acquisition 
of pCD-METRO, and not any secondary events, lead to metronidazole resistance. To generate 
isogenic strains with or without pCD-METRO, we introduced a shuttle module in the unique 
HaeIII restriction site of the plasmid and introduced the resulting vector, pCD-METROshuttle 
(pIB86; Supplemental Figure 3), into the RT012 laboratory strain 630Δerm using standard 
methods(190).  Metronidazole E-tests showed a reproducible 15-to-20-fold increase in the 
MIC from 0.064/0.19 mg/L  for the strain without pCD-METROshuttle to 2-4 mg/L  for the strain 
with pCD-METROshuttle (Figure 6). These results were confirmed using agar dilution, that showed 
a >24-fold increase (>5 doubling dilutions) from 0.125-0.25 mg/L to 8 mg/L or higher upon 
introduction of pCD-METROshuttle  (Table 1).
Figure 6. pCD-METRO confers metronidazole resistance. RT020 without plasmid (MTZS, strain IB132), 
RT020 with pCD-METRO (MTZR, strain IB133), RT012 without plasmid (MTZS, strain 630Δerm), RT012 
with pIB86 (pCD-METROshuttle, MTZR, strain IB125), RT012 with pIB80 (MTZS, IB90; pIB80 contains the 
pCD-METRO replicon but lacks the other ORFs of pCD-METRO). IB90 and IB125 are 630Δerm-derivatives 
(190). E-tests were performed on BHI agar plates with CDSS. Identical results were obtained on plates 
without CDSS. The images represent 3 independent repeats with a single replicate per condition. 2 mg/L 
indicates the EUCAST epidemiological cut-off for metronidazole that was used to define resistance in 
this study (87). E-test values for the indicated strains are shown next to their respective panels. Source 
data are provided as a Source Data file.
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 96
96
CHAPTER 4







630Δerm wild type 012 A+ B+ CDT- 0.125 (S) Laboratory (190)
IB125 630∆erm pIB86 (pCD-
METROshuttle); ThiaR
012 A+ B+ CDT- ≥8 (R) Laboratory This study
IB132 pCD-METRO - 020 A+ B+ CDT- 0.25 (S) Human This study
IB133 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB134 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB135 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB136 pCD-METRO + 020 A+ B+ CDT- 8 (R) Human This study
IB137 pCD-METRO - 078 A+ B+ CDT+ 0.125 (S) Human This study
IB138 pCD-METRO + 010 A- B- CDT- >8 (R) Human This study
IB139 pCD-METRO - 010 A- B- CDT- 1 (S) Human This study
IB140 pCD-METRO - 010 A- B- CDT- 0.25 (S) Human This study
IB141 pCD-METRO - 010 A- B- CDT- 0.125 (S) Human This study
IB142 pCD-METRO - 010 A- B- CDT- 0.125 (S) Human This study
IB143 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB144 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB145 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB146 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB147 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB148 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB149 pCD-METRO + 010 A- B- CDT- >8 (R) Animal This study
IB151 (P016134) pCD-METRO + 010 A- B- CDT- >8 (R) Unknown (287)
IB30 630∆erm pIB20 (pCD6 
replicon, PCD0716-sluc
opt); ThiaR
012 A+ B+ CDT- 0.25 (S) Laboratory This study 
IB90 630∆erm pIB80 (pCD-METRO 
replicon, Ptet-gusA); Thia
R
012 A+ B+ CDT- 0.125 (S) Laboratory This study
LUMCMM18 0002 pCD-METRO - 020 A+ B+ CDT- ND (S) Human This study
LUMCMM19 0348 pCD-METRO + 020 A+ B+ CDT- ND (R) Human This study
LUMCMM19 0830 pCD-METRO - 010 A- B- CDT - 4 (R) Unknown This study
LUMCMM19 0880 pCD-METRO + 010 A- B- CDT- >8 (R) Unknown This study
LUMCMM19 0970 
(7032989)
pCD-METRO + 010 A- B- CDT- >8 (R) Unknown (141)
LUMCMM190960 pCD-METRO + 027 A+ B+ CDT+ >8 (R) Human (111)
Table 1. Strains described in this study. Listed are strains mentioned in the main body of the manuscript. 
For a complete overview of all strains used, see Supplemental Dataset 1. * PCR ribotype determined at 
the LUMC standard PCR ribotyping ** toxin profile determined by multiplex PCR. *** Metronidazole 
MIC values in mg/L as determined by agar dilution conform CLSI guidelines. S = susceptible (MIC<2 
mg/L), R = resistant (MIC>2 mg/L) based on the EUCAST epidemiological cut-off for metronidazole (87). 
ND= not determined by agar dilution, but only by E-test (Supplemental Figure 2).
As controls, we included the MTZS (IB132) and a MTZR (IB133) RT020 strain isolated from the 
patient. In agreement with the MIC values determined by agar dilution (MIC=0.25 mg/L and 
MIC=8 mg/L), these isolates showed a MIC corresponding to those observed for the MTZS and 
MTZR RT012 isolates, respectively (Figure 6). 
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Overall, our results show that acquisition of pCD-METRO is sufficient to raise the MIC of C. 
difficile to values greater than the epidemiological cut-off value defined by EUCAST(87). 
Figure 7. The pCD-METRO replicon sustains a high plasmid copy number. A) 630Δerm is the wild 
type RT012 laboratory strain. IB30: 630Δerm + pIB20 (contains pCD6 replicon); IB90:  630Δerm + pIB80 
(contains pCD-METRO replicon); IB125:  630Δerm + pCD-METROshuttle (pIB86, contains pCD-METRO 
replicon). Copy number is determined as the ratio of a plasmid locus (catP) relative to a chromosomal 
locus (rpoB) as determined by qPCR on total DNA. Data from strains containing a plasmid with the 
pCD6-replicon are indicated in blue, data from strains containing a plasmid with the pCD-METRO 
replicon are indicated in red. Individual data points are plotted using symbols. Horizontal lines indicate 
median values. 630Δerm vs IB30: P=0.1018; IB90 vs IB125: P=0.0002; other comparisons: P<0.0001 as 
determined by two-sided ANOVA and Tukey’s test. Experiments were performed in triplicate on three 
different technical replicates. B) A strain derived from the laboratory RT012 strain 630Δerm harboring 
a plasmid containing the pCD-METRO replicon (IB90) has a growth advantage over a strain containing 
a plasmid with the pCD6 replicon (AP38) when cultured at high levels of thiamphenicol (Tm). AP38: 
630Δerm + pAP24 (pCD6 replicon); IB90: 630Δerm + pIB80 (pCD-METRO replicon). Growth is measured 
as an increase in optical density at 600nm (OD600). Solid line indicates the mean of the individual 
measurements that are shown using dots (n=3 biologically independent samples).  Source data are 
provided as a Source Data file.
pCD-METRO contains a high copy number replicon
Read depth of pCD-METRO in our WGS data indicates an estimated copy number of 100-200, 
in stark contrast with the pCD6 replicon commonly used in shuttle vectors for C. difficile (copy 
number 4-10) (234). We wanted to establish the functionality of the predicted replicon and 
determine the copy number sustained by this replicon in RT012 strains. 
A pRPF185-based vector (233) (pIB80) was constructed in which the conventional pCD6 
replicon was replaced by a 2-kb DNA fragment of pCD-METRO that includes ORF5, encoding 
the putative replication protein (Supplemental Figure 4). Transconjugants containing this 
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vector were readily obtained in the RT012 laboratory strain 630Δerm, demonstrating this 
region contains a functional replicon.
Next, we compared the relative copy number of the plasmids in overnight cultures by qPCR 
(234). Based on the ratio of plasmid-locus catP to the chromosomal locus rpoB, the copy number 
of pCD6-replicon vector was approximately 4, concordant with results of others (234). By 
contrast, the copy number of vectors with the pCD-METRO replicon ranges from approximately 
25 (for pIB80, in IB90) to 38 (pCD-METROshuttle, in IB125) (Figure 7A).  We hypothesized that a 
higher plasmid copy number would also lead to more copies of the resistance marker on the 
plasmid and thus to a possible increase of resistance to the corresponding antibiotic. Indeed, 
a strain harboring a catP-containing plasmid with the pCD-METRO replicon demonstrates 
a growth advantage over a strain harboring a similar plasmid with the pCD6 replicon when 
exposed to high levels (256 mg/L) of thiamphenicol. No significant difference in growth was 
observed at low concentrations (20 mg/L) of thiamphenicol (Figure 7B). As pIB90 containing 
strains are not MTZR (Figure 6), resistance to metronidazole is not mediated by a higher copy 
number plasmid per se, but is dependent on a determinant specific to pCD-METRO.
A difference between the read-depth estimate and the qPCR can be explained by technical 
bias or differences in strain background. Nevertheless, our experiments clearly demonstrate 
that the pCD-METRO replicon sustains plasmid levels that are approximately 10-fold greater 
than that of currently used replicons.
We investigated whether the relatively high copy number of pCD-METRO imposes a metabolic 
cost, by evaluating the growth of strains with and without plasmid in the absence or presence 
of varying concentrations of metronidazole (Figure 8). In the absence of metronidazole, the 
growth of susceptible and resistant strains of both RT012 and RT020 is indistinguishable 
(Figure 8A). This was not due to loss of pCD-METRO from the resistant strain, as all colonies 
tested after the growth experiment had retained the plasmid. With increasing amounts 
of metronidazole, susceptible strains show a clear growth defect already at the lowest 
concentration of metronidazole tested (0.125 mg/L), whereas resistant strains do not markedly 
differ in growth from the control culture at concentrations below the epidemiological cut-off 
(2mg/L) (Figure 8B and 8C). These values are in agreement with the E-tests performed on the 
same media (Figure 6). We conclude that carriage of the plasmid does not affect growth rate 
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in the absence of metronidazole, despite the high copy number, and confers a clear growth 
advantage in the presence of metronidazole.
We attempted to cure metronidazole resistant strains of pCD-METRO using serial passaging on 
non-selective liquid or solid medium. Despite our efforts (Supplemental Methods), we failed to 
obtain colonies that lacked pCD-METRO, even after non-selective culturing for >50 generations. 
We hypothesize that the high copy number of pCD-METRO contributes to its stability.
Together, these results demonstrate that pCD-METRO encodes a functional replicon that is 
responsible for a high copy number in C. difficile and is efficiently maintained in the absence 
of selection.
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 100
100
CHAPTER 4
Figure 8. The effects of carriage of pCD-METRO on growth. A) Growth as monitored by an increase 
in optical density at 600nm (OD600) of various strains in the absence of metronidazole. B) Growth of 
RT012 strains in the presence of various concentrations of metronidazole [mtz]. C) Growth of RT020 
strains in the presence of various concentrations of metronidazole [mtz]. Individual measurements are 
shown as semi-transparent dots. The median of the replicates is shown as a solid line. Source data are 
provided as a Source Data file.
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Discussion
In this study we describe the a plasmid linked to resistance against a clinically relevant 
antimicrobial in C. difficile. We show that the high-copy number plasmid pCD-METRO is 
internationally disseminated, present in diverse PCR ribotypes - including those known to 
cause outbreaks – and we provide evidence for the possible horizontal transmission of the 
plasmid. Our data suggests a possible prevalence of <0.14 % (1/721; endemic) to 3.9% (22/563; 
collection enriched for metronidazole resistant strains) of the plasmid, in line with previous 
observations (288).
Though the presence of plasmids in C. difficile has been known for many years, no phenotypes 
associated with plasmid carriage have been described (282, 284, 289). We show that 
introduction of pCD-METRO in susceptible strains leads to stable and medium-independent 
metronidazole resistance. Plasmids may play a broader role in antimicrobial resistance of C. 
difficile. A putative plasmid containing the aminoglycoside/linezolid resistance gene cfrC was 
recently identified in silico, but in contrast to our work no experiments were presented to verify 
the contig was in fact a plasmid conferring resistance (73). The presence of an antimicrobial 
resistance gene does not always result in resistance, and DNA-based identification of putative 
resistance genes without phenotypic confirmation may lead to an overestimation of the 
resistance frequencies (271, 290, 291). 
At present, it is unknown which gene(s) on pCD-METRO are responsible for metronidazole 
resistance. Nitroimidazole reductase (nim) genes have been implicated in resistance to 
nitroimidazole type antibiotics (124). Though the presence of a truncated nim gene on pCD-
METRO is intriguing, we do not believe this gene to be responsible for the phenotype for several 
reasons. Structural modelling of the predicted protein shows that it lacks the catalytic domain, 
and introduction of the ORF under the control of an inducible promoter (Supplemental Dataset 
1 and Supplemental Table 2) did not confer resistance in our laboratory strain.  Moreover, 
the RT027 strain R20291 encodes a putative 5-nitroimidazole reductase (R20291_1308) and 
is not resistant to metronidazole, implying the presence of a nim gene is not causally related 
to metronidazole resistance in C. difficile as also noted by others (124). Further research is 
necessary to determine the mechanism for metronidazole resistance in C. difficile conferred 
by pCD-METRO, and to investigate the contribution of the high copy number (Figure 6) to 
the resistance phenotype.
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Our work, combined with that of others, suggests that metronidazole resistance is multifactorial 
and other factors than pCD-METRO can cause or contribute to metronidazole resistance in 
C. difficile.  For instance, pCD-METRO may not explain low level resistance, heterogeneous 
resistance, or stable resistance resulting from serial passaging of isolated strains under 
metronidazole selection (124, 138, 141, 292). We also observed that absolute MIC values in 
agar dilution experiments differed between MTZR isolates of different PCR ribotypes despite 
carriage of pCD-METRO, suggesting a contribution of chromosomal or other extrachromosomal 
loci to absolute resistance levels. Though the SNP we identified in the RT020 strain IB136 was 
not found in other MTZR strains of RT010/RT020/RT027, we cannot exclude that it contributes 
to the resistance in this particular strain. We also observed strong medium dependent effects: 
the MICs obtained on BBA are generally higher than those on BHI (Figure 4), underscoring the 
importance of using standard conditions for susceptibility testing. Notably, for at least one 
RT010 strain (LUMCMM19 0830) this lead to conversion of the resistance phenotype. Clearly, 
medium components (possibly iron or haem) contribute to metronidazole resistance. This is 
in line with suggested metabolic changes in MTZR strains that do not harbour pCD-METRO 
(138, 140, 141). 
The pCD-METRO plasmid is internationally disseminated (Table 1, Figure 3), although further 
research is necessary to determine how prevalent the plasmid is in metronidazole resistant 
C. difficile isolates. This study attempted to enrich for metronidazole resistant strains as this 
resistance is scarce in C. difficile. We received strains which were reported to be metronidazole 
resistant by the senders. However, when performing antimicrobial susceptibility testing for these 
strains with agar dilution in our own laboratory, virtually all strains had MIC values below the 
epidemiological cut-off value from EUCAST for metronidazole and were considered susceptible. 
For this reason, we ended up having very few metronidazole resistant isolates of other PCR 
ribotypes than RT010 (RT020 and RT027). It is not entirely clear how these differences came 
into existence. Depending on handling of the sample material and freeze-thawing cycles, it 
is possible that inducible metronidazole resistance, unrelated to pCD-METRO, was initially 
measured and that this was lost after storage and lack of selection (138). Considering the 
apparent stability of pCD-METRO, we do not think that the discrepancies are due to loss of 
the plasmid during passaging on non-selective media. 
557028-L-sub01-bw-Boekhoud
Processed on: 6-4-2021 PDF page: 103
103
Plasmid-mediated metronidazole resistance in Clostridioides difficile
4
Based on the apparent stability of the pCD-METRO plasmid, we consider acquisition rather 
than loss of pCD-METRO a more likely explanation for the clonality of the RT020 patient 
isolates. As C. difficile has not been demonstrated to naturally competent for transformation, 
this suggests that pCD-METRO may be transmissible. Horizontal gene transfer is consistent 
with the observed level of sequence conservation between the RT010, RT020 and RT027 pCD-
METRO plasmids sequenced in this study (Supplemental Figure 1). Nevertheless, we failed to 
demonstrate intraspecies transfer with different donor and recipient strains of C. difficile under 
laboratory conditions (Supplemental Methods), suggesting that the strains tested (or possibly 
the species) lack a determinant required for transfer. Together with its size and the presence 
of mobilization genes (Figure 2A), we therefore hypothesize that pCD-METRO is mobilizable 
from an uncharacterized donor organism (293). We screened the complete sequence read 
archive of the NCBI (paired-end Illumina data) for potential sources of the plasmid, but failed 
to identify any entries with reliable mapping (>1% of data) to pCD-METRO.
As more reports are published associating metronidazole with higher treatment failure (276), 
a shift in consensus for using metronidazole as first line treatment for mild to moderate CDI 
is occurring (294). The reason for treatment failure is currently unknown, but no correlation 
between MTZR C. difficile isolates and treatment failure seems to exist (290).  We also observed 
that clinical isolates from subjects in which metronidazole treatment failed, were metronidazole 
susceptible and pCD-METRO negative (Supplemental Dataset 1) (286). These observations, 
however, do not rule out a role for (other) metronidazole resistant organisms, potentially 
harboring pCD-METRO, in treatment failure. Indeed, levels of metronidazole at the end of 
the colon and in fecal material are low (most likely due to absorption of the drug in the 
small intestine in the absence of diarrhea) (276), and members of the microbiota involved in 
inactivation or sequestering of metronidazole may allow for growth of MTZS species (295-298).
  
Our observation of a putatively transmissible plasmid associated with metronidazole resistance 
in C. difficile and the gut microbiome has implications for clinical practice. First, it warrants a 
further investigation into the role of the plasmid in metronidazole treatment failure in CDI, 
and – more broadly – in metronidazole resistance of organisms other than C. difficile. Second, 
though this work can be seen as one more argument against the use of metronidazole as a first 
line treatment of CDI, detection of the plasmid in fecal material might also guide treatment 
decisions (i.e. pCD-METRO harboring patients are excluded from metronidazole treatment). 
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And finally, screening by PCR of fecal donor material intended for FMT might be desirable 
to reduce the possibility of transferring pCD-METRO from hitherto uncharacterized donor 
organisms to C. difficile in patients. 
Materials and Methods
Strains 
The 22 strains sequenced as part of this study were isolated from a single patient at the 
Leiden University Medical Center (LUMC) or derived from the collection of the Dutch NRL for 
C. difficile, which is hosted at the LUMC and also includes animal isolates. Informed consent 
(approved by the Medical Ethical Committee of the LUMC) was given for the use of the patient 
samples for research purposes. Other clinical isolates (n=567) were obtained through the NRL 
and partners in the C. difficile typing network of the European Centre for Disease Prevention 
and Control (ECDC), or were previously collected as part of the ECDIS study and the Tolevamer 
and MODIFY I+II clinical trials(111, 174, 286). Strain IB136, for which the genome sequence 
is available from the European Nucleotide Archive (accession CAADHH010000000) has been 
deposited in the National Collection of Type Cultures (NCTC14385) of Public Health England.
Whole genome sequencing and analysis 
DNA was extracted from 9mL of stationary growth phase cultures grown in BHI (Oxoid) broth 
using a QIAsymphony (Qiagen, The Netherlands) with the QIAsymphony DSP Virus/Pathogen 
Midi Kit according to the manufacturer’s instructions. All samples were sequenced on an 
Illumina HiSeq4000 (all samples except those mentioned hereafter) or NovaSeq (LUMCMM18 
0002, LUMCMM19 0348, LUMCMM19 0880 and LUMCMM19 0960) platform with read length 
150bp in paired-end mode. All C. difficile samples isolated from the patient were assembled 
using an inhouse pipeline, which includes various QC and comparative measures, assembly 
with six different assemblers as well as scaffolding, but which are not used for all steps and 
assemblers. Ultimately, Edena v3.131028  was used on the non-trimmed reads with an overlap 
range between 76 and 146 (299). Reads were mapped back to all assemblies for quality control 
purposes with Bowtie2 v2.3.1, and SAM files were converted to sorted and indexed BAM files 
with Samtools v1.5  to obtain mapping rates to the assembly (300, 301). After this step, all 
contigs from assemblies with a length smaller than 304 bp were discarded, as well as contigs 
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corresponding to the phiX phage spike in (GenBank accession number J02482.1). To remove 
contaminating contigs, contigs from all assemblies were compared with Blastn v2.6 against 
the NCBI database (download July 10, 2018, standard parameters, except evalue of 0.0001) 
(302, 303). Taxonomy was estimated with the LCA algorithm as implemented in MEGAN, 
except that only Blast matches with a minimum length of 100bp, and as well only matches not 
deviating more than 10% in length from the longest match were considered (304). Filtering was 
performed on phylum level and the dominant phylum was determined by the amount of base 
pairs in the assigned blast matches. All contigs assigned to another phylum were discarded. 
For quality control, the expected genome size was estimated with kmerspectrumanalyzer 
download August 2013 and Jellyfish v1.1.11 (305, 306).  Using bedtools genomecov v2.2.16 
the read coverage of the assemblies were calculated (307). All sequence ranges larger than 
20 bp with less than 50% coverage and with a larger distance than 200 bp from the contig end 
were manually inspected, unless only Ns were contained in the sequence. Final evaluation 
was performed with the values for N50, assembly size (in relation to predicted genome size), 
mapping rate and manual inspection of low coverage sites. The assembly being evaluated as 
being best was performed with the Edena assembler and an overlap of 126 (IB136) or 136 
(LUMCMM19 0348), with contamination and length filtering, without additional scaffolding 
and gapfilling.
Annotation was performed with an in-house pipeline as described before (284). This annotation 
was furthermore manually reviewed and the annotations from the assembly of C. difficile 630 
(based on Blastn comparison on gene level) were transferred where applicable.
Extrachromosomal elements were predicted as described before (283, 284). To identify 
plasmids similar to the pCD-METRO, a homology search was performed with Blastn (with an 
e-value of 0.0001). A further search for non-assembled plasmid sequences was performed. 
All samples sequenced in paired-end mode on Illumina machines were downloaded from the 
NCBI with eutils prefetch, and mapped to the plasmid sequence with bowtie2 v2.3.1 to the 
plasmid sequence. The option - no-mixed was used to supress incorrectly mapping pairs (303).
SNP typing was performed after selecting the best reference assembly. The SNP typing was 
performed with the in-house pipeline Basty based on the biopet framework (308). This 
pipeline performs mapping to the reference assembly with bowtie2 v2.3.1 and SNP typing 
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with BCFtools v1.1-134 (309). Groups were investigated for homozygous SNPs differentiating 
them. Heterozygous SNPs were discarded. Genomic comparisons between assemblies were 
performed with Blastn (standard parameters, except an e-value of 0.0001). All programs were 
executed with standard parameters unless otherwise specified. Multi-locus sequence type 
was determined using stringMLST v0.6.2(310) with default settings.
Antimicrobial susceptibility testing and ribotyping 
All strains were characterized by standardized PCR ribotyping and tested multiple times for 
metronidazole resistance by agar dilution according to CLSI guidelines, with the inclusion of 
appropriate microbiological controls (13, 86).  No formal breakpoints have been defined for 
metronidazole resistance in C. difficile; here we use the EUCAST epidemiological cut-off of 
2 mg/L to define resistance (87). Details of all strains and their characteristics are available 
in Table 1 and Supplemental Dataset 1. For E-tests (BioMerieux), bacterial suspensions 
corresponding to 1.0 McFarland turbidity were applied on BHI agar supplemented with 0.5% 
yeast extract (Sigma-Aldrich) and Clostridium difficile Selective Supplement (CDSS, Oxoid) or 
on Brucella Blood Agar plates without antimicrobials. MIC values were read after 48 hours of 
incubation as recommended by CLSI (86).
Molecular biology techniques
Escherichia coli was cultured aerobically at 37oC in Luria-Bertani (LB) broth, supplemented 
with 20 mg/L chloramphenicol and 50 mg/L kanamycin when appropriate. C. difficile was 
cultured in BHI supplemented with 0·5% yeast extract, CDSS and 20 mg/L thiamphenicol when 
appropriate, in a Don Whitley VA-1000 workstation (10% CO2, 10% H2 and 80% N2 atmosphere). 
Plasmids and oligonucleotides are listed in Supplemental Tables 1 and 2, respectively. pIB86 
(pCD-METROshuttle, Supplemental Figure 3 and Supplemental File 1) was constructed using 
Gibson assembly using HaeIII-linearized pCD-METRO and a fragment from pRPF185 (Addgene 
106367) (233). This fragment was obtained by PCR, and contained the requirements for 
maintenance in, and transfer from, E. coli. Cesium chloride purified pCD-METRO (see below) 
was linearized using restriction endonuclease HaeIII. Primers oWKS-1663 and oWKS-1664 
annealed on pRPF185 generating a PCR shuttle-fragment containing pBR322ori-catP-oriT-
traJ. To assemble pIB86, 100 ng of insert was assembled against a four-fold molar excess of 
linearized pCD-METRO backbone using a homemade Gibson Assembly Master Mix (4 U/μl 
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Taq Ligase (Westburg), 0.004 U/μl T5 exonuclease (New England Biolabs), 0.025 U/μl Phusion 
polymerase (Bioké), 5% polyethyleneglycol (PEG-8000), 10 mM MgCl2, 100 mM Tris-Cl pH=7.5, 
10 mM dithiothreitol, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM dCTP, 0.2 mM dGTP, and 1 mM 
β-nicotinamide adenine dinucleotide) for 30 minutes at 50oC and transformed into MDS42 
cells. Transformants were screened by colony PCR using primers oBH-5 and oWKS-1387. The 
entire sequence of pIB86 was verified by Sanger sequencing using primers oBH-1, oBH-5, 
oBH-6, oBH-8, oBH-9, oBH-10, oBH-11, oBH-12, oIB-120-, oIB-121, and oIB-122, oWKS-1241-, 
oWKS-1383, oWKS-1388, oWKS-1537, oWKS-1539, oWKS-1540, oWKS-1574, oWKS-1656, 
oWKS1658, oWKS-1659, oWKS-1661, oWKS-1663, oWKS-1664 and oWKS-1678. Plasmid pIB80 
(Supplemental Figure 4 and Supplemental File 2) was constructed by ATUM (Newark, CA) 
and contains a pCD-METRO derived fragment inserted in between the KpnI and NcoI sites of 
pRPF185 (233).
Transfer of plasmids from E. coli CA434 to C. difficile 630Δerm (190) was done using standard 
methods (222). Routine DNA extractions were performed using the Nucleospin Plasmid Easypure 
(Macherey-Nagel) and DNeasy Blood and Tissue (Qiagen) kits after incubating the cells in an 
enzymatic lysis buffer according to instructions of the manufacturers.
Isolation of cloning-grade pCD-METRO
Plasmid pCD-METRO was extracted from 400 mL of culture containing the MTZR strain IB138 
using the Macherey-Nagel Nucleobond Xtra Midi kit. Using the CsCl2 plasmid purification method 
this plasmid prep was further cleaned as summarized hereafter. pCD-METRO plasmid prep was 
added to TE buffer (10 mM Tris pH=8.0, 1 mM EDTA) and CsCl2 was added to a density of 1g/g. 
Approximately 220 µg/ml ethidium bromide was added to this solution after which samples 
were spun down in a Beckman Coulter Optima XE-90 ultracentrifuge for 17 hours at 65.000 
rpm, 20oC. Bands were visualized with UV light and plasmid DNA was collected by withdrawing 
the lowest of the two resulting bands with an 18 gauge needle. To remove ethidium bromide 
1x vol/vol 5M NaCl saturated N-butanol was used to remove the upper (purple) phase after 
centrifugation. Samples were ethanol precipitated twice prior to resuspending purified plasmid 
DNA in TE buffer.
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Plasmid copy number determination
Real time quantitative PCR (qPCR) experiments were performed essentially as described (234). 
In short, total DNA was isolated after 17h of growth using a phenol-chloroform extraction 
protocol and diluted to a concentration of 10 ng/µl. 4 µl of the diluted DNA sample was added 
to 6 µl of a mixture containing SYBR Green Supermix (Bio-Rad) and gene-specific primers (0.4 
µM total) for a total volume of 10 µl per well. Gene specific primers used were targeting rpoB 
(chromosome) and catR (plasmid) and copy number was calculated using the ΔCT method. 
Experiments were performed in triplicates on three different technical replicates. Statistical 
significance was calculated using two-way analysis of variance (ANOVA) and Tukey’s test for 
multiple comparisons (Prism 8, GraphPad) (Supplemental Table 3). 
Preparation of Figures
Agarose gel and E-test images were acquired using a BioRad GelDoc XR, processed in Adobe 
Photoshop CC 2018 (Adobe). Plasmid maps were generated using Artemis and DNAPlotter 
(311, 312). Graphs were generated using PlotTwist (https://huygens.science.uva.nl/PlotTwist/) 
and PlotsOfData (https://huygens.science.uva.nl/PlotsOfData/). All figures were prepared for 
publication in Adobe Illustrator CC 2018 (Adobe).
Data availability
Sequence data that support the findings of this study are available in the European 
Nucleotide Archive under BioProject number PRJEB24167 (https://www.ncbi.nlm.nih.
gov/bioproject/?term=PRJEB24167) with accession numbers ERR2232520- ERR2232537, 
ERR3611150-ERR3611153 and ERR3772426.  The annotated genome assembly for IB136, 
including pCD-METRO, can be found under accession number CAADHH010000000 (https://
www.ebi.ac.uk/ena/browser/view/CAADHH010000000) and as Supplemental Dataset 2. 
The source data underlying Figs 1, 2b, 2c, 3, 4, 5, 6, 7 and 8 and Supplemental Figure 2 are 
provided as a Source Data file. 
Code availability
Computer code related to the analysis from this paper is based on published tools, as described 
in the Methods, and details are available from the authors on request.
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Supplemental Figure 1. Variants of pCD-METRO as identified in this study. Assembly and SNP 
calling was performed as described in Supplemental Methods. Strain IB136 is the reference for pCD-
METRO, and most strains are similar to this plasmid. Variants are indicated with vertical bars. Amino 
acid changes are indicated in single letter genetic code for non-synonymous substitutions (in ORFs). 
Nucleotide changes are given in between brackets with the relevant nucleotide position in relation to 
the scale bar below (forward strand).
Supplemental Figure 2. Metronidazole resistance of RT020 strains obtained from routine surveillance. 
Strains LUMC19 0348 (pCD-METRO negative) and LUMC19 0830 (pCD-METRO positive) from the 
patient were tested for metronidazole resistance using E-test. 2 mg/L is the EUCAST epidemiological 
cut-off for metronidazole that was used to define resistance in this study. Source data are provided as 
a Source Data file.
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Supplemental Figure 3. Schematic representation of the construction of pCD-METROshuttle (pIB86): 
the PCR-amplified conjugation module from pRPF185 was inserted in the unique HaeIII restriction site 
through Gibson assembly as described in Supplemental Methods.
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Supplemental Figure 4. pIB80 was generated by cloning the region containing the ORF encoding the 
putative replication protein from pCD-METRO into the indicated area of pRPF185, disrupting the pCD6 
replicon (orfB + repA), as indicated in the Supplemental Methods.
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Name Relevant features Source/reference
pRPF185 tetR Ptet-sluc
opt; catP A Oliveira Paiva et al., 2016
pCD-METRO (see: accession number ERZ807316) This study
pIB20 pRPF185 PCD0716-sluc
opt; catP This study
pIB76 tetR Ptet-nimB;  catP  This study
pIB80 tetR Ptet-gusA-pCD-METROreplicon This study
pIB86 pCD-METRO containing shuttle fragment; pCD-METRO-oriT-
pBR322-traJ catP; catP
This study
Supplemental Table 1. plasmids used in this study
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ANOVA table SS DF MS F (DFn, DFd) P value
Row Factor 6,189 2 3,094 F (2, 6) = 1,344 P=0,3294
Column Factor 2945 3 981,8 F (3, 6) = 426,4 P<0,0001
Residual 13,82 6 2,303
Tukey’s multiple 
comparisons test
Mean Diff, 95,00% CI of diff, Significant? Summary Adjusted 
P Value
630∆erm vs. IB30 -3,543 -7,832 to 0,7457 No Ns 0,1018
630∆erm vs. IB90 -25,25 -29,54 to -20,96 Yes **** <0,0001
630∆erm vs. IB125 -38,07 -42,36 to -33,78 Yes **** <0,0001
IB30 vs. IB90 -21,71 -26,00 to -17,42 Yes **** <0,0001
IB30 vs. IB125 -34,53 -38,82 to -30,24 Yes **** <0,0001
IB90 vs. IB125 -12,82 -17,11 to -8,531 Yes *** 0,0002
Supplemental Table 3. Statistics associated with the qPCR analysis. These data relate to Figure 7A 
of the main text of the manuscript.
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Until recently, metronidazole was the first-line treatment for Clostridioides difficile infection 
and it is still commonly used. Though resistance has been reported due to the plasmid pCD-
METRO, this does not explain all cases. Here, we investigate resistance to metronidazole in a 
collection of clinical isolates of C. difficile. We find that nearly all isolates demonstrate a heme-
dependent increase in the minimal inhibitory concentration (MIC) for metronidazole, which 
in some cases leads to isolates being qualified as resistant (MIC > 2 mg/L). Moreover, whole 
genome sequence analysis reveals a single nucleotide polymorphism in the heme responsive 
gene hsmA, which defines a metronidazole resistant lineage of PCR ribotype 010 / multilocus 
sequence type 15 isolates that also includes pCD-METRO containing strains. Together our data 
demonstrate that heme is crucial for medium-dependent metronidazole resistance in C. difficile.
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Introduction 
Clostridioides difficile is a gram-positive, anaerobic enteropathogen capable of causing a C. 
difficile infection (CDI) upon disruption of the normal intestinal microbiota by for instance 
antimicrobial therapy (20, 225). It is the primary cause of nosocomial diarrhea, but is also found 
in cases of community-acquired disease (20, 313). Although the use of antibiotics is a risk factor 
for CDI, antimicrobials are also used to treat the infection. Until recently, metronidazole was 
considered the drug-of-choice for treatment of mild CDI. Though vancomycin and fidaxomicin 
are currently indicated as first-line therapeutics for the treatment of CDI, (80, 264) metronidazole 
is still commonly used (83, 84). 
Our understanding of the mechanisms of resistance to metronidazole in C. difficile is still limited. 
For Clostridia, studies are complicated by reports of unstable, inducible metronidazole resistance 
which is lost upon removal of antibiotic pressure or after the strain undergoes freeze-thawing 
cycles (124, 134). Recently, however, we have demonstrated that metronidazole resistance in 
diverse strains of C. difficile can be mediated by the plasmid pCD-METRO through a mechanism 
that is not yet understood (235). Notably, the presence of pCD-METRO explains at least part of 
independently reported cases of metronidazole resistance (141, 314, 315). However, strains 
that lack pCD-METRO can still be resistant to metronidazole. For instance, we have previously 
identified a pCD-METRO negative strain that demonstrated medium-dependent metronidazole 
resistance (235). This suggests that other, potentially chromosomal, determinants contribute 
to resistance.
Information on pathways that could contribute to resistance comes from laboratory strains 
with evolved resistance to metronidazole. Using a laboratory-evolved PCR ribotype (RT) 027 
strain exhibiting stable metronidazole resistance, mutations were identified in genes affecting 
electron transport and iron utilization, but the individual contribution of these mutations to 
the resistance phenotype was not further investigated (138). More recently, a mutator strain 
defective in DNA mismatch repair was evolved in the presence of metronidazole (139). The 
study discovered mutations in a gene encoding an iron transporter (feoB1) in metronidazole 
resistant strains and showed that sequential mutations in nifJ (encoding the pyruvate-ferredoxin 
oxidoreductase, PFOR), xdh (encoding xanthine dehydrogenase) or iscR (encoding an iron-
sulfur cluster regulator) could further increase metronidazole resistance (139). Though studies 
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with laboratory evolved strains are informative, it is unclear how these findings translate to 
metronidazole resistant strains isolated from subjects outside the laboratory. 
Here, we leverage the potential of strains collected within a project to develop a detailed 
understanding of the epidemiology and clinical impact of CDI across Europe (COMBACTE-
CDI) that were investigated for metronidazole resistance. Four strains demonstrated stable 
metronidazole resistance, but lacked pCD-METRO. We show that there is a heme-dependent 
increase in the minimal inhibitory concentration (MIC) for metronidazole across PCR ribotypes 
and that a higher MIC, at least in a subset of strains, correlates with a specific mutational 
signature in the gene hsmA.
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Results
Metronidazole resistance is observed in the COMBACTE-CDI strain collection
The Combatting Bacterial Resistance in Europe – Clostridioides difficile infections (COMBACTE-
CDI) is a multi-centre European-wide project with an aim to provide detailed understanding of 
the epidemiology and clinical impact of CDI across the whole healthcare economy in Europe. 
Sites testing both in-patient and community samples were recruited from 12 countries across 
Europe. All diarrheal fecal samples (regardless of tests requested by physician) were submitted 
to a central laboratory (Leeds, UK) on two selected days between July and November 2018. 
From these samples C. difficile was isolated and tested by PCR ribotyping. The metronidazole 
Minimum Inhibitory Concentration (MIC) for 213 clinical isolates (Belgium n=3, France n=4, 
Greece n=4, Ireland n=1, Italy n=23, Netherlands n=8, Poland n=29, Romania n=37, Slovakia 
n=1, Spain n=43, Sweden n=12, UK n=48) were determined by Wilkins-Chalgren agar dilution. 
(271) Of these, 22 isolates (10%) were found to be resistant to metronidazole using the EUCAST 
criteria as a cut-off (MIC≥2 mg/L) and were sent to the C. difficile reference laboratory of the 
Leiden University Medical Center for further study. (87) When possible, an RT-matched isolate 
with an MIC<2 mg/L from the COMBACTE-CDI collection was also provided. PCR ribotypes 
submitted were RT002 (n=3); RT010 (n=7); RT016 (n=1); RT018 (n=3); RT027 (n=12); RT176 
(n=1); RT181 (n=4) and RT198 (n=1) (Table 1).  
As metronidazole is generally quite rare, our findings underscore the importance for investigating 
large collections of clinical isolates to enrich for strains that are resistant, in order to investigate 
possible underlying causes of resistance.
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Figure 1. Medium-dependent resistance to metronidazole is independent of base broth. Strain GSK241 
was grown and resuspended to 2.0 McFarland turbidity and spread on BHI agar, Brucella Blood Agar 
(supplemented with 1 µg/ml vitamin K and 5 µg/ml hemin) and BHI Blood Agar (BHI broth supplemented 
with 5% sheep blood, 1 µg/ml vitamin K and 5 µg/ml hemin). An E-test was placed and plates were 
incubated for 48h prior to imaging. Red lines indicate the epidemiological cut-off value for metronidazole 
as determined by EUCAST and have been used to determine resistance in this study (87). Numbers 
between brackets at the top of the image correspond to the reported MIC value on BHI agar, Brucella 
blood agar and BHI blood agar, respectively.
Low level resistance to metronidazole is not due to carriage of the pCD-METRO plasmid
We further investigated the clinical isolates from the COMBACTE-CDI strain collection (n=32; 
Table 1). To correct for interlaboratory differences and to make the results directly comparable 
to our previous study, (235) we performed PCR ribotyping and antimicrobial susceptibility 
testing by agar dilution according to CLSI standards on Brucella Blood agar (BBA) in a second 
laboratory (235, 316). A single strain showed discrepant results in PCR ribotyping and was 
therefore excluded from further analysis. We found 4/31 strains resistant to metronidazole 
(13% of the preselected isolates, Table 1). Three of these 4 strains belonged to RT010 (MIC=4 
mg/L) and the fourth isolate belonged to RT016 (MIC=2 mg/L). All of these strains were also 
identified as resistant in the initial susceptibility testing in Leeds. The interlaboratory difference 
in antimicrobial susceptibility may be explained by differences in testing methodology, but 
were not further investigated here.
To determine whether the observed resistance was due to the presence of the pCD-METRO 
plasmid, we performed a reference assembly of the sequence reads obtained from whole 
genome sequencing of these isolates against the pCD-METRO reference sequence (obtained 
from the European Nucleotide Archive BioProject number PRJEB24167). No reliable mapping 
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of reads to the reference sequence was found and – in line with this finding – the strains were 
negative in a PCR assay directed against pCD-METRO (data not shown) (235). We therefore 
conclude that these strains do not carry pCD-METRO and that a different mechanism confers 
metronidazole resistance in these isolates.
Resistance to metronidazole is medium dependent
We have previously described a strain that demonstrated medium-dependent metronidazole 
resistance (MIC=4 mg/L) independent of pCD-METRO (235). In order to test if the metronidazole 
resistant phenotype of the four strains from the COMBACTE-CDI study could similarly be 
medium-dependent, strain GSK241 (MIC=4 mg/L) was plated on BHI agar that is routinely used 
in our laboratory, BBA (containing 5% defibrinated sheep blood, 1 µg/ml vitamin K and 5 µg/
ml hemin), and BHI blood agar (BHI agar supplemented with 5% defibrinated sheep blood, 
1 µg/ml vitamin K and 5 µg/ml hemin) after which a metronidazole E-test was applied. We 
found that strain GSK241 was susceptible to metronidazole (MIC=0.25 mg/L) on BHI medium 
but resistant (MIC≥2 mg/L) on both BBA agar and BHI blood agar (Figure 1). These results 
indicate that components present in blood agar are responsible for this medium-dependent 
resistant phenotype.
We wondered whether the medium-dependent change in MIC values was a general 
characteristic of C. difficile irrespective of the resistance phenotype, or specific to the resistant 
strains. For this reason, we tested selected COMBACTE-CDI strains by E-test on both BHI agar 
and BBA (Table 2). All strains were clearly susceptible on BHI agar (MIC < 0.5 mg/L) but, with 
the exception of GSK234, showed a 4-to-32-fold increase in MIC when tested on BBA compared 
to BHI agar. This medium-dependent increase in MIC was not restricted to a specific RT, as 
the phenotype was seen for strains belonging to diverse types (RT010, RT016, RT018, RT027, 
RT176, RT181 and RT198). 
Taken together, our data suggest that components present in BBA/BHI blood agar result in 
reduced susceptibility of strains to metronidazole through a general mechanism. In the case 
of strains GSK184, GSK241, GSK242NEW and GSK313 this leads to these strains being qualified 
as metronidazole resistant.
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Figure 2. Heme supplementation increases the MICs to metronidazole, but not to vancomycin. A) Strains 
GSK64 and GSK241 were resuspended in PBS to 2.0 McFarland turbidity and plated on BHI agar and on 
BHI agar supplemented with 5 µg/ml hemin. Subsequently E-tests for metronidazole and vancomycin 
were applied and plates were incubated for 48h prior to imaging. Red lines indicate the epidemiological 
cut-off value for metronidazole as determined by EUCAST and have been used to determine resistance 
in this study (87). For a complete overview of the MICs to metronidazole of these strains on BHI agar 
and BHI agar supplemented with hemin, see Table 2. B) Typical metronidazole (top) and vancomycin 
(bottom) E-test results performed on strains GSK64 (orange) and GSK241 (red) and when grown on BHI 
supplemented with various concentration of hemin (0; 0.5; 1; 2.5; 5; 10; 15 mg/L). The dashed line indicates 
the epidemiological cut-off value for metronidazole and vancomycin as determined by EUCAST (2 mg/L). 
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Isolate Location of participant at time of 
sample
Country of origin PCR ribotype MIC (mg/L)
GSK234 Inpatient Sweden 002 0.25
GSK6 Community doctor UK 002 0.25
GSK7 Inpatient UK 002 0.125
GSK22bis Inpatient UK 010 0.125
GSK211 Inpatient Romania 010 0.25
GSK241 Inpatient France 010 4
GSK242new Inpatient France 010 4
GSK246 Inpatient France 010 0.5
GSK313 Inpatient Spain 010 4
GSK184 Inpatient Poland 016 2
GSK39 Community doctor Italy 018 0.5
GSK302 Inpatient Italy 018 0.5
GSK303 Inpatient Italy 018 0.25
GSK54 Inpatient UK 027 0.25
GSK55 Inpatient Romania 027 0.25
GSK60 Inpatient Poland 027 0.5
GSK61 Inpatient Poland 027 0.5
GSK62 Inpatient Poland 027 0.5
GSK63 Inpatient Poland 027 0.5
GSK64 Inpatient Poland 027 0.5
GSK65 Inpatient Poland 027 0.5
GSK179 Inpatient Poland 027 0.5
GSK318 Inpatient Poland 027 0.5
GSK325 Inpatient Poland 027 0.5
GSK327 Inpatient Poland 027 0.5
GSK258 Inpatient Slovakia 176 0.5
GSK110 Inpatient Romania 181 0.5
GSK113 Inpatient Romania 181 0.25
GSK114 Inpatient Poland 198 0.5
GSK180 Community doctor Romania 181 0.5
GSK190 Inpatient Romania 181 0.25
 
Table 1. Characteristics of the strains from this study. MIC refers to the minimal inhibitory concentration 
for metronidazole as determined by agar dilution at the Leiden University Medical Center (see Materials 
and Methods).
Heme is required for medium-dependent differences in metronidazole susceptibility
The fact that the medium-dependent increase in MIC was observed for both BBA and BHI 
blood agar (Figure 1) suggests that the phenotype is independent of the base broth and is 
likely to be mediated by the supplementation with vitamin K, hemin, and/or blood. 
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For practical purposes, we evaluated the effect of hemin on the metronidazole resistance 
phenotype of strains GSK64 (metronidazole susceptible) and GSK241 (metronidazole resistant). 
We found that supplementation of BHI with 5 µg/ml hemin raised the metronidazole MIC to 
levels similar to those observed for the BBA and BHI blood agar plates (Table 2; Figure 2A). 
Strain name PCR Ribotype E-test MIC 
BHI 
E-test MIC  
BBA 
E-test MIC  
BHI + hemin 
GSK234 002 0.064 0.064 0.064
GSK241 010 0.25 4 6
GSK242new 010 0.25 6 6
GSK313 010 0.38 4 8
GSK246 010 0.125 1 1
GSK184 016 0.25 2 ND
GSK39 018 0.125 1.5 1
GSK318 027 0.125 1 1
GSK327 027 0.125 2 2
GSK325 027 0.125 1.5 ND
GSK60 027 0.125 4 ND
GSK61 027 0.125 2 1.5
GSK62 027 0.094 1.5 ND
GSK63 027 0.125 1.5 ND
GSK64 027 0.125 1.5 1.5
GSK65 027 0.094 1 ND
GSK179 027 0.125 1.5 ND
GSK258 176 0.16 1 1.5
GSK110 181 0.125 1 1.5
GSK180 181 0.094 1 1
GSK114 198 0.125 2 2
 
Table 2. Metronidazole minimal inhibitory concentrations on different agar media as determined by 
E-test. Strains were tested on BHI agar, BHI agar supplemented with 5 µg/ml hemin or BBA as determined 
by E-test. ND = not determined. MIC = minimal inhibitory concentration of metronidazole under the 
conditions tested
We extended this finding to a selection of COMBACTE-CDI strains and found that, with the 
exception of strain GSK234, all tested strains showed an 8-to-24-fold increase in metronidazole 
MIC on BHI supplemented with hemin compared to BHI alone (Table 2). These results mirror 
those obtained for the E-test on BBA, indicating that hemin is the main determinant of 
medium-dependent differences in metronidazole MIC for these strains. Under our experimental 
conditions, the hemin-dependent increase in MIC appears to be specific to metronidazole, as 
no increase in MIC was observed for vancomycin (Figure 2A). 
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We next assessed the MIC of both metronidazole and vancomycin of strains GSK64 and GSK241 
with a range of 0-15 µg/ml hemin. Both strains show a gradual increase in MIC for metronidazole 
that in the case of GSK241 saturates at > 5µg/ml hemin; the MIC for GSK64 appears to increase 
further at higher concentration of hemin. In contrast, no increase in vancomycin MIC was seen 
even in the presence of the highest concentrations of hemin tested (Figure 2B).
Altogether these results demonstrate that the presence of heme is crucial for a medium-
dependent resistance phenotype in C. difficile and that this appears to be specific for 
metronidazole. 
Figure 3. TAT-C signature in hsmA correlates to metronidazole resistance in RT010 isolates. The 
horizontal black bars represent the median MIC. A) hsmA signature sequences based on SNP analysis in 
the COMBACTE-CDI clinical isolates. Strains containing the GGCAT signatures belong to RT016, RT027, 
RT176, RT181 and RT198. The TAT-C and TATAC signatures correspond to RT010 in this study, whereas 
RT002 and RT018 containing sequence TGTAC. B) hsmA signature based on SNP analysis in the clinical 
isolates sequenced in the pCD-METRO study (235). The signature sequence GGCAT is found in RT027, 
TAT-C and TATAC in RT010 and TGTAC in RT012 and RT020.
An hsmA genetic signature is associated with increase metronidazole MICs in PCR ribotype 
010 strains
Recent work has shown that four genes (hsmA, hsmR, hatT, hatR) are differentially regulated 
in response to heme, and that the products of the hsmAR operon improve growth of a C. 
difficile PCR ribotype 027 strain in the presence of metronidazole (257, 317). For this reason 
we performed a single nucleotide polymorphism (SNP) analysis on the genes hatR, hatT, hsmR 
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and hsmA using the sequences from the RT027 strain R20291 (GenBank accession FN545816) 
as a reference. 
Using variant positions, we identified signatures for these genes for each strain from the 
COMBACTE-CDI collection. In the case of hatR, hatT and hsmR these signatures were conserved 
within a PCR ribotype, and even across closely related PCR ribotypes (e.g RT027, RT198, 
RT181 and RT176 share the same signatures) (Supplemental Table 1). However, for hsmA, we 
observed two distinct but related signatures within a single PCR ribotype. SNPs were identified 
in the 399-bp hsmA gene at positions 129, 249, 366, 372 and 392, resulting in a 5-base pair 
signature sequence. This signature is GGCAT for the RT027 and RT027-like isolates, TGTAC 
in RT002 and RT018 isolates and TATAC in some RT010 isolates (Figure 3A). Interestingly, 
the signature sequence TAT-C was found in all 3 metronidazole resistant RT010 isolates. The 
deletion at position 372 results in a frameshift and alters the primary amino acid sequence 
of the C-terminus of the HsmA protein.
In order to validate the significance of the signature, we performed the same hsmA SNP 
analysis on whole genome sequences obtained from another collection of isolates enriched 
for metronidazole resistance (235). This collection contains RT010, RT020 and RT027 isolates 
which have been characterized with respect to metronidazole MIC and pCD-METRO carriage. 
We expected to find a similar clustering of hsmA signature sequence and PCR ribotype and 
predicted that the previously described RT010 isolate showing medium-dependent resistance 
(MIC=4 mg/L) would carry the 1-bp deletion in hsmA. Indeed, we found this was the case 
(Figure 3B). Strikingly, all highly resistant RT010 strains that carried pCD-METRO also contained 
the TAT-C hsmA signature sequence (Figure 3B). 
We wondered how frequently this deletion could be found in RT010 isolates, as metronidazole 
resistance is most commonly observed in this RT. For this reason, we performed whole genome 
SNP (wgSNP) analysis through the Enterobase platform on sequences available in the Sequence 
Read Archive (SRA) of multilocus sequence type 15 (ST15; which includes RT010) (n=57) and 
ST15-like strains (n=4) as well as the sequences of the RT010 isolates described earlier in this 
study (n=21) (235, 284, 318, 319). We found that the TAT-C signature in hsmA was detected in 
a specific lineage of ST15- and ST15-like strains originating from different countries (Figure 4). 
One out of 61 (1.6%) of the ST15- and ST15-like isolates was found to contain the 1-bp hsmA 
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deletion (accession number ERR125985), but no metadata was available for this strain in the 
SRA to confirm metronidazole resistance. Interestingly, pCD-METRO carriage is distributed 
throughout the lineage with the TAT-C hsmA signature, suggesting that pCD-METRO may be 
preferentially acquired in strains with pre-existing low-level metronidazole resistance. 
Altogether our results demonstrate that a specific signature of hsmA, resulting in an altered 
C-terminal protein sequence, is associated with heme-dependent metronidazole resistance 
as well as pCD-METRO carriage in RT010 strains of C. difficile.  
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Figure 4. The C-terminal deletion in hsmA is associated with a lineage of ST15 and ST15-like isolates. 
When available, metronidazole susceptibility data and pCD-METRO carriage are indicated as illustrated 
in the legend. Country flags prior to strain name indicate the strain origin, when known. Strain names 
(235) or SRA accession numbers are included. Distances in tree are shown in logarithmic scale. 
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Discussion
In this study we describe a collection of clinical C. difficile isolates that demonstrate a heme-
dependent increase in MIC to metronidazole and make the observation that four strains 
determined to be resistant to metronidazole required heme supplementation for this 
phenotype. Additionally, we show that a C-terminal deletion at position 372 in hsmA correlates 
to metronidazole resistance in RT010 isolates.
The observation that the MICs for certain antibiotics vary depending on the type of medium 
used has been well documented in other organisms, but little to no data is available for C. difficile 
(178, 235). One of the best known examples is the effect of divalent calcium on daptomycin 
susceptibility of a variety of organisms but other examples have been documented as well 
(320). For instance, Escherichia coli was sensitive to bleomycin in LB broth, but was resistant 
to this antibiotic in glucose minimal medium, though the mechanism behind this difference 
remains unclear (321). Similar results were obtained for Moellerella wisconsensis and Proteus 
spp. for fosfomycin resistance when comparing MICs on IsoSensitest broth and (cation-adjusted) 
Mueller Hinton broth (322, 323). Additionally, medium-dependent activity of gentamicin 
sulfate against enterococci has also been encountered, showing medium-dependent activity of 
antibiotics against bacteria is not a phenomenon restricted to Gram-negative organisms (324).
In this study we observed that almost all strains showed an increase in metronidazole MIC 
when grown on blood agar compared to BHI (Figure 1, Table 2). We note the limitation that 
the COMBACTE-CDI collection we analyzed here does not encompass an unbiased collection of 
PCR ribotypes, and in particular clade 2 strains (RT016, RT027, RT176, RT181, RT198) appear 
to be overrepresented. We found that heme supplemented to the blood agar plates was the 
causative determinant for this phenotype (Figure 2, Table 2), presumably through the ability 
of heme to detoxify the nitro-radicals generated by metronidazole activation (325). As lethal 
concentrations of antimicrobials are thought to generate toxic radicals by altering cellular 
metabolism, we expected to find heme-dependent alterations in antibiotic susceptibility for 
other antibiotics than metronidazole (255, 326). However, no heme-dependent reduction in 
vancomycin susceptibility was found in our study, suggesting that the effect of heme shows 
specificity for metronidazole under the conditions tested. 
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Elegant work by Knippel et al. has demonstrated that reduced metronidazole susceptibility 
upon heme supplementation in R20291 was largely mediated by the hsmRA operon, leading 
to the question whether presence/absence or sequence variants of these genes underlie 
heme-dependent resistance in other RTs (257). Based on the present dataset, however, we 
were unable to identify specific sequence variants of this operon (or in the hatRT operon also 
involved in heme detoxification) that could explain why the vast majority of strains are less 
susceptible to metronidazole upon heme supplementation. The genes appear to be (near-)
universally conserved amongst different C. difficile types (data not shown) and the same 
signature is found in strains that do or do not respond to heme supplementation, and those 
that do or do not qualify as resistant (Table 1, Table 2, Supplemental Table 1). These results 
imply that other factors than the genome sequence of the hatRT and hsmRA operons can 
contribute to heme-dependent reduction in metronidazole susceptibility. 
Nevertheless, we did identify a C-terminal deletion in hsmA that correlated to heme-dependent 
metronidazole resistance in RT010 (ST15) isolates (Figure 3, Figure 4). Isolates without this 
deletion did become less susceptible to metronidazole in presence of heme, but did not 
exceed the EUCAST criterium for resistance to this antibiotic (87). We validated our findings 
in the collection of clinical isolates used in the pCD-METRO study (235). At present, there is 
no structural information on the HsmA protein, though homology between the protein and 
heme-containing cytochromes has been noted (257). HsmA has been postulated to act through 
sequestration of heme, but the effect of the altered C-terminal sequence on the affinity for 
heme remains to be elucidated.
The COMBACTE-CDI collection analyzed here includes a limited number of strains per RT 
(Table 1). It will be interesting to see whether targeted analyses of larger collections of 
specific ribotypes will reveal additional sequence variants of hsmAR associated with reduced 
susceptibility or resistance to metronidazole.
Our data hint at a possible cumulative effect of chromosomal and extrachromomal determinants 
in metronidazole resistance as strains carrying the pCD-METRO plasmid are dispersed over the 
resistant ST15/ST15-like (RT010) lineage characterised by the TAT-C hsmA signature (Figure 
4). Strains that possess both the C-terminal adenine deletion in hsmA and the pCD-METRO 
plasmid have a higher metronidazole MIC (MIC ≥ 8 mg/L vs 4 mg/L in the pCD-METRO negative 
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RT010s). As no pCD-METRO positive RT010 isolate containing the TATAC signature sequence 
was present in this collection, we do not know if pCD-METRO carriage without the deletion 
can still result in an MIC of ≥ 8 mg/L, though this appears to be the case in RT020 and RT027 
(235). Irrespective of the effect on metronidazole MICs, pCD-METRO carriage is associated 
with the 1-bp deletion in hsmA in RT010 isolates. Though this might result from a selection bias 
(by preferentially characterizing isolates with higher MICs), it is conceivable that the deletion 
facilitates pCD-METRO carriage in some way. 
Our findings suggest that the heme-dependent reduction in metronidazole susceptibility is 
common in C. difficile (Table 2). Though heme levels can be elevated at the host-pathogen 
interface during CDI, (317) pathogenicity does not seem a requirement for the heme-dependent 
reduction in MIC as it is also found in non-toxigenic strains such as those belonging to RT010. 
For the same reason, it is unlikely that extensive and continued use of metronidazole provided 
the selective pressure for the acquisition and/or persistence of this phenomenon during 
evolution (83, 84, 294).  In the majority of the strains the MIC will likely not be raised over the 
EUCAST cut-off (2 mg/L) for resistance, (87) but they clearly do become less susceptible to 
metronidazole. Due to absorption in the small intestine and sequestration- or inactivation of the 
microbiota, levels of metronidazole at the end of the colon are potentially low as determined by 
concentrations found in fecal material (276, 295, 297, 298). It is therefore quite possible that a 
moderate increase in metronidazole MIC could in fact facilitate growth of C. difficile in patients 
treated with metronidazole. Whether or not heme-dependent reduced susceptibility plays 
a role in treatment failure (that does not appear to correlate with metronidazole resistance) 
remains to be established (15, 235).
An important implication of our findings is that a well-described testing method in diagnostic 
antimicrobial susceptibility testing is of the utmost importance. The type of media and 
supplementation used can influence the MIC of certain antibiotics as we have demonstrated 
for heme supplementation and metronidazole susceptibility. It is our experience that small 
interlaboratory differences in standard operating procedures exist despite conforming to CLSI 
standards, which may explain the differences in MICs sometimes found between institutions. 
As medium-dependent differences in antimicrobial susceptibility may be both antibiotic- and 
organism-specific, this argues for a standardized method per genus rather than a standard 
testing method for all anaerobic organisms.
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In conclusion, we have demonstrated that heme is the causative agent of medium-dependent 
reduction in metronidazole susceptibility in clinical C. difficile isolates of different ribotypes, 
but does not influence vancomycin susceptibility. Additionally, we have found a deletion in 




The strains analyzed here were collected as part of the COMBACTE-CDI study. Strains were 
characterized by PCR ribotyping following the C. difficile Ribotyping Network of England 
and Northern Ireland protocol and tested for metronidazole susceptibility in agar dilution 
experiments at the Healthcare Associated Infection group of the University of Leeds, United 
Kingdom (271, 327). Confirmation of PCR ribotype and additional susceptibility testing was 
performed at the Netherlands Reference Laboratory of C. difficile, hosted at the Leiden 
University Medical Center, The Netherlands (13). Use of the strains for the present study was 
approved by the Management Board of the COMBACTE-CDI Consortium. Strains were further 
characterized by whole genome sequencing (see below). 
Metronidazole minimal inhibitory concentrations were determined using the agar dilution 
method according to CLSI guidelines  on either Wilkins-Chalgren agar (in Leeds) or Brucella 
Blood Agar (BBA) (in Leiden) (86). Although no formal breakpoints have been defined, we 
used the EUCAST epidemiological cutoff of 2 mg/L to define metronidazole resistance in C. 
difficile in this study (87).
Determining medium-dependent metronidazole resistance
Agar plates on which C. difficile was grown were always incubated anaerobically at 37oC in a 
Don Whitley A55 workstation (10% CO2, 10% H2 and 80% N2 atmosphere). For determining 
medium-dependent metronidazole resistance, C. difficile strains were first grown on reduced 
Brain Heart Infusion (BHI) agar plates supplemented with 0,5% yeast extract (Sigma-Aldrich) 
and Clostridium Difficile Selective Supplements (CDSS, Oxoid) for 24-48 hours. From these 
plates bacterial suspensions corresponding to 2.0 McFarland turbidity were made in PBS. These 
suspensions were then applied on BBA plates (bioMérieux) or on BHI agar supplemented with 
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0.5% yeast extract and when applicable with 1 µg/ml vitamin K (Sigma-Aldrich), 5% sheep 
blood (Thermo Fisher Scientific) and/or 5 µg/ml hemin (Sigma-Aldrich). Metronidazole or 
vancomycin E-tests (bioMérieux) were then applied and growth was evaluated after 48 hours 
of anaerobic incubation. Pictures were taken with an Interscience Scan 500 Automatic colony 
counter. Figures were prepared using ggPlotteR (http://huygens.science.uva.nl/ggPlotteR/) 
and Adobe Illustrator CC.
Whole genome sequencing and signature analysis
As part of the COMBACTE-CDI project, DNA extracts of the selected isolates were processed 
for whole genome sequencing at GSK Bio, as per their standard operating procedures. Briefly, 
total genomic DNA’s were quantitated using Quant-iT dsDNA High-Sensitivity Assay Kit (Life 
technologies) and SYNERGY H1 microplate reader. Sequencing libraries were prepared from 
1 ng of DNA using the Nextera XT DNA Library Prep kit (Illumina) and libraries concentrations 
were normalized using bead normalization as described by the manufacturer. Sequencing was 
performed on the Illumina MiSeq platform with MiSeq v3 600-cycles kit or on the Illumina 
NextSeq 500 platform with NextSeq 550 High-Output v 2.5 300-cycles kit. FASTQ files passed 
the quality control checks and strain identification confirmation (C. difficile), as performed in the 
BIOMERIEUX EPISEQ® CS beta platform (https://www.biomerieux-episeq.com/). Sequence data 
for this study is publicly available under BioProject number PRJNA679767 (sample accessions: 
SAMN16845917-16845948). 
For the SNP analysis, reads were mapped to the hsmA, hsmR, hatT and hatR genes obtained 
from the reference sequence of strain R20291 (GenBank entry FN545816.1). Mapping of reads 
to the reference sequences was done with Bowtie2 tool (version 2.3.4, options: --local --qc-
filter) and results of this mapping were analyzed using Samtools (version 1.7, default options) 
and depth of the reads coverage was calculated using IGV tool (version 2.3.98, options: -w 1) 
(301, 328, 329). Average depth calculated for all positions of the analyzed isolates is shown in 
Supplemental Table 1. Values of depth of coverage obtained for each position (nucleotides or 
indels) for all samples were filtered using a minimum coverage of 5 reads for each position. 
Mapping results for all positions were compared between all strains. Positions where at least 
one strain has a mutation or variation compared to the corresponding reference sequence 
were included in the generation of the genetic signature of hsmA, hsmR, hatT and hatR.
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ST15 and 15-like publicly available whole-genome sequencing data (Supplemental Table 2) 
were selected based on a previous analysis, and corresponding FASTQ files were downloaded 
from the SRA (n=85) (284). wgSNP analysis was performed on the Enterobase platform with a 
selected minimum frequency threshold of 0.1 (318, 319). Three entries were excluded from 
the analysis, as they did not pass the quality control of the Enterobase platform (Supplemental 
Table 2) (319). A wgSNP maximum likelihood tree was generated with RaxML and tree branches 
were represented in a log scale for clarity (330). Figure was further prepared for publication 
using Adobe Illlustrator CC.
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Antimicrobial resistance (AMR) is a contemporary problem that results in approximately 700.000 
deaths per year globally (331). As modern health care systems are reliant on antimicrobial 
use,  this number is predicted to rise to 10 million by 2050 if no action is taken, and will be 
accompanied by an enormous reduction in the Gross Domestic Product (GDP) (66). The 
general principle behind antimicrobial resistance generation is that antimicrobial use will 
select for resistant bacteria by killing susceptible ones, allowing propagation of the resistant 
strains. Additionally, antimicrobials can facilitate de novo resistance generation by providing 
an environment in which particular changes resulting in reduced susceptibility (for instance 
uptake of extrachromosomal elements or mutagenesis) lead to an increase in fitness (332, 333). 
Widespread and excessive antimicrobial use can thus contribute to the abundance of resistant 
bacteria in different settings. These resistant bacteria in humans, animals, healthcare settings 
and other environments such as water, soil and food  (so called ‘resistomes’), contribute to 
further transmission of resistant bacteria (334). The problem of AMR is therefore not restricted 
to human medicine, but should be regarded in the context of ‘One Health’: the approach in 
which  human health is regarded as closely related to animal health and the environment (335).
Clostridioides difficile is an organism with intrinsic and acquired resistance to various 
antimicrobials. Infection with this bacterium is associated with a substantial economic burden 
(20, 45). Antimicrobial use disrupts the healthy intestinal microflora normally providing 
colonization resistance against C. difficile and in this manner predisposes individuals to a C. 
difficile infection (CDI) (23). C difficile is traditionally regarded as a nosocomial pathogen since 
hospitalized patients frequently use antibiotics, have significant comorbidities and stay in an 
environment with spread- and transmission of spores  (20). However, an increasing number of 
CDIs appear to be unrelated to hospitals and antimicrobial use, and instead can be traced back 
to the community: Community-Associated CDI (CA-CDI) (56). The highly resilient endospores 
produced by C. difficile are ubiquitous and it is possible humans are asymptomatically colonized 
by C. difficile (60). PCR ribotype 078 (RT078) isolates are associated with CA-CDI and are 
isolated from both humans and farm animals, suggesting animal reservoirs have a role in 
the spread of C. difficile (65). However, it is also important to increase our understanding of 
the molecular mechanics behind antimicrobial resistance in C. difficile, of which aspects are 
explored in this thesis. 
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The role of σB in the pleiotropic effects following DNA polymerase inhibition
As disruption of the healthy intestinal microflora is a risk factor for CDI, it is important to use 
a narrow-spectrum antibiotic in order to disturb the resident microbiota as little as possible. 
Currently, the only narrow-spectrum antibiotic used in treatment of CDI is fidaxomicin. The 
novel antibiotic ibezapolstat (formerly known and referred to as ACX-362E) is currently tested in 
phase 2 clinical trials. Ibezapolstat inhibits the DNA polymerase IIIC subunit, which is required for 
replication in Gram-positive organisms with low [G+C]-content (105). Ibezapolstat is therefore 
presumed inactive against many bacteria part of the gut microbiota.  Results from the phase 
1 clinical trial indeed demonstrated that, compared to vancomycin, ibezapolstat treatment 
resulted in a distinct microbiome profile with an increase in Actinobacteria. (105). Preliminary 
results of the phase 2A trial indicated that all CDI patients treated with ibezapolstat met the 
primary- and secondary endpoint of clinical cure at the end of the study, and sustained clinical 
cure of no recurrence in the 28 following days (acurxpharma.com). In Chapter 2 we have 
demonstrated that exposure of 630∆erm with ibezapolstat leads to a gene-dosage shift. This 
shift is characterized by an increase in copy number of genes in close proximity to the origin 
of replication (oriC) resulting from multifork replication (Chapter 2, Figure 3). As multifork 
replication is a process occurring during fast, exponential growth to accommodate short 
doubling times, this effect is amplified when the replisome responsible for DNA replication is 
stalled (336). Indeed, in Bacillus subtilis it was shown that replisome inhibition did not abolish, 
but potentially even stimulated replication (187). We have shown that DNA polymerase 
inhibition increases the copy number as well as the expression of genes in close proximity 
to the oriC. 
One of the genes whose copy number and expression was increased as a result of ibezapolstat 
treatment, was the alternative sigma factor B (σB) which regulates the general stress response 
in many Gram-positive organisms (337). The general stress response is important for the 
ability of the organism to cope with various environmental stresses and nutrient availability 
(200). Close proximity of a regulator gene to the oriC may reflect its importance during early 
replication or replication inhibition, and we hypothesized that a similar genomic organization 
could be a conserved response to replication stress (199). There is indeed evidence that genome 
organization is not random. When the laboratory adapted 630∆erm strain was sequenced, 
differences in genome sequence were found compared to its parental strain 630 (190). An 
additional rRNA/tRNA cluster was found in close proximity to oriC in the laboratory strain, 
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resulting in an extra copy of ribosomal RNA (rrn) operons. Fast growing organisms more 
frequently contain a higher number of rrn operons, and an origin-proximal location results in 
more rapid availability of ribosomes during early replication to cope with increased protein 
demand during fast growth (338, 339). Though costly, constant growth under nutrient-rich 
conditions, which are the conditions often used in the laboratory, may allow acquisition of extra 
rrn operons and consequently improve fitness (340). This example illustrates how genome 
organization can lead to direct fitness effects and selection. The origin-proximal existence 
of a transcriptional regulator is therefore an interesting observation and could imply early 
activation of σB during replication inhibition is beneficial to C. difficile growth, despite very 
costly expression (Chapter 3, Figure 2) (169). To test if σB activity could change ibezapolstat 
susceptibility in C. difficile, a disk diffusion test, a growth curve in liquid culture or agar dilution 
could be performed on wildtype 630∆erm and IB56 (630∆erm∆sigB).  Although both 630∆erm 
and IB56 grew similarly in the presence of subinhibitory concentrations of ibezapolstat in liquid 
culture (data not shown), we have not looked at the effect of adding this antibiotic at the levels 
of the MIC or above. It is possible σB does not provide a fitness advantage during replication 
inhibition and is not involved in reduced ibezapolstat susceptibility, in which case no differences 
between wildtype 630∆erm and IB56 will be found in the previously proposed experiments. 
Instead, σB could be beneficial to the bacteria during normal (fast) growth, which is in itself 
a stressful condition and may have led to the origin proximal location of this sigma factor.
Approximately 13% of the 630∆erm genome was shown to be differentially regulated by 
ibezapolstat exposure (Chapter 2, Figure 2). This differential regulation is effectuated by a 
direct effect of the gene-dosage shift but is also mediated by indirect effects, such as the 
increase in expression of transcriptional regulators. During our work on the gene-dosage effect 
of ibezapolstat treatment in 630∆erm, a study was published describing the putative C. difficile 
σB regulon. A large overlap was seen between genes demonstrating an increase in expression 
after ibezapolstat treatment and those positively regulated by σB, even after we significantly 
refined the regulon (Chapter 3). We showed that removal of σB reduced or abolished the 
increase in gene expression following ibezapolstat treatment. This result demonstrated that 
DNA polymerase inhibition increased the expression of σB and some of its target genes as a 
result, contributing to the large number of detected differentially regulated genes. Situations 
that perturb replication, such as DNA replication inhibition, are believed to result in single 
stranded DNA (ssDNA), potentially activating the SOS response regulated by LexA/RecA (217, 
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341). Similarly, the heat shock response regulated by HrcA/CtsR could also be activated by 
replication inhibition. Although none of the regulators of these stress responses, including 
sigB, were found to be differentially regulated after 5 hours of subinhibitory ibezapolstat 
treatment based on the RNA-seq experiments, differential regulation of the sigB operon 
after DNA polymerase inhibition could be demonstrated using luciferase reporters (Chapter 
2, Figure 5). As a result it could be possible that both the SOS response and the heat shock 
response could result in differential regulation of genes following ibezapolstat treatment, as 
was seen for σB (213, 214). It is unclear if DNA polymerase inhibition increases σB expression 
as a result of the gene dosage shift or due to direct activation of σB, but it is likely both effects 
contribute to this transcriptional response. Marker frequency analysis (MFA) demonstrated 
that the relative increase of origin-proximal genes compared to terminus-proximal genes could 
be as high as a 10-fold (Chapter 2, Figure 4). Although the fold changes were averaged, the 
results obtained from the RNA-seq also demonstrated a clear correlation between the change 
in amount of RNA transcripts and genome location of the gene (Chapter 2, Figure 3). These 
results imply the increase in σB may be primarily caused by the gene dosage shift resulting 
from ibezapolstat treatment. Genetically modifying strain 630∆erm by moving sigB from its 
origin-proximal location to one closer to the terminus (terC) and repeating the experiment 
and transcriptome analysis (Chapter 2) will provide more information on whether this is 
indeed the case. However, all these results apply to a transcriptional level and do not provide 
information on any posttranslational modifications resulting from ibezapolstat treatment. Using 
a quantitative proteomics approach such as SILAC (Stable Isotope Labeling by Amino acids 
in Cell culture), more information can be acquired on the changes in protein levels following 
DNA replication inhibition.
DNA replication inhibition and mutagenesis mediated by the general stress response
DNA polymerase inhibition and the role of the general stress response in this process remains 
poorly understood in C. difficile. Several studies have demonstrated a link between mutagenesis 
resulting from DNA damage and the general stress response, although the SOS response is 
also involved in this process, as will be illustrated below. It has been shown in E. coli that 
overexpression of the SOS response by the general stress response leads to overexpression 
of translesion synthesis (TLS) (error-prone) polymerases and, in combination with existing 
DNA damage, to mutagenesis, potentially facilitating antimicrobial resistance (342-347). In 
C. difficile the SOS response was demonstrated to control biofilm- and toxin production and 
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sporulation in addition to DNA repair and could be induced by the fluoroquinolone levofloxacin 
(152). It is not yet known if the SOS response (possibly in combination with the general stress 
response) is also associated with error-prone DNA repair and mutagenesis in C. difficile.  The 
capacity for antibiotic resistance generation by DNA damage, the SOS response and the 
general stress response has been shown recently in E. coli. Ciprofloxacin, a fluoroquinolone 
class of antibiotic and DNA-gyrase inhibitor, stalls the bacterial replication fork and, similarly to 
ibezapolstat, increases the copy number of origin-proximal genes (188).  It is known that sub-
inhibitory concentrations of ciprofloxacin can induce de novo mutations resulting in resistance 
generation in E. coli (348). This ability of ciprofloxacin to induce novel mutations leading to 
antibiotic resistance was found to be mediated by the general stress response sigma factor 
σS (RpoS), the equivalent of σB in various gram-negative organisms (337). Ciprofloxacin use 
resulted in double-stranded breaks (DSBs) which activated the SOS response in E. coli (349). 
The activated SOS response in turn inhibited cellular respiration and disturbed the electron 
transport chain (ETC), which resulted in an increase in radical oxygen species (ROS). These 
radical species induced σS and initiated mutagenic break repair (MBR) by activating error-
prone DNA polymerases, resulting in mutations in rpoB and ampD that generated resistance 
to rifampicin and ampicillin, respectively (Figure 1A) (349). Activation of σS was only seen 
in a fraction of cells, leading to a bet hedging population of so called ‘gambler’ cells that 
risked acquiring debilitating mutations for a chance of becoming more resistant to different 
antibiotics. General stress response mediated mutagenesis was also observed after β-lactam 
addition in E. coli (350). 
Interestingly, σB was shown to be similarly stochastically expressed in C. difficile (169). Our 
refined σB regulon also demonstrated that σB positively regulated recA and uvrBAC endonucleases 
involved in the SOS response and DNA repair (Chapter 3), implying that σB could enhance the 
SOS response (152, 217, 351). Additionally, the SOS-inducible subunit of the PolIII complex, 
DnaE, was demonstrated to be error-prone in, for instance, Streptococcus pyogenes (352-354). 
Although DnaE lacks proofreading activity, it was found to be essential for DNA replication in 
B. subtilis. DnaE appears to be involved in a ‘handoff’ mechanism in vitro, in which the RNA 
primers in lagging strand synthesis were briefly extended by this part of the PolIII complex, 
after which more extensive elongation by PolC followed (355). Time-lapse microscopic imaging 
experiments confirmed the brief association of DnaE with the replisome in vivo, supporting the 
results obtained in vitro (356). Despite this short interaction time, DnaE was reported to be 
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involved in mutagenesis in B. subtilis (353). Based on our regulon, DnaE was positively regulated 
by σB in C. difficile. DnaE was shown to be a part of the SOS response in other organisms, but 
based on in silico analysis this gene was not regulated by LexA in C. difficile (217, 352, 354). 
However, the results described above do indicate a certain degree of convergence for the SOS 
response and the general stress response, as uvrBAC are activated early in the SOS response, 
but were also clearly regulated by σB in C. difficile (Chapter 2, Figure 6 and Chapter 3, Figure 
4) (217, 351). It is not impossible that replication disturbed by DNA polymerase inhibition 
activates or reinforces the SOS response in a σB dependent manner. Based on this information, 
an interesting question to answer is whether σB could be similarly involved in mutagenesis after 
ibezapolstat exposure or other forms of DNA replication inhibition (figure 1B). Although no 
resistance to this antibiotic was found in C. difficile, it is possible resistance to other types of 
antibiotics could be induced as has been reported in E. coli (232, 350). It should be mentioned 
that no increase in dwelling time of DnaE in association with the replisome was found in B. 
subtilis after DNA polymerase inhibition by HPUra (a DNA polymerase inhibitor), but perhaps 
this may not be relevant for mutagenesis (if it is indeed mediated by DnaE), or other error 
prone polymerases may still be involved in mutagenesis resulting from DNA damage and the 
general- and SOS stress response (356). Ames tests have been used to evaluate the mutagenic 
(carcinogenic) potential of compounds by incubating auxotrophic bacterial strains with the 
desired compound and determining if this auxotrophy is lost. A similar approach can be used 
to determine if ibezapolstat treatment is involved in σB dependent mutagenesis in C. difficile 
(Figure 2).  In this assay, wildtype 630∆erm and IB56 (∆sigB) can be incubated with ibezapolstat 
(or other compounds such as metronidazole, mitomycin C and hydrogen peroxide), after which 
they are plated on agar medium containing an antibiotic (for instance rifampicin). In parallel 
these two strains will be plated without having been exposed to ibezapolstat or another 
compound to determine the ‘background’ mutation frequency. Comparing the number of 
(resistant) colonies that emerge will indicate if the tested compound increases the mutation 
frequency (in a σB dependent manner) in C. difficile. Genes known to be often involved in 
resistance to these antibiotics can be sequenced in these resistant colonies to determine 
what mutations have occurred, or this could be determined by whole genome sequencing 
analysis (WGS). It should be mentioned that these kind of mutagenic processes are believed 
to be mediated by ROS which may not be formed under anaerobic conditions (357). Similarly, 
ampicillin treated E. coli developed resistance to norfloxacin while this process was inhibited 
by the presence of radical scavengers such as thiourea and strict anaerobic conditions (358). 
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Figure 1. Mechanisms for antibiotic-induced resistance generation. A) Ciprofloxacin induced 
mutagenesis leading to antibiotic resistance, mediated by the SOS- and general tress response (σS) 
through mutagenic break repair (MBR) as was shown in E. coli. B) Hypothetical situation of ibezapolstat 
induced mutagenesis in C. difficile, mediated by the SOS and general stress response (σB) through 
mutagenic break repair. DSBs: Double-stranded breaks; SOS: SOS response; ROS: Radical Oxygen 
Species; MBR: Mutagenic break repair; AMR: Antimicrobial resistance. Image adapted from (349).
 
However, many central metabolic processes and electron transport chains differ in facultative 
anaerobes from strictly anaerobic organisms and not many studies are conducted on the 
latter type of organism. It would therefore still be novel and of interest to further study these 
stress-response based mutagenic processes in C. difficile. 
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Figure 2. Adaptation of the ‘Ames test’ to determine the (σB-mediated) mutagenic potential of 
certain compounds and antimicrobials in C. difficile.
Antibiotics disturb cellular downstream processes which may lead to σB activation
The general stress response in C. difficile is involved in protection against physiological- (host) 
and inflammatory responses such as ROS, reactive nitrogen species (RNS), nitric oxide (NO) and 
antimicrobial peptides (20, 172). It has also proven crucial for survival under oxygen tension, an 
observation reinforced by our results indicating approximately a third of the entire σB regulon 
is designed to regulate genes putatively involved in oxidative and nitrosative stress responses 
such as thioredoxin reductases (Chapter 3) (161). A role for the general stress response and 
antimicrobial resistance was demonstrated in other organisms, and for reduced susceptibility 
to rifampicin and mitomycin C in C. difficile (160, 170, 230, 231). Preliminary results hinted 
at a relationship between σB and metronidazole resistance (data not shown) which was the 
premise in which we wanted to study the role of the general stress response and antibiotic 
resistance in C. difficile. Our work was complicated by the toxicity of σB leading to loss of the 
plasmid used for in trans overexpression of this sigma factor (Chapter 3, Figure 3). 
In an attempt to work around this toxicity the plate-based luciferase assay was designed to 
establish an indirect relation between activation of the general stress response and antibiotic 
exposure. In this assay we could measure σB dependent promoter activation of genes in its 
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regulon and analyze if antibiotic exposure would therefore alter activation of the general stress 
response. We found this to be the case for a subset of σB target genes after metronidazole 
exposure, which could be explained by the fact certain genes in the regulon appear to be 
regulated by other factors as well (Chapter 2, and Chapter 3). Additionally, although CD2963 
expression appeared to be strictly dependent on σB, no clear activation attributable to 
metronidazole could be detected. As CD2963 is a L,D-transpeptidase it is possible that σB strongly 
induces transcription of this gene for cell wall synthesis to facilitate growth under nutrient-rich 
conditions. In such a situation high background levels will cloud the chemiluminescent signal of 
activation attributable to metronidazole exposure. However, for CD0350 (encoding a putative 
hydrolase involved in oxidative stress) we observed σB dependent activation induced by the 
presence of all compounds tested, which included antibiotics with a different mechanism of 
action (Chapter 3, Figure 6). Although we expected metronidazole and hydrogen peroxide 
to activate σB due to their role in redox and Fenton reactions, respectively, it was surprising 
to observe this effect for the other tested antibiotics as well (124, 130). These are believed 
to target processes unrelated to DNA damage or oxidative and nitrosative stress responses, 
but instead act on the cell wall (vancomycin), DNA replication (ibezapolstat), or translation 
(lincomycin). Furthermore, despite clear activation of σB dependent genes, no effect on the 
minimal inhibitory concentration (MIC) was seen between wildtype 630∆erm and the sigB 
knockout for metronidazole when tested by E-test (data not shown). In contrast, a moderate 
difference in metronidazole susceptibility between 630∆erm and the sigB mutant was found 
when tested with a disk diffusion assay (359). Although there is apparent overlap between the 
transcriptional response following metronidazole treatment and σB activation, these results 
imply the effect of σB on metronidazole susceptibility is minor and strongly dependent on the 
resolution of the assay used.
Interesting results have been published and - although far from conclusive - may provide part 
of an explanation on how toxic compounds with different mechanism of action could activate 
σB. Over the years a dividedness has followed the so-called ‘ROS’ debate, in which bactericidal 
antibiotics are believed to generate ROS and/or hydroxyl radicals (360). These deleterious 
radical species are believed to disrupt cellular processes such as depleting NADH, destabilizing 
iron-sulfur clusters and causing oxidative damage, and that these species strongly contribute 
to antibiotic lethality (253-256, 358, 360, 361). Relationships between antibiotic susceptibility 
and ROS production have been demonstrated in Staphylococcus aureus, Enterococcus faecalis, 
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Pseudomonas aeruginosa and E. coli (362). Despite the great number of studies demonstrating a 
relationship between antibiotics and oxidative stress responses, this claim has been questioned. 
One study performed by Liu et al. did not find ROS formation after exposing E. coli to antibiotics, 
and antibiotic lethality persisted even under anaerobic conditions (357). Similarly, another 
study reported no differences in antibiotic killing under aerobic- or anaerobic conditions 
even in the presence of a radical quencher (363). Part of these results are believed to be 
explained by the slowed respiration and subsequent inhibition of reactive species formation 
under anaerobic conditions. Supplementation with nitrate, frequently used as a terminal 
electron acceptor under anaerobic conditions, facilitated killing by various antibiotics under 
anoxia and imply reactive nitrogen species, just like ROS, contribute to antibiotic lethality 
(253). The results obtained from these studies all imply that usage of different antibiotics 
ultimately result in the formation of radical species, be they oxygen- or nitrogen based or 
otherwise, but may not be the sole reason for antibiotic lethality. Based on the σB regulon 
and its seemingly extensive role in dealing with these kind of stresses, it seems likely these 
radical species could also be involved in σB activation. Additionally, interesting ideas about the 
proximal effects (the conventional ‘mechanism of action’) and ultimate effects (physical or 
genetic destabilization leading to cell death) of antibiotics have been discussed (364). There 
is a growing body of evidence that antibiotics with different proximate effects converge in 
disrupting downstream processes, inducing cell damage and destroying critical processes 
required for metabolism and cellular- and genomic integrity, limiting the ability of bacteria 
to cope with antibiotic exposure, the ultimate effect (Figure 3) (364). Although the primary 
antibiotic target is important in determining how- and which of these downstream processes 
are disrupted, it appears the latter is what truly leads to cell death. It is likely that a variety 
of these so called ‘death processes’ induced by the ultimate antibiotic effects also lead to σB 
activation (365). The implications of potential activation of the general stress response under 
these conditions warrants further study.
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Figure 3. Downstream effects of antibiotic exposure. Antibiotics exert downstream cellular effects 
after target inhibition inducing active death processes. The resulting damage could activate stress 
responses which may facilitate further disruption. Environmental factors such as nutrient availability 
and population heterogeneity can influence various aspects of these interrelated processes. Image 
adapted from (365).
 
Heme (ab)use in C. difficile
We have observed that heme supplementation reduced metronidazole susceptibility and 
sometimes lead to resistance in C. difficile (Chapter 4). Although radical species are important 
in synergistic killing, it is not the ultimate effect of each and every kind of antibiotic (361, 364). 
No significant effect on heme supplementation and vancomycin susceptibility was seen in C. 
difficile, while we did see this for metronidazole (Chapter 5, Figure 2). As the ultimate effects 
of metronidazole lethality are believed to be mediated by nitro-radical formation, the putative 
in vivo function of heme may explain how it could act protectively in these conditions. Heme 
is an iron-containing protoporphyrin with homology to the cytochrome b561 family (366). 
It is known to be toxic to numerous organisms such as S. aureus, Bacillus anthracis, Listeria 
monocytogenes and E. faecalis as illustrated by the presence of detoxification system hatRT 
and hsmRA orthologs such as hrtAB and hssRS (367-370). C. difficile R20291 hatR, hatT, hsmR 
or hsmA ClosTron mutants were significantly more susceptible to heme toxicity than the 
wildtype strain (257, 317). Heme toxicity is thought to originate from nonspecific redox cycling 
occurring between heme and oxygen, and by destabilization of the cell membrane (369, 371). 
Despite the apparent necessity for heme detoxification systems in organisms able to infiltrate 
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vertebrate hosts, heme can be utilized for processes beneficial to bacteria as well. In respiring 
bacteria b561 family cytochromes such as heme can act as carriers of electrons originating 
from catabolized carbon sources in order to generate a proton-motive force (372, 373). No 
respiration occurs in C. difficile, but it is able to utilize heme as a nutrient source under iron-
depleted conditions (374). Additionally, the observation that hsmA clostron mutants generated 
more radical oxygen species (ROS) when treated with heme compared to its untreated control, 
implies hsmA bound heme may be used as an electron sink comparable to the function of 
cytochrome b561 (257). It is possible heme can be used to ‘catch’ the damaging nitro-radicals 
formed by metronidazole activation, but that vancomycin mediated toxicity originates from 
other disturbed downstream processes not compensated for by heme.
Based on the effects on the host resulting from CDI it could indeed be beneficial for C. difficile 
to carry genes involved in heme detoxification. Damage to the gut epithelium from toxin 
exposure can lead to blood leaking into the intestinal lumen and after hemolysis may result 
in free heme (375, 376). Severe C. difficile infections can indeed result in bloody diarrhea 
and C57BL/6 mice infected with the RT027 strain R20291 demonstrated accumulation of 
hemoglobin in the cecum during CDI (20, 317). For this reason, carriage of the hatRT and 
hsmRA operons for heme detoxification may be found frequently in C. difficile. Indeed, 
performing a BLAST search of these operons against 5336 assembled C. difficile genomes 
available at the NCBI database demonstrated that approximately 60% of all available isolates 
contained a chromosomal sequence with significant homology to the R20291 hatRT operon, 
and approximately 80% demonstrated this for hsmRA (data not shown). If the widespread 
availability of heme detoxification systems in C. difficile is indeed associated with  the frequent 
encounter of blood in the intestinal lumen from toxin production, it is puzzling to see these 
operons being present in nontoxigenic isolates as well. Additionally, heme-mediated resistance 
to metronidazole by a C-terminal deletion in hsmA was also detected in nontoxigenic RT010 
isolates. Several explanations for this may exist. First, as 10% of the genome of C. difficile is made 
of mobile genetic elements (MGEs) it may be possible that the pathogenicity loci containing 
the various toxin genes were lost after acquisition of the hatRT and/or hsmRA-like operons 
(27, 35, 51, 199). Performing in silico analysis on the evolutionary ‘age’ of RT010 isolates in 
relation to toxinogenic strains would give a good indication if this could indeed have occurred. 
Nontoxigenic C. difficile isolates are often isolated from dogs and metronidazole is frequently 
used for treatment of CDI and Giardia spp. infections in these pets, and extensively used to 
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treat enteric diseases and protozoal infections in animals in veterinary medicine (377, 378). It 
is therefore possible that sufficient metronidazole pressure contributed to retention of heme 
detoxification mechanisms as these may facilitate heme-mediated metronidazole resistance. 
Second, it may be possible that colonization by nontoxigenic strains occurs frequently in 
conjunction with an infection caused by a toxigenic strain. Nontoxigenic strains are believed 
to not cause diarrhea but are still sometimes isolated from patients suffering from diarrhea. 
In routine diagnostics usually only one- or a few colonies are picked for laboratory typing, 
and it is possible the symptoms are caused by a toxigenic strain missed at that point in time. 
It may be worthwhile to investigate if patients with CDI indeed are also frequently colonized 
by nontoxigenic strains, by picking and typing multiple colonies during (routine) diagnostics.
It is not yet clear why the deletion in hsmA leads to metronidazole resistance in the tested 
C. difficile isolates. The deletion at position 372 in hsmA results in a frameshift, adding 6 
additional amino acids to the C-terminus in comparison to wildtype protein. Introducing this 
hsmA deletion in the chromosome of 630∆erm by Allelic-Coupled Exchange (ACE) and testing 
metronidazole susceptibility in this mutant and the wildtype, would confirm if this deletion 
is indeed responsible for an increase in metronidazole MIC or associated with reduced heme 
toxicity. Alternatively, hsmA could be knocked out and wildtype and mutant hsmA could be 
overexpressed in trans. Testing metronidazole and heme susceptibility in these mutants would 
provide valuable information on the role of hsmA in C. difficile. Wildtype and mutant hsmA could 
be overexpressed in E. coli with and without heme addition, and in vitro spectrophotometric 
assays as described in Knippel et al. would then indicate if heme binding affinity would increase 
as a result of this deletion (257).
hsmA and pCD-METRO in metronidazole resistance
The deletion in hsmA leading to a frameshift and subsequent extension of the C-terminus was 
found in sequence type 15- (ST15, RT010) and a ST15-like isolate and lead to heme-dependent 
metronidazole resistance in the RT010s (Chapter 5, Figure 3). Based on the phylogenetic 
analysis (Chapter 5, Figure 4) it appears this deletion was introduced at a certain point in 
time in a specific divergent clade of ST15 and ST15-like isolates. It was surprising to see that 
all strains carrying the metronidazole resistance conferring plasmid pCD-METRO (Chapter 
5) also carried the deletion in hsmA. pCD-METRO carriage was demonstrably involved in 
metronidazole resistance, as introduction of pCD-METROshuttle in the metronidazole susceptible 
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630∆erm caused this strain to become resistant to this antibiotic (MIC ≥ 8 as determined by 
agar dilution). pCD-METRO is also found in multiple PCR ribotypes that lack the hsmA deletion 
((235) and unpublished observations). Furthermore, pCD-METRO carriage was associated with 
higher MICs and unconditional (heme-independent), stable metronidazole resistance. As the 
deletion in hsmA also caused metronidazole resistance (MIC=4) in RT010 isolates lacking pCD-
METRO, carrying both of these determinants seems at least partially redundant. Despite this 
apparent redundancy,  pCD-METRO carriage did not occur in ST15- and ST15-like strains with 
‘wildtype’ hsmA, which is puzzling. As mentioned previously, this deletion in hsmA was found 
in strains often isolated from dogs, which are frequently exposed to metronidazole (377, 378). 
Based on our data (Chapter 4) it is likely that pCD-METRO is transferred to C. difficile under 
metronidazole pressure, at least in human patients. Perhaps the deletion in hsmA occurs most 
rapidly under metronidazole pressure, and a further increase in MIC resulting from subsequent 
pCD-METRO acquisition could still be beneficial to the bacterium (379). Alternatively, it is 
possible that the deletion in hsmA predisposes isolates for pCD-METRO uptake in an as of yet 
unknown manner. More information on this process could be provided by further enlarging the 
collection of metronidazole resistant isolates in order to see if there truly are no pCD-METRO 
positive RT010 isolates that do not carry the deletion in hsmA, and to study the evolutionary 
diversity between these isolates. As we currently understand very little about the transfer and 
origins of pCD-METRO, further elucidating the occurrence of these events will also contribute 
to our understanding in these processes.
The origin of pCD-METRO
Above we mention that we still understand little about the origins of the plasmid (Chapter 4). 
The plasmid conferring metronidazole resistance in C. difficile, pCD-METRO, was found in clinical 
isolates of different ribotypes, including RT010, RT020 and RT027, from various (European) 
countries. On multiple occasions, we have found potential transfer by comparing longitudinally 
obtained  susceptible and resistant isolates, including – recently – a new PCR ribotype, RT005 
(data from the National Reference Laboratory for Clostridioides difficile at the Leiden University 
Medical Center, not shown). Our data imply that this plasmid can be acquired by horizontal 
gene transfer (HGT) from an unknown donor organism. However, several conditions need to 
be met in order for HGT to occur. Sufficient donor cells carrying the transferable determinant 
are required for HGT to be adaptive. This is difficult in a mobile environment, but could be 
facilitated in biofilms due to closer proximity of donor and recipient cells (380). There is 
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evidence that subinhibitory concentrations of metronidazole can increase biofilm formation in 
C. difficile. The RT010 strain carrying pCD-METRO did not exhibit increased biofilm production 
after exposure with subinhibitory concentrations of metronidazole, whereas this increase was 
observed in the other (metronidazole sensitive) RT010 isolates (381). This implies metronidazole 
susceptibility is required for increased biofilm formation in the presence of metronidazole in 
these strains. An acquired extrachromosomal element needs to be sufficiently beneficial to 
the recipient to compensate for the energetic costs associated with competence, as well as 
for the risk of taking up selfish genetic elements (382). Additionally, our data seems to imply 
that this plasmid was acquired under metronidazole pressure, as after failed metronidazole 
treatment a resistant, pCD-METRO positive clonal isolate was detected in two unrelated 
patients suffering from C. difficile infection (CDI). 
To date we have no experimental proof for which donor organism could have been involved 
in the transfer of pCD-METRO to C. difficile. Performing BLAST analysis of the pCD-METRO 
nucleotide sequence on the nucleotide collection (nr/nt) at the NCBI did not provide relevant 
results. Repeating this BLAST analysis using amino acid sequences demonstrated some homology 
for the putative truncated nitroimidazole reductase (nim) gene with those found in Bacteroides 
fragilis, whereas parts of the replicon could be detected in Campylobacter jejuni (data not 
shown). As our results imply that pCD-METRO might be common in the donor, it is possible 
that this species has not been cultured yet or a pCD-METRO containing strain of the organism 
has not yet been whole genome sequenced. Very recent data indicates that the plasmid may 
have been found in metagenomic data, but as this was unbinned it is not possible to trace 
which organism this was (Quinten Ducarmon, personal communication) (383). A partial hit was 
found for the metallohydrolase and Tn5 ORFs and this hit was binned as Phascolarctobacterium 
sp CAG:207 (unknown Phascolarctobacterium) (383, 384). Phascolarctobacterium faecium 
is a Gram-negative obligate anaerobe that utilises succinate, can be isolated from feces and 
appears to be a commensal in humans (385). A complete pCD-METRO sequence was recovered 
from another metagenomic dataset, but could not be assigned to a particular genus or species 
(383). In an attempt to elucidate which organism contained (part of) pCD-METRO in these 
metagenomic datasets, it could be informative to perform Pacific Biosciences (PacBio) long 
and high accuracy circular consensus sequencing (CCS). This was shown to improve taxonomic 
binning and genome reconstruction as compared to Illumina HiSeq and would help identify the 
pCD-METRO donor organism (386). Alternatively, Hi-C sequencing could be performed. This 
557028-L-sub01-bw-Boekhoud




technique utilizes cross-linking of molecules in close proximity, for instance using formaldehyde, 
to identify intra- and inter-chromosomal associations (387, 388). This method has been 
successfully applied in associating plasmids with the host chromosome (389, 390). Performing 
Hi-C on patient fecal material containing pCD-METRO in which C. difficile is likely not the sole 
host, would allow us to determine the original donor by analyzing the chromosomal sequence 
cross-linked to pCD-METRO. This experiment was not performed at the time due to lack of 
available stored fecal material, as well as suboptimal fecal storage conditions potentially 
affecting microbial community profiles (391).
The mechanism of pCD-METRO mediated metronidazole resistance
Another current outstanding question is how pCD-METRO confers metronidazole resistance 
in C. difficile. Potential mechanisms in which C. difficile becomes resistant to metronidazole 
is by reductive inactivation of metronidazole, drug efflux, alterations in pyruvate-ferredoxin 
oxidoreductase (PFOR) activity or adaptation by various stress responses (124). The most 
likely candidate to mediate one of the aforementioned effects present on the plasmid was 
open reading frame (ORF) 6. This ORF demonstrated homology to nimB, sometimes detected 
in metronidazole resistant B. fragilis (134). However, in trans overexpression of this gene did 
not confer metronidazole resistance in 630∆erm. No changes in MIC were observed when 
ORF6 was expressed together with the upstream putative metallohydrolase under the control 
of either an inducible or its native promotor (Chapter 4). The nimB sequence as encoded by 
ORF6 is truncated, however, and based on structural predictions, obtained using phyre2, it is 
likely the active site of this nim protein is missing. Based on these results, a different gene or 
combinations of genes are possibly responsible for the metronidazole resistant phenotype. 
In an attempt to analyze this further we attempted to perform QuickChange site-directed 
mutagenesis to introduce a premature stop-codon into every ORF to sequentially disrupt each 
gene present on pCD-METROshuttle. We were successfully able to introduce a premature stop 
codon into ORF1 (a hypothetical protein) but this disruption did not influence metronidazole 
resistance conferred by pCD-METROshuttle (data not shown). No mutations could be introduced 
in the other ORFs, primarily due to unwanted secondary mutations in the replicon (ORF5) of the 
plasmid, potentially due to its toxicity in E. coli. Alternative strategies would be to clone each 
ORF or parts of the plasmid under an inducible promoter and conjugate these into C. difficile 
and test metronidazole susceptibility using an E-test. Using pRPF185-based vectors with both 
ermB and catP resistance markers will allow us to make gene combinations on two separate 
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plasmids. A transposon mutagenesis based approach could be used to generate disruptions 
in the different ORFs on pCD-METROshuttle to analyze the effect of the resulting mutant plasmid 
on metronidazole resistance (392). Additionally, thermal proteome profiling (TPP) could be 
used to find which of the proteins encoded by pCD-METRO bind to metronidazole and could 
be involved in its inactivation. This technique is based on the principle that proteins denature 
and become insoluble when heated, and these properties will change when proteins are bound 
to a ligand, in this case metronidazole (393). An experimental setup that has been described 
as 2D-TPP uses liquid chromatography mass spectrometry (LC-MS/MS) and computational 
approaches to identify proteins with significantly altered thermal stability, which is an indication 
they interact with the added ligand (394). Performing 2D-TPP on C. difficile carrying or not 
carrying pCD-METRO and adding various concentrations of metronidazole, may indicate which 
of the proteins encoded by pCD-METRO have a different thermal profile. This would imply 
these proteins interact with metronidazole and could be involved in its inactivation.
In conclusion, the work described in this thesis has demonstrated how antibiotic use and the 
general stress response act in concert, exerting both direct targeted and aspecific secondary 
effects. Although the consequences of these observations are unknown in C. difficile, this 
discussion outlines how ultimate antibiotic effects relate together to these processes. 
Additionally, the work presented in this thesis described two novel mechanisms conferring 
metronidazole resistance in C. difficile, one of which was acquired from an as of yet unknown 
donor organism. Altogether this information will facilitate our understanding of antibiotic 
resistance in C. difficile and the role of antimicrobial resistance determinants in the resistome 
(from a One Health perspective), and contribute to the development of novel therapeutics. 
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De darmbacterie Clostridioides difficile, ook wel bekend als Clostridium difficile, is overal in het 
milieu aanwezig. Vanwege het strikt anaerobe karakter van dit organisme is de bacterie niet in 
staat om in aanwezigheid van zuurstof te groeien. Als aanpassing op deze zuurstofintolerantie 
is C. difficile in staat om (endo)sporen te vormen die zeer resistent zijn tegen o.a. zuurstof, 
antibiotica, hitte en chemicaliën zoals ontsmettingsmiddelen, maar die niet in staat zijn te 
groeien alvorens de omgeving gunstiger voor het organisme is. Aangetroffen sporen kunnen de 
gastheer oraal binnentreden en in de darm ontkiemen tot vegetatieve cellen, wat kan leiden tot 
asymptomatische kolonisatie of een symptomatische infectie.  Zodra kolonisatie gepaard gaat 
met symptomen van een darmontsteking,  wordt er gesproken van een Clostridioides difficile 
infectie (CDI), wat kan resulteren in (milde) diarree, enterocolitis of een levensbedreigende 
pseudomembraneuze colitis (ernstige darmontsteking). Deze symptomen worden veroorzaakt 
door verscheidene toxines uitgescheiden door C. difficile die schade toebrengen aan het 
darmepitheel. Normaliter draagt een divers en stabiel microbioom van de darm (alle daarin 
aanwezige micro-organismen) bij aan bescherming tegen C. difficile kolonisatie en infectie. Pas 
wanneer de darmflora wordt verstoord door bijvoorbeeld antibioticumgebruik of significant van 
compositie verandert door stijgende leeftijd of onderliggende aandoeningen, kan ingestie van 
sporen tot kolonisatie en CDI leiden. Antibioticumgebruik, hoge leeftijd en onderliggend lijden 
zijn hierdoor significante risicofactoren voor CDI. Mede hierdoor is CDI de belangrijkste oorzaak 
voor nosocomiale (ziekenhuis) diarree en is ziekenhuisverblijf een additionele risicofactor voor 
de ontwikkeling van deze infectie. De extra maatregelen voor infectiepreventie en de relatief 
lange opnameduur bij CDI patiënten zorgen ervoor dat de kosten geassocieerd met deze infectie 
aanzienlijk zijn, variërend van 5- tot 6 miljard per jaar in de Verenigde Staten en 3 miljard in 
de Europese Unie. De laatste jaren is er ook een toename in CDI die niet teruggevoerd kan 
worden op de gezondheidszorg. Deze patiënten voldoen ook niet aan het typische profiel 
van antibioticumgebruik en onderliggend lijden. Hoewel de reden hiervoor niet bekend is, 
wordt C. difficile ook veel aangetroffen in het milieu en bij dieren. Het wordt daarom ook wel 
beschouwd als een typisch ‘One Health’ pathogeen, waarbij One Health er van uitgaat dat de 
gezondheid van de mens afhankelijk is van dieren en het milieu.
Hoewel antibioticumgebruik het risico op CDI kan verhogen, is antimicrobiële therapie de 
standaardbehandeling voor deze infectie. Het antibioticum metronidazol is lange tijd gebruikt 
voor de behandeling van milde infecties, maar vanwege gebleken inferioriteit aan vancomycine 
(ook een antibioticum) zijn de richtlijnen voor CDI behandeling reeds aangepast in Amerika en 
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zullen de Europese richtlijnen ongetwijfeld spoedig volgen. Desondanks wordt metronidazol over 
de hele wereld nog veelvuldig gebruikt voor de behandeling van CDI en andere infecties. Voor 
infecties met ernstiger beloop wordt doorgaans vancomycine gebruikt, en voor infecties met 
een hoge kans op een recidiverende (terugkerende) infectie wordt fidaxomcine geadviseerd. 
In de praktijk wordt  meestal voor vancomycine gekozen vanwege de hoge kosten van een 
behandeling met fidaxomicine. Hoewel C. difficile resistent kan zijn tegen zeer veel verschillende 
soorten antibiotica, komt resistentie tegen metronidazol, vancomycine en fidaxomicine nog 
niet veel voor. Antibiotica slaan echter niet bij alle patiënten aan en recidiverende infecties 
komen relatief vaak voor. Fecale microbiota transplantatie (FMT), het transplanteren van de 
ontlasting van een gezonde donor naar een patiënt met een ernstige recidiverende CDI, is 
zeer effectief gebleken in het behandelen van recidieven, maar de gevolgen hiervan op lange 
termijn zijn onbekend. Er zijn verschillende waarschuwingen afgegeven door de Amerikaanse 
Food and Drug Administration (FDA) omtrent het gebruik van FMT omdat er een kans bestaat 
dat ongewenste (antibioticumresistente en/of pathogene) bacteriën van de donor worden 
doorgegeven aan de ontvanger en een infectie veroorzaken. Ook bestaat er op deze manier 
de kans dat genen die zorgen voor antibioticumresistentie worden doorgegeven aan gevoelige 
bacteriën.  Meer onderzoek naar de neveneffecten van FMT in vergelijkbare processen is 
noodzakelijk. Om deze redenen is het belangrijk onderzoek te verrichten om ons begrip 
van antimicrobiële resistentie (AMR) in C. difficile beter te begrijpen, opdat deze kennis kan 
bijdragen in de ontwikkeling en/of verbetering van nieuwe therapieën alsook de ontwikkeling 
van nieuwe antibiotica.
Het vermogen van bacteriën om zich aan te passen aan de omgeving is een belangrijke 
overlevingsstrategie. In de levenscyclus van C. difficile komen de cellen in aanraking met 
schadelijke concentraties zuurstof, pH waarden, temperatuurwisselingen, osmotische druk 
en antimicrobiële peptiden geproduceerd door nabijgelegen bacteriën of de gastheer. Door 
zogeheten stress-responsen zijn bacteriën in staat de transcriptie van hun genen te veranderen 
(het bijbehorende ‘regulon’), en deze veranderingen kunnen bijdragen aan de overleving. Twee 
belangrijke stress-responsen zijn de SOS respons, welke voornamelijk bij DNA schade wordt 
geactiveerd, en de algemene stress-respons die gereguleerd wordt door de alternatieve sigma 
factor B (σB). Het is bekend dat de algemene stress-respons belangrijk is voor de tolerantie voor 
lage concentraties zuurstof in C. difficile, maar lijkt ook een rol te spelen bij de gevoeligheid 
voor de antimicrobiële middelen rifampicine en mitomycine C. Daar mitomycine C DNA schade 
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veroorzaakt lijkt er een verband te zijn tussen de DNA schade, de algemene- en de SOS stress 
responsen.
Een nieuw antibioticum, ibezapolstat (ook wel ACX-362E genoemd) dat sinds kort in klinische 
ontwikkeling is, remt DNA replicatie door een DNA polymerase te inhiberen. Lage concentraties 
van dit antibioticum leidde ertoe dat er relatief meer kopieën gemaakt werden van genen (en 
dientengevolge ook transcripten van deze genen) die zich dichtbij het startpunt van replicatie 
bevonden ten opzichte van die genen die verder van dit replicatiepunt af lagen (hoofdstuk 2). 
Het gen coderend voor σB bevindt zich dichtbij het replicatie startpunt en werd dus geïnduceerd 
door lage concentraties ibezapolstat, hetgeen resulteerde in het aanzetten van σB -afhankelijke 
genen. Het is mogelijk dat deze respons bijdraagt aan het aanpassingsvermogen van C. difficile 
tegen DNA replicatie inhibitie.
Om de algemene stress respons in C. difficile beter te karakteriseren is het regulon (alle genen die 
door σB worden geactiveerd of gedeactiveerd) van σB bepaald (hoofdstuk 3). Hieruit is gebleken 
dat een significant gedeelte van de algemene stressrespons gericht is op het afhandelen 
van schadelijke zuurstof- en stikstofradicalen. Omdat het antibioticum metronidazol geacht 
wordt bacteriën te doden door middel van stikstofradicalen lijkt er een verband te bestaan 
tussen de algemene stress respons en de wijze waarop metronidazol cellen doodt. Aangezien 
ongereguleerde activiteit van σB toxisch was voor C. difficile, is er door middel van constructen 
met een promotor, gekoppeld aan een expressiecasette (reporterconstructen), aangetoond 
dat verschillende antibiotica (metronidazol, ibezapolstat, vancomycine en lincomycine) en 
waterstofperoxide transcriptie van een aantal σB gereguleerde genen activeerden. Op basis 
van deze resultaten bestaat het vermoeden dat antibiotica, maar ook andere stoffen die lijden 
tot dood van cellen, het metabolisme en de homeostase dermate beïnvloeden dat σB wordt 
geactiveerd of dat er hierdoor radicalen worden geproduceerd die eveneens tot activatie 
van σB leiden.
In dit proefschrift zijn twee nieuwe ontdekkingen gedaan omtrent metronidazolresistentie in 
C. difficile (hoofdstuk 4 en 5). Uit een patiënt die leed aan recidiverende C. difficile infecties 
werden twee stammen geïsoleerd van hetzelfde type waarvan er één gevoelig was voor 
metronidazol en één resistent tegen metronidazol, ondanks dat er maar 1 puntmutatie in 
het chromosoom aantoonbaar was (hoofdstuk 4). Verder onderzoek toonde aan dat de 
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metronidazol-resistente stam een plasmide bevatte dat wij pCD-METRO hebben genoemd. 
Introductie van dit plasmide in een metronidazol gevoelige laboratoriumstam zorgde ervoor 
dat deze metronidazol resistent werd. Screening van een grote, wereldwijde collectie klinische 
C. difficile stammen op de aanwezigheid van dit plasmide liet blijken dat pCD-METRO in vrijwel 
alle stammen aanwezig was met een stabiele metronidazol-resistentie en dus een belangrijke 
oorzaak van deze resistentie in C. difficile is.
In dit onderzoek naar pCD-METRO was er één metronidazol-resistente stam die het plasmide 
niet bevatte, maar wel minder hoge -  en bovendien medium-afhankelijke -  resistentie liet zien 
(hoofdstuk 5). Deze stam was resistent tegen metronidazol wanneer deze werd opgekweekt op 
medium waar vitamine K, heem en schapenbloed was verwerkt, maar was gevoelig wanneer de 
stam groeide op een voedingsbodem zoals deze veel gebruikt wordt in het moleculair biologisch 
laboratorium. Gedurende de COMBACTE-CDI studie, een 3-jaar durende Europese studie met 
als doel om de epidemiologie en klinische impact van CDI te karakteriseren, waren er stammen 
verzameld die resistent- of verminderd gevoelig bleken voor metronidazol. Nader onderzoek 
toonde aan dat de metronidazol-resistente stammen in deze collectie niet het pCD-METRO 
plasmide bevatten. Wel werd duidelijk dat deze stammen medium-afhankelijke resistentie 
vertoonden wat terug te leiden was naar de aanwezigheid van heem. Nagenoeg alle stammen 
lieten eenzelfde heem-afhankelijke verhoging van de Minimaal Inhiberende Concentratie (MIC) 
zien, ook al leidde dit niet per definitie tot resistentie. Wij hebben aangetoond dat stammen van 
een bepaald type van C. difficile met heem-afhankelijke metronidazol-resistentie een mutatie 
(deletie) hebben in het gen hsmA, waarvan de transcriptie verandert in in de aanwezigheid van 
heem. Deze deletie was verrassend genoeg ook aanwezig in de isolaten die het pCD-METRO 
plasmide bevatten. Fylogenetische vergelijkingen lieten zien dat de stammen met de deletie 
een aparte groep vormen, waarbij een deel van de stammen waarschijnlijk later ook het 
plasmide heeft opgenomen. Hoewel het niet bekend is hoe heem in alle andere stammen tot 
een verhoging van de MIC voor metronidazol leidt, heeft dit onderzoek het belang van hsmA 
en heem afhankelijke metronidazolresistentie in RT010 stammen aangetoond.
In conclusie heeft het werk in dit proefschrift een verband gelegd tussen remming van de 
DNA polymerase en de algemene stress-respons in C. difficile. Deze algemene stress respons 
is in dit werk beter gekarakteriseerd en we hebben een relatie met antimicrobiële resistentie 
en σB aangetoond. Tevens beschrijft het werk in dit proefschrift twee nieuwe mechanismen 
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DUTCH SUMMARY / NEDERLANDSE SAMENVATTING
die tot metronidazolresistentie in C. difficile leiden: we hebben het allereerste plasmide dat 
antibioticumresistentie geeft in C. difficile beschreven en we hebben aangetoond dat heem 
leidt tot verminderde metronidazolgevoeligheid in verschillende klinische isolaten. 
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